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Invasive lobular breast cancer (ILBC) is the second most common histological subtype 
of breast cancer and accounts for 10-15% of all cases. Loss of e-cadherin protein is a 
hallmark of ILBC and contributes to its characteristic discohesive morphology. In 
addition to distinct histological features, several subtype-specific molecular and clinical 
features have been described. However, ILBC remains understudied relative to other 
breast cancer subtypes, despite its frequency. 
 
In this era of precision medicine, there is a growing interest in further refining breast 
cancer tumour subtyping by identifying additional discriminating molecular features. 
However, there is limited data to pursue this for ILBC as it is often not well-represented 
in study samples. For instance, the seminal work on breast cancer classification based on 
gene-expression levels by Perou et al., (2000) included only two ILBC cases. It is 
important to identify ways to refine the subtyping of ILBC tumours so that women with 
ILBC can benefit from a more precise treatment plan, prognosis and targeted therapy 
options. 
 
The main objectives of this PhD project were: i) to examine the distinguishing 
methylation patterns between ILBC (n=151) and non-ILBC (n=341) tumours ii) to 
investigate the ILBC methylome to identify methylation signatures for prognostication 
(n=130) and iii) to subclassify ILBC into subgroups with increased homogeneity based 
on their genome-wide DNA methylation profiles (ILBC, n=151, non-ILBC=341) and to 




Three subgroups of ILBC were defined via unsupervised cluster analysis of genome-wide 
DNA methylation measured using the Infinium HumanMethylation450K assay. Of these, 
Subgroup 1 was identified as the most distinct ILBC subgroup, characterised by a 
predominant hypomethylation across 27,675 CpGs compared with Subgroup 2 and across 
13,067 CpGs compared with Subgroup 3. Subgroup 1 showed more similarity to the 
TNBC (non-ILBC) cases compared with the other two methylation-defined subgroups in 
terms of their genome-wide methylation pattern. Survival analysis showed that women 
with ILBC tumours in Subgroup 1 had the poorest overall survival when compared with 
women in Subgroup 2 (hazard ratio (HR): 0.59, 95% confidence interval (CI): 0.19-1.79) 
and Subgroup 3 (HR: 0.16, 95% CI: 0.03-0.88), after adjusting for age and year of 
diagnosis. Subgroup 3 had an enrichment for women who had a first-degree relative with 
a history of any cancer. Both Subgroup 2 and Subgroup 3 were enriched with women who 
had a female relative with a history of breast cancer. This suggests that women in 
Subgroup 2 and Subgroup 3 may be genetically or epigenetically predisposed to 
developing breast cancer. 
 
The somatic genetic variant profiles of the ILBC DNA methylation-defined subgroups 
were further investigated by performing whole-exome sequencing (WES) on five ILBC 
tumours representing each of the three subgroups (n=15). The mismatch repair deficiency 
(MMRd) associated mutational signature SBS6 was the most frequently observed 
mutational signature in the ILBC tumours, detected in 12/15 (80%) cases. Microsatellite 
instability (MSI) was also predicted in 13/15 (87%) of the cases, including all 12 tumours 
with SBS6. Although distinct somatic (genetic) characteristics for tumours of individual 
subgroups were not observed, this research highlighted the potential role of MMRd in 
ILBC tumourigenesis and progression. 
 
 iii 
DNA methylation of ILBC was also investigated as a possible prognostic biomarker. The 
analysis revealed 2,771 variably methylated regions within the ILBC tumours (n=130). 
A pooled survival analysis of the study set and TCGA data identified APC, TMEM101, 
HCG4P3 and CELF2 promoter methylation as potential prognostic biomarkers for 
women with ILBC. 
 
Comparing the DNA methylation profiles of ILBC (n=151) and non-ILBC (n=341) 
tumours, 13,763 genes and 8,456 intergenic regions showing statistically significant 
differences in DNA methylation (false discovery rate (fdr), P-value < 0.01) were 
identified. Gene set enrichment analysis revealed that the differentially methylated genes 
were found to be involved in biological pathways related to metabolism of RNA (R-HSA-
8953854), mRNA processing (GO:0006397), RNA splicing (GO:0008380), cell cycle (R-
HSA-1640170) and DNA repair (GO:0006281). 
 
This study brings together several lines of evidence to indicate that distinct molecular 
features of ILBC can enable further subtyping, identify important features for targeted 
therapies (e.g., MMRd) and provide additional information for prognostication. This 
research identified Subgroup 1 as an important subgroup with similarities to TNBC and 
more aggressive clinical behaviour. Further investigation of samples from Subgroup 1 
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Chapter 1 
1 
Chapter 1 Literature Review 
1.1 Human breast anatomy 
Breast cancer is a heterogeneous disease where malignant (cancer) cells develop in 
the breast epithelial tissue (Harris et al., 1992). Human breasts are composed of two main 
groups of tissues: i) the stroma, which consists of adipose tissue, connective tissue and 
extracellular matrix, and ii) the epithelium, which contains a network of ducts and lobules 
(Hassiotou & Geddes, 2013). Both the male and female breasts have glandular tissues 
that specialise in milk production; however in females, the glandular tissues are more 
developed (Hassiotou & Geddes, 2013). Each female breast contains 15 to 20 lobes, and 
within each lobe, there are 20 to 40 smaller sections called lobules or terminal duct lobular 
units (TDLUs) (Hassiotou & Geddes, 2013). TDLU is the functional unit of female 
breasts and is composed of milk-producing glands. During lactation, milk is produced in 
these lobules or TDLUs that travels through a network of tubes called ducts and exit the 
skin through the nipple. The space between lobes in the breast is mainly occupied by 
adipose tissues. Female breasts are supported by connective tissues and ligaments that 
also define their shape. A network of lymph vessels and lymph nodes is also present in 







Figure 1.1: Anatomy of the human female breast from The National Breast Cancer 
Foundation (National Breast Cancer Foundation, 2020) © Terese Winslow LLC, 
U.S. Govt. has certain rights. 
 
The breast is a tissue overlying the pectoral muscles. Female breasts are made of glandular 
tissues that produce milk and fatty tissues that determine the size of the breast. The milk-
producing unit of the breast is organised in lobes (15-20) that further divide into lobules 
where milk is produced. The milk travels through a network of ducts and eventually exit 
through the nipple. The dark area of skin surrounding the nipple is called the areola. 
Connective tissue and ligaments provide support to the breast and define its shape. The 
breast also contains blood vessels, lymph vessels, and lymph nodes.
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Female breasts undergo more changes than any other part of the human body. At 
puberty, female breasts develop in response to the female hormones estrogen and 
progesterone. The proliferation of epithelial and connective tissues and increased 
deposition of adipose tissues (fat) lead to breasts enlargement. At the time of pregnancy, 
female breasts further increase in volume and density in response to estrogen, 
progesterone, prolactin and placental hormones and develop secretory cells that produce 
milk proteins (Hassiotou & Geddes, 2013). After pregnancy, estrogen and progesterone 
levels decrease, while the levels of prolactin and growth hormones increase, leading to 
the production and secretion of milk. Once lactation ceases, female breasts decrease in 
size due to the degeneration of glandular tissues, ducts and lobules (Hassiotou & Geddes, 
2013). With ageing and at menopause, ducts and lobules decrease in number and female 
breasts predominantly contain fat and stroma thus, leading to a reduction in the breast 
size (Hassiotou & Geddes, 2013). 
1.2 The global trend in breast cancer incidence and mortality 
Breast cancer is the most commonly diagnosed cancer and the leading cause of 
mortality in women worldwide. It is estimated that 1 in 7 women in Australia will be 
diagnosed with breast cancer in their lifetime (Cancer Council Australia, 2020). 
According to the recent data from GLOBOCAN 2018, there were more than 2 million 
newly diagnosed cases of breast cancer among women worldwide and an estimated 
626,700 breast cancer deaths in over 100 countries in 2018 (Bray et al., 2018). 
 
Breast cancer incidence has constantly been rising over the past decades in most 
countries around the world. The global breast cancer incidence increased from 641,000 
cases in 1980 to over 2 million cases in 2018, and this trend is likely to continue (Bray et 
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al., 2018). The highest incidence rates were recorded for developed regions such as 
Australia and New Zealand (age-standardised rate (ASR), 94.2 per 100,000), Western 
Europe (ASR, 92.6 per 100,000), Northern Europe (ASR, 90.1 per 100,000) and Northern 
America (ASR, 84.8 per 100,000) (Bray et al., 2018). Increased awareness and a higher 
number of women undergoing regular breast screening in these regions, along with other 
risk factors such as lifestyle, dietary habits and environmental factors may be the likely 
explanation for an increased incidence. In contrast, many developing countries in Asia, 
Africa, and Latin America, where the incidence rates have been historically lower, are 
also witnessing a rapid increase in the number of breast cancer cases (Bray et al., 2004). 
This trend may be related to changes in socio-economic conditions and changes in 
lifestyle and behaviour of women in these regions such as late pregnancy, having fewer 
children, reduced physical activity leading to obesity, increased awareness of breast 
cancer risks and regular breast screening. 
 
Although the incidence rates have increased, the mortality rates of breast cancer 
have declined since 1993 in developed countries like the USA, Canada, Australia and 
many European countries primarily because of the availability of early detection 
techniques and advanced treatment options (Bray et al., 2018). In contrast, the mortality 
rates remained high in many countries in Asia, Africa and Latin America (Bray et al., 
2018). Lack of breast cancer screening, late-stage diagnosis and lack of adequate 
treatment facilities are likely to contribute to this increase. The highest estimated 
mortality rates worldwide have been reported in Fiji, Melanesia (ASR, 25.5 per 100,000) 
(Bray et al., 2018). 
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1.3 Risk factors of breast cancer 
Breast cancer is a multifactorial disease, and several factors can increase a woman’s 
chance of developing this disease such as age, ethnicity, lifestyle and family history. 
Some of the risk factors of breast cancer are detailed in the sections below. 
1.3.1 Age 
Breast cancer risk increases proportionally with increasing age with a sharp 
increase in risk observed after the age of 40 years (Bray et al., 2018). In Australia, women 
aged 50 years are estimated to be at ten times increased risk of developing breast cancer 
than women aged 30 years (AIHW, 2014). The median age of breast cancer diagnosis 
varies across the world, with the peak age at breast cancer diagnosis estimated to be 40-
50 years in Asian countries, 60-70 years in western countries and approximately 45 years 
in African countries (Bray et al., 2018). 
1.3.2 Reproductive history 
Exposures to female hormones (both endogenous and exogenous) are known to 
influence breast cancer risk. Several factors that influence the hormonal exposures such 
as early onset of menarche, late menopause, delayed first birth and low parity are 
associated with risk of breast cancer (Kelsey et al., 1993). 
 
A large, pooled analysis of data from 117 international studies conducted between 
1970 and 1999 including 118,964 women with invasive breast cancer and 306,091 
controls, reported an increased risk of 1.05 (95% confidence interval (CI):1.04-1.06) for 
each year younger at menarche and an increased risk of 1.03 (95% CI: 1.02-1.03) for each 
year older at menopause. Both these associations were found to be stronger for invasive 
Chapter 1 
 6 
lobular breast cancer (ILBC) compared with invasive ductal breast cancer (IDBC) (P-
value < 0.006) (Collaborative Group on Hormonal Factors in Breast, 2012). Both early 
menarche and late menopause increase the lifetime exposure to estrogen, which may be 
part of the explanation for the increased risk of breast cancer. 
 
Nulliparity (no history of giving birth) has been associated with an increased risk 
of breast cancer, whereas parity (history of giving birth) has been associated with a 
decreased risk of breast cancer. A pooled analysis of data from 47 epidemiological studies 
including 50,302 women with invasive breast cancer and 96,973 controls, reported that 
women with breast cancer had, on average, fewer childbirths than the controls (2.2 versus 
2.6) (Collaborative Group on Hormonal Factors in Breast Cancer, 2002). Another pooled 
analysis of data from 17 studies; 3 cohorts, 13 case-control and one nested case-control 
study reported that women who have not had any children had an increased risk of breast 
cancer (relative risk (RR) = 1.16, 95% CI: 1.04-1.26) compared with women who have 
had at least one child (Nelson et al., 2012). It was also noted that each childbirth reduced 
the risk by 7% especially for the estrogen receptor (ER) positive subtypes (Nelson et al., 
2012). 
There is considerable evidence that women who are older at the birth of their first 
child are at an increased risk of breast cancer compared with women who are of younger 
ages. Data from a recent study including 3,768 women with breast cancer showed that a 
woman’s risk of breast cancer increases by 3% for each year older she is at the first full- 
term pregnancy (RR = 1.03, 95% CI: 1.02-1.03) (Sisti et al., 2016). The RR for breast 
cancer in women aged 30 years and older at first birth compared with women age 25-29 
years at first birth has been estimated to be 1.20 (95% CI:1.02-1.42) (Nelson et al., 2012). 
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Breastfeeding has been weakly associated with a decreased risk of breast cancer 
in the mother (Martin et al., 2005; Wise et al., 2009). The RR for breast cancer has been 
reported to be 0.61 (95% CI:0.44-0.85), in women who have breastfed compared with 
women who have never breastfed (Ying Zhou et al., 2015). There is also evidence of a 
dose-response relationship, which means that women who have breastfed for a longer 
duration have proportionally larger reduced risk, with the risk of breast cancer estimated 
to be 0.98 (95% CI: 0.97-0.99) for per 5-months increase in the duration of breastfeeding 
(Chan et al., 2019). 
1.3.3 Menopausal hormone therapy 
Use of combined estrogen and progesterone menopausal hormone therapy (MHT) 
increases a woman’s risk of developing breast cancer. An increased risk of 1.33 (95% 
CI:1.30-1.36) has been reported for women who have used MHT compared with women 
who have never used MHT and the risk was estimated to be higher in current users 
compared with past users (RR = 1.72, 95% CI:1.55-1.92) (Munsell et al., 2014). The 
duration of MHT use has also been reported to have an influence, with an increase in 
breast cancer risk with the duration of MHT use and higher among women who started 
using combined MHT close to menopause (Beral et al., 2011). 
1.3.4 Mammographic breast density 
Mammographic breast density is assessed by mammography and can be expressed 
as percentage mammographic density (PMD). Variations in PMD are related to the 
difference in the amount of collagen and number of epithelial and non-epithelial cells in 
the breast (AT Wang et al., 2014). It has been estimated that women with dense breasts 
(breasts with a higher proportion of epithelial and connective tissues than adipose tissues) 
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are 1.53 times more likely to develop breast cancer than women with average breast 
density (Pettersson et al., 2014). 
 
Breast density has a strong genetic component, and up to 60% of the variations in 
breast density can be explained by heritability (Boyd et al., 2002). It is also associated 
with other risk factors of breast cancer. For instance, breast density was found to be 
inversely associated with parity (P-value = 0.02) and this association was stronger in 
women with a history of hormone therapy usage (P-value < 0.001) (Yaghjyan et al., 
2012). 
1.3.5 Family history and genetic factors 
A family history of breast cancer has been shown to influence a woman’s risk of 
developing breast cancer (Pharoah et al., 1997). The increased breast cancer risk 
associated with one affected first-degree relative has been estimated to be 1.80 (95% CI: 
1.70-1.91), with two affected first-degree relatives to be 2.93 (95% CI: 2.37-3.63) and 
with three or more affected first-degree relatives to be 3.90 (95% CI: 2.03-7.49), 
compared with women with no family history of breast cancer (Collaborative Group on 
Hormonal Factors in Breast, 2001). The RR associated with having one or more affected 
second-degree relatives has been estimated to be 1.5 (95% CI:1.4-1.6) (Pharoah et al., 
1997). Similar RRs have been reported by other studies (Bevier et al., 2012; Kharazmi et 
al., 2014; Beebe‐Dimmer et al., 2015). It was also noted that the increased risk associated 
with having a first-degree relative is likely to be higher for younger women and for 
women, whose relative was diagnosed with breast cancer at a younger age (Collaborative 
Group on Hormonal Factors in Breast, 2001). Family history of other cancers such as 
ovarian cancer, prostate cancer and colorectal cancer are also known to increase a 
Chapter 1 
 9 
women’s risk of developing breast cancer (Beebe‐Dimmer et al., 2015). Breast cancer 
risk has been estimated to increase by 2.36 (95% CI: 1.59-3.37) for women with one or 
two first-degree relatives with ovarian cancer (Sutcliffe et al., 2000). 
 
Around 15-20% of breast cancers are familial (Pharoah et al., 2002). The heritable 
component in familial breast cancers has been estimated to be 73%, whereas 27% has 
been considered to be due to the environmental factors (Couto & Hemminki, 2007). The 
heritable component is further higher in women with younger age at diagnosis (Couto & 
Hemminki, 2007). Inherited pathogenic variants in breast cancer susceptibility genes can 
partially explain the increased familial risk for breast cancer. Breast cancer susceptibility 
genes and the pathogenic variants in them are classified into further categories based on 
their minor allele frequency (MAF) and conferred risk as: i) high-risk variants (very rare, 
MAF < 0.005, conferred RR of breast cancer > 4), ii) moderate-risk variants (rare, MAF 
= 0.005-0.01, conferred RR = 2-4), and iii) low-risk variants (MAF > 0.01, conferred RR 
< 1.5) (Mavaddat et al., 2010). High-risk variants in BRCA1 (Miki et al., 1994), BRCA2 
(Wooster et al., 1995), TP53 (Malkin et al., 1990), STK11 (A Hemminki et al., 1998), 
CDH1 (Berx et al., 1995) and PTEN (J Li et al., 1997) account for ~20% of the familial 
risk (Ghoussaini & Pharoah, 2009). Moderate-risk variants in CHEK2 (Meijers-Heijboer 
et al., 2002) and ATM (Renwick et al., 2006) account for up to 5% of the familial risk. 
Variants in PALB2 were initially classified as moderate-risk variants (Rahman et al., 
2007). However, more recent research suggests that it confers a similar risk as BRCA2 (A 
Antoniou et al., 2003; AC Antoniou et al., 2014). 
 
Genome-wide association studies (GWAS) have been a standard approach for 
identifying low-risk breast cancer susceptibility loci (Douglas F. Easton et al., 2007). It 
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allows hundreds of thousands of common genetic variants or single nucleotide 
polymorphisms (SNPs), with a MAF of 1% or more to be analysed in case-control studies. 
To date, more than 170 breast cancer low-risk loci have been identified that explain ~18% 
of the familial risk of breast cancer (Douglas F Easton et al., 2007; Thomas et al., 2009; 
W Zheng et al., 2009; Turnbull et al., 2010; RL Milne et al., 2014; Michailidou et al., 
2015; Michailidou et al., 2017; Zhang et al., 2020). Taken together, these currently known 
risk variants and loci only explain less than half of the genetic risk of familial breast 
cancer and the genetic component for the remaining half is still unknown (AC Antoniou 
& Easton, 2006). 
 
BRCA1 and BRCA2 are the most prominent of all the breast cancer susceptibility 
genes, accounting for most of families with multiple cases of breast and ovarian cancer 
(A Antoniou et al., 2003). They are involved in several cellular pathways such as cell 
cycle, transcriptional regulation, apoptosis and DNA repair mechanism such as 
homologous recombination of double-stranded breaks (Roy et al., 2012). The frequencies 
of BRCA1 and BRCA2 pathogenic variants in the general population have been estimated 
to be 1 in 400 and 1 in 800, respectively (Ford et al., 1994; Claus et al., 1996). A large 
case-control study, using a panel of 25 genes tested 95,561 women for hereditary breast 
cancer risk and estimated the increased risk of breast cancer associated with BRCA1 
mutations as 5.91 (95% CI: 5.25-6.67) and with BRCA2 mutations as 3.31 (95% CI: 2.95-
3.71) (Kurian et al., 2017). Kuchenbaecker et al., (2017) in a prospective study, reported 
that for BRCA1 mutation carriers, the incidence increased rapidly with age, up to the age 
of 41-50 years and remained constant after that, throughout the remaining lifetime, 
whereas for BRCA2 mutation carriers, the incidence kept increasing up to the age of 51-
60 years (5-10 years later than BRCA1 mutation carrier) (Kuchenbaecker et al., 2017). 
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The cumulative risk of breast cancer to age 80 years, for BRCA1 and BRCA2 mutation 
carriers, has been estimated to be 72% (95% CI: 65%-79%) and 69% (95% CI: 61%-
77%), respectively (Kuchenbaecker et al., 2017). 
1.4 Classification of breast cancer 
The heterogeneity of breast cancer is evident in its various molecular features and 
therapeutic responses. This heterogeneity poses a pronounced challenge in the 
management of the disease. Classifying breast cancer into clinically relevant subtypes has 
the potential for more accurate prognostication and precision medicine by identifying 
subtype-specific diagnostic and prognostic markers and therapeutic targets. Traditional 
methods for breast cancer classification are based on the clinicopathological features of 
the tumour, mainly tumour grade and tumour stage (Rakha, Reis-Filho, Baehner, et al., 
2010). Although these methods are well validated and still have clinical value, they fail 
to cover the broad and diverse spectrum of breast cancer heterogeneity. With 
advancements in molecular technologies, breast cancer classification has evolved from 
traditional histopathological classification to a more advanced sub-classification system 
based on the molecular level information (Rakha & Green, 2017). Different approaches 
to breast cancer classification are detailed below. 
1.4.1 Histology, grade and stage 
Histology refers to the growth pattern of tumours and numerous breast cancer 
subtypes have been defined based on the tumour morphological characteristics. The most 
common histological subtype of breast cancer is invasive ductal breast cancer (IDBC), 
also known as Invasive Carcinoma of No Special Type. It accounts for 40-70% of all 
breast cancer cases and is a heterogeneous group of diseases that do not show sufficient 
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special differentiation pattern to be classified as the special subtype (Lakhani et al., 2012). 
The remaining 25-30% of breast cancers are classified as special subtypes based on their 
specific growth patterns (Lakhani et al., 2012). According to the 4th edition of the WHO 
classification of breast cancers published in 2012, more than 18 special subtypes of breast 
cancer have been described (Lakhani et al., 2012). Of those, invasive lobular breast cancer 
(ILBC) is the most common special subtype accounting for 10-15% of all cases. Other 
special breast cancer subtypes include tubular carcinoma, cribriform carcinoma, 
mucinous carcinoma, neuroendocrine carcinoma, micropapillary carcinoma, papillary 
carcinoma, carcinoma with medullary properties, and metaplastic carcinoma (Lakhani et 
al., 2012). Although the breast cancer subtypes defined based on histology have been 
shown to display different biological and clinical behaviour (Weigelt et al., 2008), the 
implication of histological classification has limited precision due to the subjective nature 
of the histopathological imaging. The heterogeneity of breast cancers in a single subtype 
further limits the clinical utility of the histological classification. 
 
Grade represents the degree of differentiation of tumour tissues and is one of the 
most important prognostic factors that inform about the tumour clinical behaviour 
(Rakha, Reis-Filho, Baehner, et al., 2010). Nottingham grading system is a widely 
accepted system that assigns tumour grades by evaluating the morphological features 
such as degree of tubule formation, degree of nuclear pleomorphism and tumour mitotic 
count (Elston & Ellis, 1991). Tumours are scored based on the above-mentioned 
parameters and graded as grade I (total score between 3 to 5), grade II (total score 6 or 7) 
and grade III (total score 8 or 9) (Elston & Ellis, 1991). Tumour grade has been reported 
to be an independent prognostic factor (Saimura et al., 1999; Rakha et al., 2008; Wirapati 
et al., 2008), used in many clinical prediction tools such as the Nottingham prognostic 
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index and Adjuvant online, together with other biomarkers to predict patient prognosis in 
breast cancer (Olivotto et al., 2005; Fong et al., 2015). High-grade breast tumours are 
associated with higher rates of metastasis, higher rates of recurrence and poor patient 
outcome compared with low-grade breast tumours (Rakha, Reis-Filho, Baehner, et al., 
2010). 
Breast tumour staging is another factor, which is used to inform about the tumour 
status, patient prognosis and to guide treatment decisions. The TNM system for breast 
cancer staging is a globally accepted system established by The American Joint 
Committee on Cancer (AJCC) in 1977. It assigns the tumour stage based on the anatomic 
extent of the disease, including tumour size (T), nodal involvement (N) and distant 
metastasis (M) (Edge et al., 2010). Although the anatomical staging remains an important 
factor in clinical decision making, it is purely based on the anatomical features of the 
tumour and does not account for other important tumour features that have significant 
prognostic and predictive values such as tumour grade and biological factors such as 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2) expression status (see section 1.4.2). Therefore, the recent edition of 
the AJCC has established a new prognostic staging system that incorporates other 
biological features and also incorporates molecular level information (Hortobagyi et al., 
2017). Savage et al., (2019) in a retrospective cohort study including 1,703 women, 
showed that the prognostic staging system displayed improved prognostic accuracy with 
respect to the overall survival compared with the anatomical staging system (Savage et 
al., 2019). A similar finding has been reported by other studies (SB Lee et al., 2018; 
Weiss et al., 2018). 
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1.4.2 Hormone receptor and HER2 expression status 
In routine clinical practice, breast cancer is commonly classified based on the 
expression status of ER, PR and HER2 (Rakha, Reis-Filho, & Ellis, 2010), which is 
commonly determined by immunohistochemistry (IHC) or fluorescent in-situ 
hybridisation and the tumours are termed positive or negative based on the expression 
status. 
ER expression status has been used for the clinical management of breast cancer 
since the 1970s, where it was originally used to predict endocrine therapy response and 
as a prognostic biomarker for early recurrence (Rakha, Reis-Filho, & Ellis, 2010). Most 
breast tumours (~80%) are estimated to be ER positive (Anderson et al., 2002). ER 
positive breast tumours are typically well-differentiated, display less aggressive tumour 
features and are associated with better short-term patient outcome compared with ER 
negative breast tumours (Dunnwald et al., 2007). A difference in gene expression profile 
has been reported based on the ER positive or ER negative status of breast tumours (Perou 
et al., 2000; Sørlie et al., 2001). 
 
Around 55-65% of breast tumours are estimated to be PR positive and are 
associated with a better prognosis compared with PR negative breast tumours (Rakha, 
Reis-Filho, & Ellis, 2010). PR expression status is generally used in combination with 
ER expression status for classifying breast tumours and based on this combinatorial 
approach four subtypes of breast tumours have been defined; i.e., ER positive/PR 
positive, ER positive/PR negative, ER negative/PR positive and ER negative/PR 
negative. Among these, the ER positive/PR positive subtype represents 55-65% of breast 
tumours. The women with these tumours are usually of older age, present with lower 
grade and smaller size tumours and have a better prognosis than women with other tumour 
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subtypes (Dunnwald et al., 2007; Rakha et al., 2007). Around 75-85% of the ER 
positive/PR positive breast tumours show a good response to hormone therapy (Dowsett 
et al., 2006). In contrast, the ER negative/PR negative subtype accounts for 20-25% of 
the breast tumours and are associated with higher grade, higher recurrence rates, worse 
prognosis and poor response to hormone therapy (Kinne et al., 1987; Anderson et al., 
2001; Bardou et al., 2003). Breast tumours, which are positive for a single hormone 
receptor; i.e., from the ER negative/PR positive or ER positive/PR negative subtypes, are 
generally characterised by higher grade and larger size tumours, respond poorly to 
endocrine therapy and show enhanced expression of EGFR and HER2 compared with the 
ER positive/PR positive subtype (Bardou et al., 2003; Rakha et al., 2007). The ER 
positive/PR negative subtype accounts for ~17% of breast cancer cases, whereas the ER 
negative/PR positive tumours are relatively rare, accounting for 0.2-10% of all cases 
(Anderson et al., 2001; Dunnwald et al., 2007; Rakha et al., 2007). 
 
HER2 gene amplification and protein overexpression has been shown to have 
predictive value for response to targeted anti-HER2 therapy (Bartlett et al., 2003; 
Kaufmann et al., 2006; Wolff et al., 2007). Around 13-20% of breast tumours are HER2 
positive, and of these, 50% are ER and PR negative (Slamon et al., 1987; Dandachi et al., 
2002). The ER negative/PR negative and HER2 positive breast tumours show a poorer 
prognosis compared with the ER positive/PR positive and HER2 negative subtype 
(Rakha, Reis-Filho, & Ellis, 2010). Around 10-15% of breast tumours are ER negative/PR 
negative and HER2 negative (Vuong et al., 2014). This subtype is often referred to as the 
triple negative breast cancer (TNBC). They represent a distinct group of tumours with 
completely different clinical presentation and patient prognosis. Women with TNBC have 
typically been reported to be of younger age and present with higher grade and larger size 
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tumours compared with women with other breast cancer subtypes (Dent et al., 2007). 
TNBC tumours were also found to be associated with an increased risk of distant 
recurrence (hazard ratio (HR): 2.6, 95% CI: 2.0-3.5, P-value < 0.001) and a poorer 5-
years survival (HR: 3.2, 95% CI: 2.3-4.5, P-value < 0.001) (Dent et al., 2007). The 
spectrum of TNBC is diverse, and it exemplifies the heterogeneity present in breast cancer 
subtypes. 
In addition to ER, PR and HER2, other biomarkers have been proposed to be used 
in breast cancer classification including ER-ß, androgen receptor, proliferation-related 
marker Ki-67, cytokeratin5/6 and EGFR (Vuong et al., 2014). Ki-67 has been shown to 
further refine ER positive breast tumour group, and a combined group of biomarkers (ER, 
PR, HER2 and Ki-67) has been proved to be useful in clinical settings (Cuzick et al., 
2011). These biomarkers are being used more frequently to further refine the current 
breast cancer classification (Blows et al., 2010; Green et al., 2013). 
1.4.3 Gene expression profiling-based classification 
The development of gene expression arrays enabled a more detailed analysis of 
genes expressed by breast tumours compared with IHC. In 2000, Perou et al. performed 
complementary DNA microarray gene expression analysis of 8,102 genes in 38 invasive 
breast cancer cases that included 36 IDBC and two ILBC, one ductal carcinoma in-situ 
(DCIS), one fibroadenoma and four normal breast samples, and defined four main 
intrinsic subtypes of breast cancer: i) luminal ii) basal-like iii) HER2-enriched and iv) 
normal like (Perou et al., 2000). A subsequent study from the same group further sub-
classified the luminal subtype into luminal A and luminal B differing in the expression of 
proliferation related genes and also demonstrated that these subtypes were different in 
terms of their clinical outcome (Sørlie et al., 2001). 
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Luminal A tumours tend to express ER and PR and are more likely to be negative 
for HER2. Of the four intrinsic subtypes, luminal A subtype has been shown to have the 
best prognosis with relatively lower recurrence and higher survival rates (Carey et al., 
2006; Dawood et al., 2011). In contrast, luminal B tumours are ER positive and/or PR 
positive and are highly proliferative with a high Ki-67 score. The proliferative nature of 
luminal B tumours has been suggested to be the likely cause of poorer prognosis in 
comparison with luminal A tumours (Calza et al., 2006; Carey et al., 2006). Luminal B 
tumours are typically of higher grade, larger size and are more likely have TP53 mutations 
compared with luminal A breast tumours (Calza et al., 2006; Carey et al., 2006; Dawood 
et al., 2011). 
The basal-like tumours represent the most heterogeneous subtype with respect to 
the histopathological features, mutation profiles, clinical behaviour and patient outcome 
(Sørlie et al., 2001; Banerjee et al., 2006; Chin et al., 2006; Fulford et al., 2007). They 
are commonly characterised as grade III tumours with a high proliferative index, 
aggressive clinical course and frequent somatic pathogenic variants in TP53 (Badve et 
al., 2011). Basal-like breast cancers are a subset of TNBC in which the tumours also 
express high molecular weight cytokeratin such as cytokeratin5/6 and cytokeratin14 that 
are usually expressed in normal breasts (Rakha, Reis-Filho, & Ellis, 2010). 
 
 The HER2 enriched tumours are typically negative for ER and PR expressions 
and overexpress HER2. They are associated with high tumour grade, early and frequent 
metastases and poor prognosis (Calza et al., 2006; Carey et al., 2006). HER2 enriched 
tumours are known to benefit from antibody-based and anti-kinase based therapies that 
target HER2 and has changed the prognosis of this subtype (Slamon et al., 2001; Piccart-
Gebhart et al., 2005). 
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The normal-like subtype is characterised by the expression of genes associated 
with adipose tissues and other stromal cell types. This subtype is thought to represent 
normal cell contamination of samples and remain a controversial group (Vuong et al., 
2014). 
There are further breast cancer subtypes identified since the first gene-expression 
based classification. These are claudin-low, molecular apocrine and interferon-related 
subtypes. The claudin-low subtype is commonly enriched for metaplastic carcinoma and 
tumours with medullary-like features. The tumours in this subtype are usually triple 
negative and show enrichment for epithelial-to-mesenchymal transition markers, immune 
response genes and cancer stem cell-like features (Prat et al., 2010). The survival rates 
for claudin-low breast cancer subtype lie between those for luminal and basal-like subtype 
(Prat et al., 2010). The molecular apocrine subtype is characterised by ER positive and 
androgen receptor positive tumours with characteristic histological features related to 
apocrine breast cancer subtype (Farmer et al., 2005). They are associated with early 
recurrence; however show a good response to neoadjuvant chemotherapy (Guedj et al., 
2012). The interferon-related subtype is characterised by high expression of interferon-
regulated genes, including STAT1 (Z Hu et al., 2006). 
 Although gene expression-based stratification of breast cancer expanded our 
knowledge of breast cancer heterogeneity, its clinical application in identifying high-risk 
patients and tailoring therapy remains limited. Several prognostic signatures have been 
developed based on the expression profiling however, they have not been able to 
completely replace the traditional pathological classification system. One of the main 
reasons for this is the lack of reproducibility and the absence of a standard methodology 
for these classifications. Furthermore, most of the gene expression-based studies relate to 
IDBC as they constitute the majority of breast cancer cases. Data relating to the 
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expression profiles of special subtypes of breast cancer are limited. Molecular 
classification of the breast tumour is still evolving and there is a growing interest to 
incorporate other molecular level information for a more comprehensive view of the 
breast cancer heterogeneity. 
1.5 Invasive Lobular Breast cancer 
Lobular breast cancer was first reported by Foote and Stewart in 1941, where they 
defined both in-situ and invasive forms of the disease (Foote & Stewart, 1941). ILBC is 
the second most common histological subtype of breast cancer accounting for 10-15% of 
all cases (Lakhani et al., 2012). After its first report, ILBC remained largely 
underrepresented in major breast cancer studies mainly because of its low prevalence 
compared with the more common histological subtype, IDBC. Recent research focus has 
shifted to ILBC, and it is increasingly recognised as a distinct breast cancer subtype with 
different tumour biology and clinical presentation (Arpino et al., 2004; C. I. Li et al., 
2005). Further investigation of its unique tumour biology and molecular features has been 
pursued to identify diagnostic and prognostic biomarkers specific for this subtype. 
1.5.1 Epidemiology and risk factors of ILBC 
ILBC is more likely to occur in older women with the median age of diagnosis 
being 65 years (Arpino et al., 2004). The incidence rate of ILBC increased sharply (1.52-
fold, 95% CI: 1.42-1.63) between 1987 to 1999, which was mainly related to increased 
use of hormone replacement therapy (HRT) in the USA during that time (E Hemminki et 
al., 1988; Christopher I. Li et al., 2003). Awareness of the increased risk of breast cancer 
associated with HRT led to its reduced use and a decline in ILBC incidence rate 
(Christopher I. Li & Daling, 2007). The annual percent change in ILBC incidence rate 
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fell steadily from 1998 to 2004 (Annual percent change = -3.18%, 95% CI: -5.18 to -1.03) 
(Christopher I. Li & Daling, 2007). However, recent data suggests an increase in its 
incidence rate again (Bray et al., 2018). 
 
Several breast cancer risk factors particularly those related to female hormone 
exposures (both endogenous and exogenous) are more strongly associated with ILBC 
than other breast cancer types (Collaborative Group on Hormonal Factors in Breast, 
2012). Kotsopoulos et al., (2010) investigated the association between hormonal 
exposures and breast cancer risk in 4,655 IDBC and 659 ILBC tumours and reported a 
significantly stronger association between age at menarche (P-value = 0.03), age at first 
birth (P-value < 0.001) and postmenopausal hormone use (P-value < 0.001) in ILBC 
compared with IDBC (Kotsopoulos et al., 2010). Breast cancer risk associated with older 
age at first birth (>=30 years compared with < 20 years) was found to be more pronounced 
for ILBC (odds ratio: 2.4, 95% CI: 1.90-2.90) compared with IDBC (odds ratio: 1.3, 95% 
CI: 1.20-1.40), P-value = 0.01 (Newcomb et al., 2011). Increased risk associated with 
nulliparity compared with women with age at first birth < 20 years was also found to be 
stronger for ILBC (odds ratio: 1.7, 95% CI: 1.34-2.20) compared with IDBC (OD: 1.2, 
95% CI: 1.1-1.3), P-value = 0.004 (Newcomb et al., 2011). Another large meta-analysis 
based on 14,102 breast cancer cases including 1,526 ILBC cases, observed that the RRs 
of breast cancer in current HRT users compared with women who have never used HRT 
was larger for ILBC (RR = 2.3, 95% CI: 2.0-2.5) and tubular breast cancer (RR = 2.7, 
95% CI: 2.2-3.3) compared with mixed ductal lobular (RR = 2.1, 95% CI: 1.7-2.7), IDBC 
(RR= 1.6, 95% CI: 1.5-1.7) and mucinous breast cancers (RR = 1.6, 95% CI: 1.1-2.3). 
The RRs varied significantly according to tumour histology overall (P-value < 0.0001) 
(Reeves et al., 2006). 
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ILBC has been shown to have higher familial risk compared with IDBC. Allen-
Brady K et al., (2005) reported that the relatives of women affected by ILBC had an 
increased risk for ILBC (first-degree relative: familial relative risk (FRR) = 4.51, 95% 
CI: 2.8-6.9) and an increased risk for any type of breast cancer (first-degree relative: FRR 
= 2.5, 95% CI: 2.1-2.9) (Allen-Brady et al., 2005). These estimates were significantly 
higher than all breast cancer and early-onset breast cancer FFR estimates (1.83, 95% CI: 
1.75-1.90 and 2.42, 95% CI: 2.21-2.63, respectively), suggesting a strong heritable 
component associated with this subtype (Allen-Brady et al., 2005). Despite this, the only 
recognised breast cancer susceptibility gene linked to ILBC predisposition is CDH1. 
Germline pathogenic variants in CDH1 was originally linked to the predisposition of 
hereditary diffuse gastric cancer (Guilford et al., 1998). It was noted that many of these 
hereditary diffuse gastric cancer families with germline pathogenic variants in CDH1 
often had cases of ILBC (Keller et al., 1999; Brooks-Wilson et al., 2004; Suriano et al., 
2005) that led to the identification of CDH1 as a susceptibility gene for ILBC as well. 
However, germline CDH1 pathogenic variants predisposing to ILBC without a family 
history of HDGC are not common, reported in 1-4% of cases (Masciari et al., 2007; 
Schrader et al., 2011; Xie et al., 2011). 
 
Women with ILBC have been reported to be more commonly BRCA2 mutation 
carriers (8-10% of cases), compared with BRCA1 mutation carriers (up to 2% of cases) 
(Mavaddat et al., 2012; Ditchi et al., 2019). Low-risk loci predisposing to ILBC has also 
been identified. A GWAS including pooled data from 36 studies that included 5,622 
ILBC, 401 lobular carcinoma in-situ (LCIS) and 34,271 unaffected women, identified a 
SNP at 7q34 specific to ILBC predisposition (Sawyer et al., 2014). 
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1.5.2 Histological subtypes of ILBC 
ILBC is highly varied in terms of its morphology, and several subtypes of ILBC 
have been described based on the growth pattern (Martinez & Azzopardi, 1979; Lakhani 
et al., 2012). The most common form or subtype of ILBC is classic ILBC representing 
~50% of all cases (Lakhani et al., 2012). It is characterised by small, round and 
discohesive cells that grow in a single file without forming any distinct clusters. Classic 
ILBC cells maintain a uniform size, have pale cytoplasm with uniform and clear nuclei 
without any hyperchromatism. Mitotic structures in the nucleus are rare and nuclear 
pleomorphism (variation in nuclear size, shape, hyperchromatism, nucleoli) is low to 
moderate (Rakha & Ellis, 2010). 
 
Tumours that lack the characteristic discohesive non-linear growth pattern of 
classic ILBCs, while still maintaining similar cytological features, are referred to as the 
histological subtypes of ILBC (Rakha & Ellis, 2010). Several subtypes have been 
identified such as alveolar, solid, pleomorphic, tubulolobular, signet ring cell, trabecular 




Figure 1.2: Histological subtypes of ILBC taken from (Iorfida et al., 2012). 
Representative images of hematoxylin and eosin-stained histological subtypes of ILBC, 
a) Classic-ILBC; b) Alveolar ILBC; c) Pleomorphic ILBC; d) Solid ILBC; e) 
Tubulolobular ILBC and f) ILBC mixed non-classic type.
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The alveolar ILBC is characterised by an aggregation of cells (at least 20) that are 
arranged in glandular structures while the other cytological features of alveolar ILBC 
remains typical of classic ILBC (Shousha et al., 1986). The solid ILBC subtype is 
characterised by typical small and non-cohesive cells of lobular morphology, but instead 
of the single file growth pattern of classic ILBC, these cells grow in solid sheets, are more 
pleomorphic (variable in shape and size) and have a higher frequency of mitosis compared 
with the classic subtype (Fechner, 1975). Pleomorphic ILBC is another subtype that 
shows a higher mitotic rate, cellular atypia and nuclear pleomorphism (nucleus with 
varying shape and size) similar to the solid subtype, while still retaining the characteristic 
growth pattern of the classic ILBC (Weidner & Semple, 1992; Middleton et al., 2000). 
Pleomorphic ILBC accounts for less than 1% of all breast cancer cases and ~5% of all 
ILBC cases. They show more aggressive clinical behaviour than other ILBC subtypes 
with locally advanced tumours overexpressing HER2 and p53 (Middleton et al., 2000). 
Pleomorphic ILBC is more frequently associated with LCIS and may show apocrine or 
histiocytoid differentiation (Eusebi et al., 1992). Haque et al., (2019) comparing the 
clinical characteristics of classic ILBC (n = 114,859) and pleomorphic ILBC (n = 401) 
reported that pleomorphic ILBC tumours were more likely ER negative and HER2 
positive and were associated with poorer overall survival compared with classic ILBC 
tumours (P-value < 0.001) (Haque et al., 2019). The tubulolobular ILBC subtype has 
histological and molecular features common to both lobular and tubular carcinoma (a 
subtype of IDBC). It is usually characterised by low-grade tumours and associated with 
a good prognosis (Fisher et al., 1977). The mixed ILBC subgroup represents the cases 
that present as a mixture of classic ILBC and one or more histological subtype of ILBC 
(J. M. Dixon et al., 1982). The classic ILBC and the mixed ILBC subtype together 
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contribute to the majority of lobular tumours accounting for up to 75% of all ILBC cases 
(Orvieto et al., 2008; Rakha et al., 2008). 
 
Apart from being different in terms of morphology, these ILBC subtypes have 
also been associated with specific genomic alterations. For instance, somatic variants in 
ARID1A and TP53 have been more commonly reported in solid ILBC, whereas somatic 
variants in HER2 and TP53 have been commonly observed in pleomorphic ILBC (12-
19% of pleomorphic ILBC) (Ercan et al., 2012; Lien et al., 2015; Deniziaut et al., 2016; 
Zhu et al., 2018; Rosa-Rosa et al., 2019). PYGM, encoding the myophosphorylase 
enzyme, has also been found to be frequently mutated in pleomorphic ILBCs (Ciriello et 
al., 2015). 
1.5.3 Clinical features of ILBC 
ILBC is generally associated with older age at diagnosis, higher tumour stage, 
lower histological grade and a higher percentage of multicentric, bilateral and multifocal 
tumours compared with IDBC (Arpino et al., 2004; Chen et al., 2017). ILBC tumours are 
typically ER and PR positive and HER2 negative (Arpino et al., 2004; Chen et al., 2017). 
HER2 overexpression has been reported in up to 5% of ILBC tumours (Desmedt et al., 
2016; Chen et al., 2017). HER2 positive ILBCs are more likely to be negative for 
hormone receptors (ER and PR), have higher grade tumours and have poorer survival 
compared with HER2 negative ILBC tumours (Kee et al., 2020). HER2 positive ILBC 
commonly belong to the pleomorphic ILBC subtype (Hoff et al., 2002; Lal et al., 2005). 
 
The diffuse growth pattern of ILBC poses a major challenge for its early detection, 
which may be the likely explanation for women with ILBC more frequently presenting 
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with advanced-stage tumours (Arpino et al., 2004; Molland et al., 2004). ILBCs do not 
usually present with a firm lump in the breast and early signs may include thickening in 
parts of the breast, with or without any changes in the nipple (Biglia et al., 2013). 
Compared with IDBC, mammography has a lower sensitivity for detecting ILBC ranging 
between 57-81% with a high false-negative rate of up to 19% (Hilleren et al., 1991; Le 
Gal et al., 1992; Krecke & Gisvold, 1993). In a recent study, Porter et al., (2014), 
reviewed 361 cases of ILBC diagnosed between 1995-2010 and found that the 
mammography was negative for 30% of the cases and the most common positive finding 
was a localised spiculated mass (Porter et al., 2014). Figure 1.3 shows the mammography 
of a 70-year-old woman where ILBC can be visualised as a spiculated mass as reported 
by Porter et al., (2014). 
 
Ultrasound is relatively more sensitive (78-95%) in detecting ILBC compared 
with mammography (Butler et al., 1999; Chapellier et al., 2000; Evans & Lyons, 2000; 
Cawson et al., 2001), however there is a report suggesting an underestimation of tumour 
size on ultrasound that can have implications while surgery (Watermann et al., 2005). 
Magnetic resonance imaging has been shown to have enhanced sensitivity for detecting 
ILBC, particularly the multifocal tumours however, the applicability of this technique to 
inform about breast conservation surgery in ILBC women is low (Schelfout et al., 2004; 












Figure 1.3: Mammography of a 70-year-old woman with ILBC from (Lopez & 
Bassett, 2009). 
The mammography scan shows the left mediolateral mammogram of a 70-years-old 
woman. ILBC tumour can be seen as a low-density, irregular, spiculated mass (indicated 
by the arrow). The ILBC tumour in the mammogram presents with ill-defined margins 
and have equal opacity to the surrounding breast parenchyma.
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ILBC tumours have a distinct pattern of metastasis. Mathew et al., (2017), 
comparing the metastatic patterns of ILBC and IDBC, found that compared with IDBC, 
ILBC showed a more frequent metastasis to bone (57% of 88 ILBCs versus 38% of 673 
IDBCs, P-value = 0.001) and gastrointestinal tract (6% versus 0.3%, P-value < 0.001), 
and less frequent metastases to the lungs (6% versus 24%, P-value < 0.001) and the liver 
(5% versus 11%, P-value = 0.049), as the first site of distant recurrence (Mathew et al., 
2017). Over the entire course of the metastatic disease, more women with ILBC showed 
a metastatic preference for ovarian (6% versus 2%, P-value = 0.042) and gastrointestinal 
tracts (8% versus 0.6%, P-value < 0.001), whereas reduced tendencies to metastasise to 
the liver (21% versus 49%, P-value  < 0.001) and lungs (24% versus 52%, P-value 
< 0.001) were observed (Mathew et al., 2017). Another study, using The Surveillance 
Epidemiology and End Results 1990-2013 database, reported a higher frequency of bone 
metastasis in women with ILBC (92% of 85,048 ILBCs versus 76% of 711,287 IDBCs) 
(Chen et al., 2017). ILBCs were also shown to have multiple metastatic sites (Chen et al., 
2017). 
Current treatment protocol for ILBC is similar to other histological subtypes of 
breast cancer (Heilat et al., 2019). In most cases of early breast cancers, breast-conserving 
surgery is performed to remove the tumour with a margin of the surrounding normal tissue 
(Heilat et al., 2019). However, due to the diffuse and multifocal morphology of ILBC 
tumours, a higher mastectomy rate has been reported in women with ILBC (72% of 563 
ILBCs versus 56% of 5,889 IDBCs, P-value < 0.01) (Pestalozzi et al., 2008). Studies 
have reported that 17-65% of women undergoing breast-conserving surgery have been 
reported to undergo another surgery due to inaccurate estimation of the tumour margin 
(Silberfein et al., 2010; Kryh et al., 2014; Braunstein et al., 2015; S Sharma et al., 2015). 
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Women with ILBC are also more likely to undergo contralateral mastectomy because of 
the higher frequency of bilateral tumours in ILBC (Babiera et al., 1997). 
  
Neo-adjuvant chemotherapy has been consensually reported to be less effective 
in ILBC compared with IDBC (Cristofanilli et al., 2005; Tubiana-Hulin et al., 2006; Joh 
et al., 2012; Delpech et al., 2013; Loibl et al., 2014). Loibl et. al., (2014) reported a 
significantly lower pathologic complete response rate (absence of invasive or in situ 
cancer in the breast and/or axillary lymph nodes) in women with ILBC compared with 
non-ILBC after neo-adjuvant chemotherapy (6% of 1,055 ILBCs versus 17% of 7,965 
non-ILBCs, P-value < 0.001) (Loibl et al., 2014). Another study reported a pathologic 
complete response rate of 1% of 118 ILBC cases compared with 9% of 742 IDBCs (P-
value = 0.002) after neo-adjuvant chemotherapy (Tubiana-Hulin et al., 2006). Neo-
adjuvant chemotherapy has been advised for women with hormone receptor negative 
ILBC with advanced tumour stage (Loibl et al., 2014). 
  
As ILBC tumours typically express ER and PR, women with ILBC are considered 
to benefit from neoadjuvant endocrine therapy (Locker et al., 1991; Tubiana-Hulin et al., 
2006). A retrospective study including 61 women with ER positive ILBC reported that 
neoadjuvant treatment with letrozole (an aromatase inhibitor) reduced the tumour volume 
by 66% (mean) in three months and 81% of the women had successful breast-conserving 
surgery after the neoadjuvant treatment (J Michael Dixon et al., 2011). 
 
There is a large variability in the literature concerning ILBC patient outcome 
compared with other breast cancer types. Women with ILBC have been reported to have 
a similar (Fortunato et al., 2012), better (Cristofanilli et al., 2005; Wasif et al., 2010) or 
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no significant difference in prognosis compared with women with IDBC 
(Mhuircheartaigh et al., 2008). Chen et al., (2017) comparing ILBC and IDBC diagnosed 
between 1990 and 2013, found that women with ILBC had an early advantage, showing 
better overall survival for up to 60 months (ILBC versus IDBC, HR= 1.12, P-value 
<0.0001), however long-term (after five years) prognosis for women with ILBC was 
poorer (ILBC versus IDBC, HR= 0.78; P-value <0.0001). Regarding the disease-free 
survival, women with IDBC showed better prognosis, both early and long-term, 
compared with women with ILBC (ILBC versus IDBC, HR = 0.81; P-value <0.0001) 
(Chen et al., 2017). 
1.5.4 The somatic genomic landscape of ILBC 
Massively parallel sequencing technologies have enabled an in-depth molecular 
characterisation of breast cancer and have enhanced our understanding of the key genetic 
alterations in breast cancer tumourigenesis. However, most of the studies investigating 
the mutational landscape of breast cancer have focused mainly on IDBC (Cancer Genome 
Atlas, 2012; Curtis et al., 2012). 
 
In the first breast cancer study by The Cancer Genome Atlas (TCGA) where 466 
breast tumours were assessed by whole-exome sequencing, only 8% (36/466) of all breast 
cancer cases were ILBC (Cancer Genome Atlas, 2012). Additionally, the analysis was 
mainly focused within the context of the gene expression-based breast cancer subtypes 
and the histological subtype-specific differences were not investigated (Cancer Genome 
Atlas, 2012). Somatic variants in CDH1 and HER2 were the only genetic alterations noted 
in ILBC tumours in this study (Cancer Genome Atlas, 2012). Another recent study 
profiled 2,433 primary breast tumours using targeted sequencing of 173 genes (Pereira et 
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al., 2016). ILBC represented 8% (194/2,433) of the total sample size and again 
inactivating variants in CDH1 (observed in 53% of the ILBCs) and PIK3CA (observed in 
47% of the ILBCs), were the only somatic alterations reported in the context of ILBC 
(Pereira et al., 2016). Mutational processes active in breast tumours were investigated via 
a somatic whole-genome sequencing study that involved 560 breast cancer samples, 
including 32/560 (6%) of classic ILBCs and 6/560 (1%) of pleomorphic ILBC cases. 
Although ILBC represented 7% of the sample size, the study was not focused on pointing 
out the histological differences in mutational processes (Nik-Zainal et al., 2016). 
 
In recent years, a number of studies have investigated the somatic mutation profile 
of ILBC tumours and reported the frequently mutated genes (Ciriello et al., 2015; 
Desmedt et al., 2016; Michaut et al., 2016). By comparing the somatic genetic alterations 
in IDBC and ILBC, TCGA investigators have presented the genetic events specific to 
ILBC initiation and progression and the differentiating genetic events between ILBC and 
IDBC has also been highlighted in this study (Ciriello et al., 2015). The most recurrent 
somatic variants and copy number alterations observed in ILBC are summarised in Table 
1.1 and reviewed in detail in the following sections.
Chapter 1 
 32 
Table 1.1: Recurrent* somatic mutations and copy number alterations reported in ILBC. 
Study (Ciriello et al., 2015) (Desmedt et al., 2016) (Michaut et al., 2016) 
(Zhu et al., 
2018) 
(Rosa-Rosa et al., 
2019) 




Expression arrays, DNA 
methylation, SNP arrays, 





Targeted sequencing (613 protein kinases 
and cancer related genes), CNA (SNP6 
array), Gene expression (DNA 





(34 genes), Targeted 







mixed IDBC/ILBC (n=88) 
ILBC (n=413) ILBC (n=144) Pleomorphic 
ILBC (n=17) 





Gene Somatic mutation frequency (% cases) 
CDH1 63% 65% 43% 59% 89% NR 
PIK3CA 48% 43% 35% 53% 33% NR 
PTEN 8% 4% 1% 0% NR NR 
TP53 8% 7% 4% 12% 19% NR 
TBX3 9% 13% NR 24% 7% NR 
FOXA1 7% 9% NR 6% NR NR 
MAP3K1 6% 5% 5% 35% 19% NR 
AKT1 2% 4% 5% 6% 7% NR 
RUNX1 10% 3% NR  12% NR NR 
GATA3 5% 7% 5% 6% 7% NR 
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 Deletion. n.s: not significant. NR: Not reported. * Recurrent somatic mutations and CNAs were determined using different methods in different studies. MutSigCV2 
for somatic mutation and GISTIC for CNAs was used by (Ciriello et al., 2015); Somatic mutation obsereved in at least 2% of the cases and CNAs in at least 5% of the cases were defined as 
recurrent alterations by (Desmedt et al., 2016); Binomial test based P-value for somatic mutation and ADMIRE tool for CNAs was used by (Michaut et al., 2016); (Zhu et al., 2018) and (Rosa-
Rosa et al., 2019) reported the total somatic mutations and CNAs;  CN>= 5 (amplification), CN<5 (no amplification) were the cut-offs used by (L Cao et al., 2019).
ERBB2 4% 5% 4% 18% 26% NR 
ERBB3 n. s 4% 3% 24% NR NR 
KMT2C n. s 8% NR 35% 19% NR 
ARID1A n. s 6% NR 6% 15% NR 
BRCA2 n. s 2% 4% 0% 4% NR 
Gene Frequent copy number alterations (% cases) 
ESR1 ampa NR 25% NR NR NR 24% 
ERBB2 ampa 7% 0% 4% 6% 4% 19% 
CDH1 delb 89% 94% NR NR NR NR 
MDM4 ampa NR NR NR NR NR 17% 
ARID1A delb NR 23% NR NR NR NR 
CCND1 ampa 17% 38% 15% 12% 11% 33% 
MYC ampa NR 31% NR NR NR 17% 
IGF1R ampa NR 31% NR NR NR n. s 
FGFR1 ampa 9% 25% 8% NR 7% n. s 
TBX3 NR 19% NR NR NR NR 
PTK2 delb NR 18% NR NR NR NR 
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1.5.4.1 Loss of e-cadherin (CDH1) is the hallmark of ILBC 
E-cadherin is a transmembrane glycoprotein, encoded by the CDH1 gene that 
mediates cell-cell adhesion in epithelial tissues (Takeichi, 1991). A complete loss of e-
cadherin protein expression has been observed in ~90% of ILBC tumours (Reed et al., 
2015). 
CDH1 has been reported to be the most recurrently mutated gene in ILBC, with 
studies reporting 50-65% of ILBC cases harbouring somatic variants in this gene (Ciriello 
et al., 2015; Desmedt et al., 2016; Michaut et al., 2016) (Table 1.1). These studies also 
reported a loss of heterozygosity (LOH) at CDH1 in nearly all the cases. Comparing the 
somatic profiles of luminal A ILBC (n=106) and luminal A IDBC (n=201), TCGA 
investigators found a significant enrichment for CDH1 variants in luminal A ILBC (63% 
ILBC versus 2% IDBC, MutSigCV2, q-value = 1.4x10-30) (Ciriello et al., 2015). These 
somatic variants were found to be uniformly distributed along the CDH1 coding region 
and were mostly (83%) truncating (Ciriello et al., 2015). A heterozygous loss of CDH1 
was observed in 89% of the ILBC cases and it was associated with a downregulation of 
CDH1 mRNA and protein expression levels (Ciriello et al., 2015).  
 
Michaut et al., (2016) reported somatic variants in CDH1 in 43% of 144 ILBC 
cases and a significant reduction in mRNA (Wilcoxon, P-value = 2.4x10-5) and protein 
(Wilcoxon, P-value = 8.9x10-4) levels were also reported in CDH1 mutant samples. 
However, reduction in mRNA and protein expression levels were also observed in some 
ILBC cases that had no somatic inactivating variants in CDH1 (Michaut et al., 2016). An 
insensitive variant detection that led to a false negative finding could be one of the 
explanations in this case. Other possibility could be the existence of other mechanisms 
than somatic genetic alterations for CDH1 silencing including promoter 
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hypermethylation as proposed before (Droufakou et al., 2001). However, DNA 
methylation changes were not reported in this study to confirm this hypothesis (Michaut 
et al., 2016). While previous studies have shown promoter hypermethylation associated 
silencing of CDH1 in ILBC tumours (Droufakou et al., 2001; Sarrió et al., 2003), recent 
methylation profiling by TCGA investigators did not identify CDH1 promoter 
methylation in any of the ILBC cases in their study (Ciriello et al., 2015). 
 
Despite being the most commonly mutated gene in ILBC, the role of CDH1 
alterations alone as an ILBC driving event is not convincing. Derksen et al., (2006) using 
conditional CDH1 gene inactivation in a mouse tumour model demonstrated that 
combined loss of e-cadherin and p53, but not e-cadherin alone resulted in tumour 
formation in the mice (Derksen et al., 2006). In agreement with this, Pereira et al., (2016), 
investigating the somatic mutation profiles of 2,433 breast cancers including 194 ILBC 
cases, found a significant pattern of co-mutations in women with breast cancer between 
CDH1 and other genes such as PIK3CA (OR = 2.1, 95% CI: 1.6-2.9), TBX3 (OR = 3.2, 
95% CI: 1.7-5.7), RUNX1 (OR = 3.3, 95% CI: 1.5-6.6) and ERBB2 (OR = 5.7, 95% CI: 
2.7-12), suggesting that CDH1 inactivation together with other genes may play a role in 
ILBC initiation and development (Pereira et al., 2016). 
 
Loss of e-cadherin may be associated with the characteristic discohesive growth 
pattern of ILBC considering the important role of e-cadherin in cell-cell adhesion. It has 
also been postulated that CDH1 loss may have a role in the peculiar metastatic pattern of 
ILBC again due to its crucial role of cell adhesion (Desmedt et al., 2017). Desmedt et al., 
(2016) found an enrichment of CDH1 variants in multifocal lobular cases compared with 
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unifocal, suggesting that the loss of e-cadherin might be linked to a tendency of 
discohesive cells to spread in the breast stroma (Desmedt et al., 2016). 
1.5.4.2 Mutations in key genes of PI3K-AKT signalling pathway 
The key genes (PIK3CA, PTEN and AKT1) in the phosphatidylinositol 3-kinase 
(PI3K)/Akt pathway have been reported to be commonly mutated in ILBC (Ciriello et al., 
2015; Desmedt et al., 2016; Michaut et al., 2016). The PI3K/Akt pathway regulates many 
cellular functions related to cell growth, proliferation and survival (Bader et al., 2005). 
 
Somatic variants in PIK3CA represent the second most frequent somatic 
alterations in ILBC after CDH1, reported in 30-50% of all cases (Ciriello et al., 2015; 
Desmedt et al., 2016; Michaut et al., 2016) (Table 1.1). Somatic variants targeting 
PIK3CA were found to be mainly missense variants and commonly associated with less 
proliferative tumours (defined by ki-67) (Desmedt et al., 2016). Somatic alterations at 
PTEN (LOH and somatic variants) have been reported in up to 14% of all ILBC cases, 
whereas somatic variants in AKT1 have been reported in up to 3% of all cases in different 
studies (Ciriello et al., 2015; Desmedt et al., 2016). An association between somatic 
variants at AKT1 and increased risk of early relapse has been reported (Desmedt et al., 
2016). Notably, somatic alteration at PIK3CA, PTEN and AKT1 were reported to be 
mutually exclusive to each other, suggesting that each of these genes may be supporting 
tumour growth and progression independently (Ciriello et al., 2015; Desmedt et al., 
2016). 
TCGA investigators reported a significantly higher mutation frequency at 
PIK3CA in ILBC cases in comparison with IDBC (48% of 127 ILBCs versus 33% of 490 
IDBCs, MutSigCV2, q-value = 0.02). However, this difference was not significant when 
luminal A ILBC and luminal A IDBC were compared (Ciriello et al., 2015). Inactivation 
Chapter 1 
 37 
of PTEN (by homozygous deletion and somatic pathogenic variants) has been reported as 
a strong discriminating feature, after CDH1 inactivation, between luminal A ILBC and 
luminal A IDBC, with a significantly higher frequency of PTEN inactivation observed in 
luminal A ILBC (14% of 106 luminal A ILBCs versus 3% of 201 luminal A IDBCs, 
MutSigCV2, q-value = 9x104) (Ciriello et al., 2015). A significant reduction (P-value = 
4x10-4) in PTEN protein expression was also reported in luminal A ILBCs, as measured 
by reverse-phase protein assay (Ciriello et al., 2015). Together, these somatic alterations 
in PIK3CA, PTEN and AKT1 led to a significant upregulation of PI3K/Akt pathway-
related proteins and phospho-proteins and an activation of PI3K/Akt pathway in ILBC 
tumours was observed in 45% of the cases (Ciriello et al., 2015). 
 
Findings from these studies suggest that PI3K/Akt signalling is commonly 
disrupted in ILBC suggesting its possibly crucial role in ILBC development. Treatment 
options targeting PI3K/Akt signalling pathway have been an active area of clinical 
research and could be a possible treatment option for ILBC tumours (Hosford & Miller, 
2014; Klarenbeek et al., 2020). 
1.5.4.3 Mutations in transcriptional regulators 
FOXA1 and GATA3 are key regulators involved in the transcription regulation 
activity of the ER. ER is the master transcriptional regulator in breast cancer and is 
encoded by the ESR1 gene (Y Zheng et al., 2016). As estrogen interacts with ERs, a 
transcription factor complex is formed that binds to specific sites on the DNA leading to 
gene activation (Hua et al., 2018). FOXA1 and GATA3, mediate the transcription factor 
complex formation and thus are critical in the transcription of ER regulated genes 
(Hurtado et al., 2011). 
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Somatic variants in FOXA1 have been reported in up to 9% of ILBC cases 
(Ciriello et al., 2015; Desmedt et al., 2016) (Table 1.1). Luminal A ILBC was found to 
be enriched for somatic variants in FOXA1 (7% of 106 luminal A ILBCs versus 2% of 
201 luminal A IDBCs, MutSigCV2, q-value = 0.08) in TCGA study (Ciriello et al., 2015). 
In ILBC, somatic variants in FOXA1 were found to be specifically localised in the fork 
head DNA binding and C terminus transactivation domains, whereas in IDBC the variants 
were found in other structural elements also, without any preference (Ciriello et al., 2015). 
In contrast, somatic variants in GATA3, another key ER modulator, were significantly 
lower in luminal A ILBC (5% of 106 luminal A ILBCs versus 20% of 201 luminal A 
IDBCs, MutSigCV2, q-value = 0.003) (Ciriello et al., 2015). A significant reduction in 
GATA3 mRNA (P-value = 0.007) and protein expression (P-value = 2x10-4) levels were 
reported in luminal A ILBC compared with luminal A IDBC and was proposed as another 
discriminatory feature between ILBC and IDBC. 
 
Other transcription regulators reported to be mutated in ILBC include TBX3, a T-
box gene family of transcription factors and chromatin regulatory factors, KMT2C and 
ARID1A. Somatic variants in TBX3 has been reported in 9-13% of ILBC cases (Ciriello 
et al., 2015; Desmedt et al., 2016) (Table 1.1). A significant enrichment for TBX3 variants 
was reported in ILBC in comparison with IDBC (9% of 127 ILBCs versus 2% of 490 
IDBCs, MutSigCV2, q-value = 0.003) and this difference remained significant when 
comparing luminal A ILBC and luminal A IDBC (q-value = 0.05) (Ciriello et al., 2015). 
Somatic variants in KMT2C and ARID1A was observed in up to 8% and 6% of the ILBC 
cases, respectively (Ciriello et al., 2015; Desmedt et al., 2016) (Table 1.1). 
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1.5.4.4 Other recurrent mutations in ILBC 
Somatic variants in ERBB2 and ERBB3 have been reported in up to 5% and 3% 
of ILBC cases, respectively (Ciriello et al., 2015; Desmedt et al., 2016; Michaut et al., 
2016) (Table 1.1). Variants in ERBB2 were more commonly observed in high-grade ILBC 
or the non-classic ILBC histological subtype (Desmedt et al., 2016; Zhu et al., 2018; 
Rosa-Rosa et al., 2019). A significantly higher frequency of ERBB2 variants was reported 
in pleomorphic ILBC compared with classic ILBC (21% of 21 pleomorphic ILBCs versus 
2% of 49 classic ILBCs, P-value = 0.013) (Lien et al., 2015). In another study, Rosa-Rosa 
et al., (2019) reported ERBB2 variants in 26% of 27 high-grade ILBCs with pleomorphic 
features. 
It has been shown that CDH1 mutated ILBC cases that also harbour variants in 
ERBB2, showed a significantly worse survival compared with CDH1 mutated ILBC cases 
without ERBB2 variants (Log-rank test, DFS, P-value = 0.003, overall survival P-value 
= 0.0003) (Ping et al., 2016). This may suggest that CDH1 and ERBB2 may work 
synergistically to promote ILBC tumourigenesis as similarly shown for tumours with 
variants at CDH1 and PTEN (Derksen et al., 2006). A significant pairwise interaction 
(OR= 5.7, 95% CI: 2.7-12) between variants in ERBB2 and CDH1 has also been observed 
(Pereira et al., 2016). Furthermore, relapsed cases of ILBCs have been found to be 
enriched for ERBB2 genomic alterations, with a study reporting 86% of 22 relapsed ILBC 
cases harbouring at least one actionable alteration in ERBB2 (somatic variant, gene 
fusion, amplification) suggesting a possible role of ERBB2 in ILBC progression (Ross et 
al., 2013). This study further confirmed the enrichment of ERBB2 somatic variants or 
gene fusion in CDH1-mutated ILBC cases (23% of 22 CDH1-mutated ILBCs) compared 
with ILBC tumours harbouring no variants in CDH1 (2% of 286 ILBCs with no CDH1 
variants, P-value = 0.0006) (Ross et al., 2013). 
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These finding points towards an active functional interaction between CDH1 and 
ERBB2 in ILBC tumourigenesis. The high frequency of ERBB2 alterations in high-grade 
ILBCs and relapsed ILBC cases suggests its potential role in providing a growth 
advantage to the tumour. Therapy options targeting ERBB2/ERBB3 could benefit a subset 
of ILBC and needs further exploration (Ben-Baruch et al., 2015; Bidard et al., 2015). 
1.5.4.5 Recurrent copy number alterations in ILBC 
Although ILBC frequently harbour somatic variants at specific sets of genes, this 
tumour type is known to have typically less extensive chromosomal changes compared 
with IDBC (Reed et al., 2015). 
 
CDH1 deletion has been reported to be a common event in ILBC tumours. 
Desmedt et al., (2016) reported arm-level and focal alterations at CDH1 in 94% of 170 
ILBC cases and a loss of e-cadherin expression was confirmed in 85% of the subset of 
cases for which IHC staining was available (156/170, 92%). A more frequent reduction 
in e-cadherin expression was reported in the tumours harbouring both CDH1 somatic 
inactivating variants and deletions compared with the tumours that retained at least one 
intact copy of the gene (P-value < 0.001) (Desmedt et al., 2016). A similar finding has 
been reported in TCGA study where a heterozygous loss of CDH1 locus (16q) was 
reported in 89% of 127 ILBC cases (Ciriello et al., 2015). 
 
Apart from CDH1, copy number gains at ESR1 have been reported in up to 25% 
of ILBC cases (Desmedt et al., 2016; L Cao et al., 2019). Cao et al., (2019) observed 
ESR1 gains or amplifications in 24% of 70 ILBC samples that also showed a significantly 
high mRNA expression levels compared with the samples with normal copy number (P-
value= 0.001) (L Cao et al., 2019). A significant enrichment of ESR1 copy number gains 
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was observed in women who had subsequent recurrence compared with women that did 
not show recurrence (39% of 18 recurrent ILBCs versus 19% of 52 non-recurrent ILBCs, 
P-value = 0.047) (L Cao et al., 2019). 
 
Other common genomic alterations reported in ILBC include focal gains at 
CCND1 (11q13.3) observed in (38% of 170 ILBCs), MYC (8q24.21) (31% of 170 
ILBCs), IGF1R (15q26.3) (31% of 170 ILBCs), FGFR1 (8p11.23) (25% of 170 ILBCs), 
and TBX3 (12q24.21) (19% of 170 ILBCs) (Desmedt et al., 2016). Focal losses were 
reported in ARID1A (1p36.22) (23% of 170 ILBCs) and PTK2 (8q24.23) (18% of 170 
ILBCs) (Desmedt et al., 2016). A frequent amplification in MDM4 was observed in 17% 
of 70 ILBC cases (L Cao et al., 2019). MDM4 and CCND1 amplifications (33% of 70 
ILBCs) were found to be significantly correlated with their respective mRNA expression 
levels (MDM4, P-value = 0.02 and CCND1, P-value = 0.0004), whereas ERBB2 and MYC 
amplification (observed in 19% and 17% of 70 ILBCs, respectively) did not show a 
significant correlation with gene expression levels in ILBCs (ERBB2, P-value = 0.1 and 
MYC, P-value = 0.34) (L Cao et al., 2019). 
1.6 Epigenetic modifications and tumourigenesis 
The concept of epigenetics was first proposed by Conrad Waddington in 1939 
(Waddington & H, 1942). Epigenetics is defined as a reversible and mitotically heritable 
modification to the DNA that leads to changes in gene expression without changing the 
actual DNA sequence. 
 
DNA methylation is one of the most extensively studied epigenetic events in human 
cancers. It is a post-replication chemical modification of the DNA where, a methyl group 
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is added to the 5 prime cytosine located adjacent to a guanosine in a CpG dinucleotide 
(Bird, 1992). Most CpG dinucleotides are distributed throughout the human genome 
within repeat elements and transposons, whereas some are present in short dense clusters 
(200 bp-1000 bp) referred as CpG islands (Bird, 1992). CpG islands are mostly located 
at the transcription start site of human genes (Baylin, 2005). Approximately, half of all 
genes across the genome have CpG islands proximal to their promoter regions (near 5 
prime UTR and 1st exon) (Baylin, 2005). In some instances, CpG islands are also found 
in the gene body or 3 prime UTR region and these CpG islands, located in unusual sites, 
have been found to be more prone to methylation (Nguyen et al., 2001). 
 
During early embryogenesis, almost all methylation patterns from the paternal and 
maternal genomes are erased and a new pattern is established and maintained through cell 
divisions by the family of DNA methyltransferases (Smith et al., 2012). In a healthy cell, 
the genome-wide DNA methylation pattern has a bimodal distribution, which means that 
most of the CpG dinucleotides (~75%) within the repetitive elements and transposons are 
methylated, whereas those associated with the CpG islands within the gene promoter 
regions (<10%) are largely unmethylated (Bird, 2002). This pattern often becomes 
reversed during tumourigenesis and a global hypomethylation event together with 
hypermethylation of many tumour suppressor gene promoters is considered as a hallmark 
of cancer (Baylln et al., 1997). Global hypomethylation leads to genomic instability that 
promotes tumour progression (Kulis & Esteller, 2010). It has been shown that the levels 
of global hypomethylation progress throughout different stages of tumourigenesis (Fraga 
et al., 2004). On average, a tumour cell looses 20-30% of methylation compared with the 
adjacent normal cells and the level of global methylation reduction also varies between 
different tumour types (Ehrlich, 2000; Wilson et al., 2007). Breast cancer shows up to a 
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50% reduction in the total methylated CpG content compared to the adjacent normal 
epithelium (Wilson et al., 2007). In the past decade, numerous studies have investigated 
promoter hypermethylation landscape and suggested that unique CpG island 
hypermethylation profiles exist for specific tumour types (Costello et al., 2000; Esteller 
et al., 2001; James G. Herman & Baylin, 2003). 
1.7 DNA methylation in breast cancer 
Several factors contribute to the pathogenesis of breast cancer including DNA 
methylation (Widschwendter & Jones, 2002). DNA Methylation has been shown to be an 
early event in breast carcinogenesis, resulting in the activation of many oncogenes and 
silencing of tumour-suppressor genes, thus providing a growth advantage to the tumour 
cells (Evron et al., 2001; Widschwendter & Jones, 2002). There are several genes reported 
to be hypermethylated in breast cancer including genes involved in important cellular 
pathways such as cell cycle regulation (CDKN2A, CCND2) (Fackler et al., 2004; Radpour 
et al., 2009), DNA repair (BRCA1, GSTP1) (Radpour et al., 2009), metastasis (RASSF1A, 
RARβ2, TWIST and HIN1) (Fackler et al., 2004), cell adhesion (CDH1) (Caldeira et al., 
2006) and hormone-mediated cell signalling (ESR1, PGR) (Lapidus et al., 1996). 
Genome-wide hypomethylation is also frequently observed in breast cancers, and many 
genes have been reported to be hypomethylated including IL10 (Son et al., 2010), NAT1 
(SJ Kim et al., 2008), MDR1 (G Sharma et al., 2010), FEN1 (Singh et al., 2008), CDH3 
(Paredes et al., 2005), JAGGED1 and NOTCH1 (Y Cao et al., 2015). 
 
DNA methylation has been associated with clinicopathological features of the 
tumour such as tumour grade and tumour stage. Yan et al., (2000) showed that CpG island 
hypermethylation is related with histological grade in breast tumours with high grade 
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tumours showing an increased number of methylated CpG islands (PS Yan et al., 2000). 
Furthermore, different breast cancer subtypes have been shown to be associated with 
distinct DNA methylation pattern (Bediaga et al., 2010; Holm et al., 2010; Kamalakaran 
et al., 2011; Stefansson et al., 2015). Holm et al., (2010) using methylation levels of 807 
cancer-related genes in 189 breast cancer samples and four normal breast samples showed 
that the intrinsic subtypes display distinct methylation patterns. At the differentially 
methylated CpGs that corresponded to 163 genes, luminal B tumours were found to be 
the most and basal-like tumours were found to be the least frequently methylated (P-value 
= 2x10-7). Lee et al., (2010) assessing the methylation status in a panel of 10 gene in 57 
luminal, 24 HER2-enriched and 33 basal-like breast cancer showed that the median 
methylation levels of HIN1, RASSF1A and TWIST, and the average methylation ratio 
were significantly lower in basal-like subtype compared to luminal or HER2 subtypes. In 
contrast, BRCA1 methylation level was significantly higher in basal-like subtype than in 
luminal subtype (JS Lee et al., 2010; Stefansson et al., 2015). This suggests that DNA 
methylation may have a role in the breast cancer heterogeneity and the development of 
distinct breast cancer subtypes. 
1.7.1 DNA methylation as a biomarker for disease prognosis and 
treatment response 
DNA methylation signatures have emerged as an important tool for prognosis 
prediction as well as predicting treatment response in cancer (Mikeska et al., 2012; Hao 
et al., 2017; Leygo et al., 2017). 
 
The global DNA methylation pattern or methylation at a specific gene in tumours 
can be indicative of patient prognosis. Methylation at many gene promoters has been 
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suggested to have independent prognostic value in breast cancer including HOXA11 (Xia 
et al., 2017), ESR1 and PITX2 (Sheng et al., 2017), HOXD13 (Zhong et al., 2015) and 
CDH22 (Martín-Sánchez et al., 2017). BRCA1 promoter methylation has been shown to 
be significantly correlated with poor overall survival in women with breast cancer (pooled 
HR=1.38, 95% CI: 1.04-1.84) (Wu et al., 2013). Another study reported RASSF1 
promoter methylation to be significantly associated with poor prognosis (disease free 
survival, pooled HR = 2.54 (95% CI: 1.77-3.66) (Jiang et al., 2012). APC and p16 
promoter methylation have also been shown to predict disease outcome (X Xu et al., 
2010). Debouki-Joudi et al., (2017) evaluated APC promoter methylation in 91 sporadic 
and 44 familial breast cancer cases and found a similar frequency of APC promoter 
methylation across sporadic and familial breast cancer cases, (52% sporadic, and 54% 
familial cases). They found that in both sporadic and familial breast cancer cases, APC 
promoter hypermethylation was associated with aggressive tumour behaviour and poor 
survival (Debouki-Joudi et al., 2017). 
 
There has been a growing interest in identifying and utilising DNA methylation 
signatures to refine breast cancer molecular classification and improve the prognostic 
abilities in the clinical setting. Holm et al., (2010) showed that gene expression-based 
breast cancer subtypes had specific methylation profiles with luminal B and basal-like 
subtypes being the most and the least frequently methylated, respectively (Holm et al., 
2010). Another study, using DNA methylation levels at 3,869 CpG sites in 669 breast 
cancer samples, identified nine subgroups with significant difference in patient prognosis 
(Log-rank test, P-value < 0.004) (S Zhang et al., 2018). They identified further subgroups 
within the basal-like subtype with distinct methylation profiles with a significant 
difference in survival (Log-rank test, P-value < 0.04). They suggested that the 
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methylation-based subgroups were more elaborate compared with the gene expression-
based subtypes (S Zhang et al., 2018). Fleischer et. al., (2017), based on a hierarchical 
clustering of luminal A breast tumours using a DNA methylation signature (SAM40, that 
included 41 differentially methylated genes), further segregated luminal A tumours into 
two subgroups and found that the subgroup with low relative methylation showed a 
significantly better prognosis compared with the subgroup that had high relative 
methylation (Log-rank test, P-value = 0.001) (Fleischer et al., 2017). Another study, using 
data from TCGA, identified methylation sites including SOSTDC1, ESCO2, CDCA2, 
PTN, RGMA, KLK4 and CENPA that showed prognostic value in luminal breast cancer 
(Xiao et al., 2018). Specific to TNBCs, a study based on whole-genome methylation 
sequencing, stratified TNBCs into three methylation clusters with the hypomethylated 
cluster showing better prognosis compared with the other two highly methylated clusters 
(HR = 8.64, P-value = 0.005) (Stirzaker et al., 2015). 
 
Global changes in DNA methylation patterns and their association with breast 
cancer therapies holds a great potential in predicting treatment response and identifying 
more relevant treatment subgroups. A growing number of large-scale methylation studies 
are investigating this in breast cancer. Martens et al., (2005) investigated the promoter 
methylation status of 117 genes in 200 hormone receptor positive tumours in women who 
received the antiestrogen tamoxifen as first line of treatment for recurrent breast cancer 
and identified 10 genes for which promoter methylation was significantly correlated with 
clinical benefit to antiestrogen therapy with the strongest being for PSAT1 (P-value < 
0.0001) (Martens et al., 2005). In tamoxifen-treated, hormone receptor positive, lymph 
node negative breast cancers, PITX2 promoter methylation was associated with increased 
risk of recurrence (HR= 2.75, 95% CI: 1.40-5.41) (Harbeck et al., 2008). PITX2 promoter 
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methylation was associated with poor patient outcome in breast cancer patients treated 
with anthracycline-based adjuvant chemotherapy (HR=1.46, 95%CI: 1.05-2.01) 
(Nimmrich et al., 2008). BRCA1 promoter methylation has been shown to be an 
independent favourable predictor of disease free survival and disease specific survival in 
women with TNBC who received adjuvant chemotherapy (HR, disease free survival= 
0.45, 95% CI: 0.24-0.84, P-value= 0.02; HR, disease specific survival = 0.43, 95% CI: 
0.19-0.95, P-value= 0.04) (Y Xu et al., 2013). 
 
Taken together, these studies clearly demonstrate that DNA methylation 
signatures could be a valuable tool in clinical settings for refining breast cancer 
prognostication and management. 
1.8 DNA methylation alterations in ILBC 
Tumour DNA methylation has been shown to have great potential for refining 
breast cancer classification and also have predictive value for disease prognosis and 
therapy response (as reviewed in section 1.7.1). However, DNA methylation alterations 
associated with ILBC initiation and progression has not been studied adequately. Most 
studies focusing on ILBC specific methylation alterations have primarily investigated a 
set of specific candidate genes as summarised in Table 1.2 and data on genome-wide 




Table 1.2: Previous studies investigating the DNA methylation pattern in ILBC. 
Study Gene promoter Sample Assay Finding 
(Droufakou et al., 2001) CDH1 ILBC (n=22) Methylation 
specific PCR 
- CDH1 promoter methylation in 77% of ILBCs, of which 65% were 
negative for e-cadherin negative (measured by IHC). 




- DAPK1 promoter methylation in 53% of ILBCs and 9% of IDBCs. 
(Sarrió et al., 2003) CDH1, APC, 
CTNNB1 
ILBC (n=46) Methylation 
specific PCR 
- CDH1 promoter methylation in 41% of ILBCs. 
- APC promoter methylation in 56% of ILBCs. 
(Fackler et al., 2003) RASSF1, HIN-1,  
RAR- β, Cyclin- D2, 
TWIST 
ILBC (n=19)  





- Similar methylation profiles of ILBCs and IDBCs with respect for 
RASSF1, HIN1, RAR- β and Cyclin- D2. 
- TWIST1 promoter methylation in 16% of ILBCs and 56% of IDBCs. 
(Bae et al., 2004) 12 genes- RAR- β, 
Cyclin- D2, TWIST, 










- ILBCs and mucinous breast cancer samples showed relatively higher 
frequencies of methylation compared with IDBC (49% in ILBCs and 
mucinous versus 40% in IDBCs). 
- BRCA1 promoter methylation in 92% of mucinous breast cancer, 39% 
of ILBCs and 28% of IDBCs. 








- SFRP1 promoter methylation in 33% of ILBCs and 68% of IDBCs. 





- CDH1 promoter methylation in 80% of ILBCs and 73% of IDBCs. 




- ADAM33 promoter methylation in 76% ILBCs and 26% of IDBCs. 
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- CDH1 promoter methylation in 93% of ILBCs and all LCIS samples. 
(Tserga et al., 2012) DCR1, DAPK1, 
RASSF1A, DCR2, 
APC, MGMT, 












- MGMT promoter methylation in 11% of ILBC and 24% of IDBCs 
- GSTP1 promoter methylation in 11% of ILBCs and 21% of IDBCs  
- PTEN promoter methylation in 11% of ILBCs and 6% of IDBCs 
- APC promoter methylation in 75% of ILBCs and 55% of IDBCs 
- RASSF1 promoter methylation in 38% of ILBCs and 39% of IDBCs 
- DAPK1 promoter methylation in 50% of ILBCs and 39% of IDBCs 
- DCR1 promoter methylation in 63% of ILBCs and 35% of IDBCs 
(Medina-Jaime et al., 
2014) 




- Promoter methylation at ESR1 and PGR were found to be uncommon 
in ILBC and IDBC. 






MS-MLPA - Low TP73 and MLH1 promoter methylation and relatively high 
RASSF1A promoter methylation levels in pleomorphic ILBC 
compared with classic ILBC. 
- Low MLH1 and BRCA1 methylation levels in pleomorphic ILBC 
compared with IDBC 
- Pleomorphic ILBC and IDBC showed similar methylation patterns, 
while the methylation pattern of classic ILC was different. 
(Ciriello et al., 2015) Genome-wide DNA 
methylation 
ILBC (n=201) HM450K - No methylation at CDH1 gene promoter. 
- Promoter methylation at FOXA1 that correlated with reduction in 
gene expression. 










HM450K - ILBCs showed the highest methylation among the breast cancer types 
and had the lowest genetic instability (the number of copy number 
alteration, as measured by array-based comparative genomic 
hybridisation) 
- IDBCs with germline BRCA1 mutation showed the lowest levels of 
DNA methylation but the highest levels of genetic instability. 
- Strong evidence to support the existence of CpG Island Methylation 
Phenotype associated specifically with the ILBC type. 
ILBC: Invasive lobular breast cancer. IDBC: Invasive ductal breast cancer. LCIS: Lobular carcinoma in-situ. DCIS: Ductal carcinoma in-situ. HM450K: Illumina 
HumanMethylation 450K BeadChip array. MS-MLPA: Methylation-specific multiplex ligation-dependent probe amplification.
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Roessler et al. were the first study to perform genome-wide DNA methylation 
profiling of ILBC. They profiled ten ILBCs, ten sporadic IDBCs, ten IDBCs with a 
germline BRCA1 mutation and four normal breast tissues and investigated the existence 
of CpG island methylator phenotype in breast tumours. Based on the methylation level of 
seven genes (DNM3, mir129-2, PGLYRP2, PRKCB, RGS7, SHF and TACC1), they found 
that ILBC cases formed a distinct hypermethylation cluster with a subset of sporadic 
IDBCs while the BRCA1-mutated IDBC samples were found to cluster with the normal 
breast tissue. They also demonstrated that aberrant DNA hypermethylation was 
negatively correlated with the copy number alterations (as measured using array-based 
comparative genomic hybridisation), with BRCA1-mutated IDBC tumours harbouring a 
higher number of genomic alterations (mean = 125) compared with the ILBC tumours 
(mean = 11). This study suggested a strong association of CpG island methylator 
phenotype with the lobular phenotype. However, no further ILBC-associated DNA 
methylation alterations were reported (Roessler et al., 2015). 
 
Considering the high frequency of CDH1 somatic mutations in ILBC, CDH1 
promoter methylation has been most extensively investigated in ILBC (Droufakou et al., 
2001; Sarrió et al., 2003; Bae et al., 2004; Caldeira et al., 2006; Zou et al., 2009b). Zou 
et al., (2009) demonstrated that CDH1 promoter hypermethylation is an early event in 
ILBC tumourigenesis as it was observed in all 13 LCIS cases in the study, whereas 93% 
of 14 ILBC cases showed CDH1 promoter methylation (Zou et al., 2009a). Droufakou et 
al., (2001) reported CDH1 promoter methylation in 77% of 22 ILBC cases, of which 65% 
showed downregulation of e-cadherin protein (as measured by IHC). Caldeira et al., 
(2006) reported CDH1 promoter methylation in 73% of 77 IDBC samples and 80% of 5 
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ILBC samples. This suggests that CDH1 promoter methylation may not be an exclusive 
event in ILBC tumourigenesis. 
 
Several studies have reported genes that showed differential methylation between 
ILBC and other breast cancer subtypes (Table 1.2). TWIST, a transcription factor involved 
in early development, was found to be less frequently hypermethylated in ILBCs 
compared with IDBCs (16% of 19 ILBCs versus 56% of 27 IDBCs, P-value =0.01) 
(Fackler et al., 2003). A significant difference in DAPK1 promoter methylation between 
ILBC and IDBC has been reported in another study where they noted promoter 
hypermethylation in 53% of 19 ILBC samples compared with 9% of 85 IDBC samples, 
P-value < 0.001) (Lehmann et al., 2002). They also found that DAPK1 promoter 
hypermethylation significantly correlated with loss of mRNA expression (as measured 
by quantitative RT-qPCR), ER positive tumours and absence of TP53 overexpression (P-
value < 0.001). They suggested a possible role of DAPK1 in tumour progression as no 
promoter hypermethylation was observed in the LCIS samples (Lehmann et al., 2002). 
Furthermore, promoter hypermethylation of ADAM33 has been shown to be more 
frequently methylated in ILBCs compared with IDBCs (76% of 21 ILBCs versus 26% of 
51 IDBCs, P-value= 0.0002) and a reduction in gene expression was also observed in 
hypermethylated samples (using RT-PCR) (Seniski et al., 2009). In an attempt to 
investigate the DNA methylation profiles of different breast cancer histological types, 
Bae et. al., (2004) compared the DNA methylation profiles of ILBC, IDBC and mucinous 
breast cancer samples across a set of 12 genes and found that ILBC and mucinous breast 
cancer samples showed relatively higher frequencies of hypermethylation compared with 
IDBC samples (49% of 19 ILBCs, 49% of 30 mucinous breast cancer versus 40% of 60 
IDBCs). They also found that BRCA1 showed significantly different methylation 
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frequencies between the breast cancer subtypes with 92% of mucinous breast cancer 
showing BRCA1 promoter hypermethylation compared with 39% of ILBC and 28% of 
IDBC samples (P <0.001) (Bae et al., 2004). 
 
Recently, TCGA profiled 201 ILBC tumours at different molecular levels that also 
included genome-wide DNA methylation. However, the analysis of the study mainly 
focused on the somatic mutation profile of ILBC. Recurrently altered genes in ILBC were 
discussed in detail while little emphasis was given on the methylation data. They only 
reported the promoter methylation status at two genes, CDH1 and FOXA1. Whilst no 
CDH1 promoter hypermethylation was reported in ILBC samples, FOXA1 showed 
promoter methylation at the binding site and it was found to be negatively correlated with 
the gene expression (Ciriello et al., 2015). 
 
These findings suggest that ILBCs display a different DNA methylation profile 
compared to other breast cancer types across several genes that could impact gene 
expression. One common limitation of most of the above-reviewed studies is the small 
sample size that makes them underpowered. Additionally, many of these studies have 
been based on candidate gene approaches and have investigated methylation status at a 
specific gene promoter or a panel of gene promoters. This limits the analysis to confined 
regions of the genome. A genome-wide analysis of DNA methylation alterations may 





1.9 Statement of problem, hypothesis and aims 
This review has discussed ILBC as a distinct and heterogeneous breast cancer 
subtype, focusing on its clinical behaviour and the key genetic and epigenetic (DNA 
methylation) alterations in ILBC tumourigenesis and progression. Recent studies have 
shown that ILBC has distinct genomic features compared with IDBC. Somatic genetic 
alterations (somatic variants and LOH) targeting CDH1 have been recognised as the most 
frequent and prevalent alterations in ILBC tumours with ~90% of ILBC showing a 
complete loss of e-cadherin. Somatic variants in other genes such as PIK3CA (a key gene 
in the PI3K/Akt signalling pathway), FOXA1 and TBX3 have also been more commonly 
observed in ILBC tumours compared with IDBC. Inactivating genomic alterations 
including somatic variants and homozygous losses of the PTEN locus are another 
discriminating feature between ILBC and IDBC being more frequent in ILBC. ILBC also 
shows within-subtype heterogeneity with somatic variants in genes such as TP53, HER2 
and HER3 being more commonly observed in the solid and pleomorphic ILBC 
histological subtypes. 
 
Current breast cancer studies have demonstrated the existence of further subgroups 
within the gene expression-based subtypes with significant difference in prognosis. 
Tumour DNA methylation has been shown to have great potential for further refining 
breast cancer classification. However, data on DNA methylation alterations specific to 
ILBC initiation and progression is limited. 
 
Despite having a distinct clinical behaviour, molecular profile, patient outcome and 
response to therapy, ILBC does not yet have any specific treatment regimen. Investigation 
of genome-wide DNA methylation may further improve our understanding of ILBC. A 
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combined genomic (somatic whole-exome sequencing) and epigenomic (DNA 
methylation) approach may help refine the ILBC heterogeneity and identify subgroup-
specific prognostic markers and therapeutic targets that could improve precision medicine 
for ILBC. 
 
The hypotheses of this study are: 
1. ILBC tumours have a distinct genome-wide DNA methylation profile as compared to 
non-ILBC tumours. 
2. Genome-wide variation in DNA methylation patterns within ILBC reflect different 
tumour biologies and can be used as a prognostic biomarker. 
3. Homogeneous subgroups of ILBC may be identified using genetic and epigenetic 
data. 
These hypotheses have been addressed by the three main aims of this study. 
 
Aim I (Chapter 3): To investigate the genome-wide DNA methylation profiles of ILBC. 
Sub-aim i: To identify the differentially methylated regions between ILBC and non-
ILBC. 
Sub-aim ii: To identify the variably methylated regions across the ILBC methylome. 
Sub-aim iii: To assess the association between tumour methylation at the most variably 
methylated regions and overall survival for ILBC women. 
Aim II (Chapter 4): To use genome-wide DNA methylation data to subgroup ILBC. 




Chapter 2 Materials and Methods 
 
2.1 Study participants 
This study included 502 invasive breast cancer cases classified as invasive lobular 
breast cancers (ILBCs, n=161) and non-lobular invasive breast cancers (non-ILBCs, 
n=341), based on the International Classification of Diseases for Oncology (ICD-O) code 
(World Health Organization et al., 2000) registered for each case on the Victorian Cancer 
Registry, Cancer Council Victoria (Victorian Cancer Registry, 2020) and confirmed by 
expert Pathological review. The non-ILBC cases in this study were predominantly (91%) 
invasive ductal breast cancers (IDBCs), ICD-O code-8500. The clinical and pathological 
features of the study participants are summarised in Table 2.1. Matching adjacent normal 
breast tissue samples were available for 13 breast cancer cases as previously described in 














Table 2.1: Clinical and pathological features of the study participants. 
Sample characteristics ILBC (n=151) non-ILBC (n=341) P-value* 
Median age at cancer diagnosis, 
years [interquartile range] 
65 [25%; 57] 64 [25%; 58] 0.99 


































































































































Median tumour purity, % 
[interquartile range] 





































































ILBC: Invasive lobular breast cancer. non-ILBC: non-lobular invasive breast cancer. * P-values 
are for chi-square test and T.test for categorical and continuous variables, respectively. † Data not 
available a The Melbourne Collaborative Cohort Study. b The Kathleen Cuningham Foundation 
Consortium for Research into Familial Breast Cancer. c Australian Breast Cancer Family Registry. 
d International Classification of Diseases for Oncology cancer code (8500-Invasive ductal breast 
cancer; 8520-Invasive lobular breast cancer; 8522-Infiltrating ductal and lobular carcinoma; 
8211-Tubular carcinoma). ER: Estrogen receptor, PR: Progesterone receptor, HER2: Human 
epidermal growth factor receptor 2. The ER, PR and HER2 expression status were measured using 
immunohistochemistry as described (Blows et al., 2010).e Molecular subtypes were defined using 
definition reported by the St Gallen International Expert Consensus as: Luminal A: ER and/or PR 
positive and HER2 negative; Luminal B: ER and/or PR positive and HER2 positive; HER2 type: 
ER and PR negative and HER2 positive and Triple negative: ER negative, PR negative and HER 












The breast cancer samples were sourced from three well-characterised Australian 
studies: Melbourne Collaborative Cohort Study (MCCS) (R Milne et al., 2017), 
Australian Breast Cancer Family Registry (ABCFR) (John et al., 2004) and The Kathleen 
Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) 
(Mann et al., 2006). Study designs and the data collection methods of the three studies 
are presented in detail in the sections below. 
2.1.1 The Melbourne Collaborative Cohort Study 
The Melbourne Collaborative Cohort Study (MCCS) is one of the largest 
prospective cohort studies conducted in Australia (R Milne et al., 2017). It was set up in 
1990 to prospectively investigate the role of diet and other lifestyle factors in the 
predisposition of cancer mainly in prostate cancer, breast cancer and bowel cancer. 
Between 1990 and 1994, 41,513 people aged between 40-69 years were recruited to this 
study. All participants were of white European origin; 69% born in Australia or New 
Zealand, 13% born in Italy, 11% in Greece and 6% in the UK. 
 
Baseline information in the MCCS was collected by interviewer-administered 
questionnaires on lifestyle, personal medical history and medications taken. A self-
administered questionnaire on diet was also filled by the participants. Blood samples were 
collected from 41,133 participants. Plasma, peripheral blood mononuclear cells and buffy 
coats were separated and stored in liquid nitrogen. From the second year of recruitment, 
dried blood spots were stored on Guthrie Cards (GCs). Formalin-fixed paraffin-embedded 
(FFPE) tissue was collected from 3,070 tumours diagnosed in cohort participants, the 
majority being breast, colorectal and prostate cancers (R Milne et al., 2017). 
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The first follow-up occurred between 1995 and 1998, around four years after 
recruitment where information on lifestyle, medical history and diet was collected. The 
second follow-up occurred between 2003 and 2007 where further blood samples were 
collected, and repeated measures of key lifestyle exposures were recorded. Since 2005, 
the participants are contacted every year for an update. Incidences of cancer cases and 
mortality were updated regularly by matching the study to the Victorian Cancer Registry, 
Cancer Council Victoria and death indices. 
2.1.2 The Kathleen Cuningham Foundation Consortium for Research 
into Familial Breast Cancer 
The Kathleen Cuningham Foundation Consortium for Research into Familial 
Breast Cancer (abbreviated to “kConFab”) is a familial breast cancer consortium, which 
was established in 1997 (Mann et al., 2006). Families with a strong history of breast and 
breast-ovarian cancers were recruited to the kConFab through Family Cancer Centres in 
Australia and New Zealand. 
 
As of 2018, 1,848 families were recruited to kConFab including 1,074 families 
with a strong history of breast cancer. All cancer cases reported in the family were verified 
with clinical pathology reports. Biological specimens (blood, normal and tumour tissues), 
family history, epidemiological, clinical and psychosocial data were collected from 
affected and unaffected female and male participants over 18 years of age. The blood 
samples collected were returned to the central core laboratory and processed following 
the standard protocol (kConFab biospecimen protocol). The normal and tumour tissue 
specimen were collected after surgery and dissected into 3 mm sections by a clinical 
pathologist. After initial assessment of the specimen, five 10 μm thick tissue sections 
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were stored in a cryovial for each sample in liquid nitrogen at the kConFab tissue bank. 
Details about the biological specimens and clinical data were stored in a de-identified 
central relational database which has been made available to peer-reviewed, ethically 
approved, and funded research projects both nationally and internationally. 
2.1.3 The Breast Cancer Family Registry 
The Breast Cancer Family Registry was established in 1995 by the National 
Cancer Institute (NCI, USA) (John et al., 2004). The participating institutes were from 
the USA, Canada and Australia and the families were recruited either directly by the 
cancer registries (population-based families) or from the clinics (clinic-based families). 
 
Australian Breast Cancer Family Registry (ABCFR) is a component of the BCFR 
carried out in Melbourne and Sydney, Australia (Hopper et al., 1994; McCredie et al., 
1998). It is a population-based case-control family study of breast cancer with an 
emphasis on early-onset disease. In this study, all adult women living in metropolitan 
Melbourne and Sydney who were diagnosed with a histologically confirmed primary 
breast cancer were invited to participate. Cases were identified by the use of the Victorian 
and New South Wales cancer registries, to which notification of cancer diagnosis is a 
legislative requirement. From 1992 to 1999 in Melbourne and from 1993 to 1998 in 
Sydney, women younger than 40 years at diagnosis were recruited to this study; after 
1996, random samples of women aged 40-49 years and 50-59 years at diagnosis were also 
selected. Eligible women were recruited irrespective of family history of breast cancer. 
 
Unaffected control subjects were randomly selected from general population 
living in Melbourne and Sydney using the electoral poll. A risk factor and family cancer 
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history questionnaire involving all known first- and second-degree relatives were 
completed by each participating case patients and control subjects. Blood and tumour 
specimen were collected from each affected woman. A risk factor and family cancer 
history questionnaire involving all known first- and second-degree relatives were 
completed by all participating case patients and control subjects. 
2.2 Study governance and data acquisition 
This project was formally approved via an application to the governance groups 
establish by each of the research resources included in these analyses. Clinical, 
pathological and epidemiological data was requested using a Data Request Form provided 
by each research resource. The following information was requested and made available: 
i) tumour details ii) breast cancer treatment and outcome data iii) immunohistochemical 
data related to the tumour iv) family history and v) lifestyle data. The data were obtained 
in a spreadsheet and a data dictionary was provided explaining the data fields. Data that 
were not available were marked as “Missing”. 
2.3 DNA extraction 
2.3.1 Formalin-fixed paraffin-embedded tumour tissue 
Tumour enriched DNA was prepared from formalin-fixed paraffin-embedded 
(FFPE) tumour tissue sections using the QIAamp DNA FFPE Tissue kit (Qiagen, 
Germany) following the manufacturer’s instructions. Areas enriched with tumour cells 
were marked up by a trained pathologist on the hematoxylin and eosin-stained slides by 
matching the section on the FFPE slide (10 μm thick). To remove the paraffin wax from 
the tumour tissues, the FFPE slides were repeatedly washed three times each with xylene 
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and 100% ethanol. The slides were washed briefly in 2 changes of distilled water and 
stained using 0.1% methyl green solution. 
 
The tumour-enriched area was macrodissected using a 21G needle (Terumo, 
Japan) and transferred to a 1.5 mL microfuge tube (Eppendorf, Germany) to which 180 
μl of ATL lysis buffer (Qiagen, Germany) and 20 μl of proteinase K (Sigma-Aldrich, 
Germany) were added and vortexed thoroughly. The mixture was incubated at 56°C for 
48 hours with intermittent vortex mixing. After incubation, the mixture was vortexed, 
briefly centrifuged and incubated at 90°C for 55 minutes. To the mixture, 200 μl of AL 
buffer and 200 μl of 100% ethanol were added and vortexed thoroughly to precipitate the 
DNA. The entire lysate was transferred to a QIAamp MinElute column (Qiagen, 
Germany) placed in a 2 ml collection tube (Qiagen, Germany) and centrifuged at 6000 
relative centrifugal force (rcf) for 1 minute. The flow through was discarded and DNA 
was washed using 500 μl of buffer AW1. Another wash was performed using 500 μl of 
AW2 buffer. The column was centrifuged at full speed for 3 minutes to completely dry 
the membrane. A triple elution was performed to elute the DNA whereby 30 μl of 
nuclease-free water were added and incubated at room temperature for 5 minutes. The 
column was centrifuged at full speed for 1 minute. DNA was stored long-term at 4°C in 
a microfuge tube. 
2.3.2 Guthrie Card 
DNA was extracted from archival dried blood spots using the QIamp Mini kit 
(Qiagen, Germany) using the manufacturer’s instructions with some modifications. 
Briefly, 10 circles of blood-stained Guthrie Card (GC) spots were punched using an 
ethanol-sterilised stainless-steel hole puncher. PBS (180 μl) and Protease (20 μl) (Qiagen, 
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Germany) were added to the GC punches in a 1.5 ml microfuge tube and mixed 
thoroughly by vortexing. The tube was mixed on a plate shaker for 20 minutes and 
incubated at 56°C overnight. After the overnight incubation, the tube was homogenised 
by a TissueLyser II (Qiagen, Germany) for 30 seconds at 25 l/s to lyse the GC spots with 
the tungsten bead. The tube was centrifuged at maximum speed for 1 minute to pellet the 
homogenised GC. The tungsten bead was removed carefully from the microfuge tube and 
the supernatant was separated from the mulched GC and collected into a clean microfuge 
tube. To the supernatant, 200 mL of AL buffer were added, and the mixture was incubated 
at 65°C for 20 minutes. To the mixture, 200 μl of 100% ethanol were added followed by 
a second incubation at room temperature for 30 minutes. The entire volume was 
transferred to a QIamp mini column (Qiagen, Germany) and centrifuged at 6000 rcf for 
30 seconds. The flow-through was discarded and two washes were performed using 500 
μl of AW1 and AW2 buffer. The column was centrifuged at 13,000 rcf for 5 minutes to 
remove any residual wash buffer and transferred to a clean microfuge tube. A double 
elution was performed whereby, 100 μl of nuclease-free water were added to the column 
and left for incubation at room temperature for 2-5 minutes and centrifuged at 6000 rcf 
for 3 minutes to elute the DNA. The elution step was repeated with 50 μl of nuclease-free 
water to obtain a final elution volume of 150 μl. The DNA was stored long-term at 4°C. 
2.4 DNA quantification using Qubit Assay 
DNA was quantified using the Qubit dsDNA broad-range (BR) assay (Thermo 
Fisher Scientific, USA) using the standard protocol. Prior to DNA quantification, all 
solutions were equilibrated to room temperature. A Qubit working solution was prepared 
using Qubit dsDNA BR reagent and Qubit dsDNA BR buffer (1:200). For each standard, 
190 μl of the working solution were added to 10 μl of the standard DNA. For each sample, 
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199 μl of the working solution were added to 1μl of sample DNA. The microcentrifuge 
tubes were mixed by vortexing for 10-15 seconds, spun down and incubated for 2 minutes 
at room temperature. The fluorometer was calibrated using standard 1 (0 ng/μl) and 
standard 2 (100 ng/μl). For each DNA sample, two replicate readings were taken using a 
fluorometer, and an average DNA concentration was calculated. 
2.5 Genome-wide DNA methylation profiling 
Genome-wide DNA methylation was measured using the Infinium 
HumanMethylation450K (HM450K) BeadChip assay as per the manufacturer’s 
instructions (Illumina, USA). Sample preparation for the HM450K assay was done 
following an in-house developed workflow (Wong et al., 2015) that included a novel 




Figure 2.1: Sample preparation workflow for the Illumina HumanMethylation 
450K BeadChip assay, adapted from (Wong et al., 2015). 
Flow chart illustrating the workflow for measuring the genome-wide tumour DNA 
methylation from formalin-fixed paraffin-embedded (FFPE) tumour derived DNA. 
Tumour DNA was first prepared by macrodissecting the tumour enriched area on the 
FFPE slide. The DNA was quantified using the Qubit dsDNA BR assay (QC checkpoint 
1) and the DNA quality was estimated using the Infinium HD FFPE QC qPCR assay (QC 
checkpoint 2). Tumour samples that passed the initial quality checks were proceeded to 
sodium bisulfite conversion and restoration. The restored DNA samples were assessed on 
a final QC, (Bisulfite specific qPCR) developed in-house (QC checkpoint 3). The samples 
that passed the final QC were proceeded to the HM450K assay. 
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2.5.1 Infinium HD FFPE QC qPCR assay 
To assess the quality of the DNA samples, a qPCR-based assay was performed 
prior to the HM450K methylation assay using Infinium HD FFPE QC Kit (Illumina, 
USA) according to the manufacturer’s instructions. Briefly, the DNA was diluted to 
1ng/μl and a 100-folds dilution of the QC Template was prepared using nuclease-free 
water. PCR reaction (10 μl) was prepared using the qPCR master mix and QC Primers. 
The following qPCR cycling program was used: initial incubation at 50°C for 2 minutes, 
enzyme activation at 95°C for 10 minutes, followed by 40 cycles of DNA denaturation at 
95°C for 30 seconds, primer annealing at 57°C for 30 seconds and extension at 72°C for 
90 seconds. All the samples were assayed in triplicate. The Cq values (number of 
quantification cycles) were obtained for each well and average Cq values were calculated 
for the DNA sample and the QC Template. ΔCq was calculated for all the sample DNA 
by subtracting the average Cq value for the QC Template from the average Cq value for 
the sample. Samples with ΔCq value ≤ 5 were proceeded to the next step. 
2.5.2 Sodium bisulfite conversion 
To differentiate the methylated cytosine from unmethylated cytosines, the tumour 
DNA was bisulfite converted prior to DNA methylation profiling. This process leads to 
the deamination of unmethylated cytosines to uracils, whereas the methylated cytosines 
remain unchanged (Figure 2.2). In subsequent PCR reaction, the uracils are amplified as 
thymines, whereas methylated cytosines get amplified as cytosines, thus the methylated 






Figure 2.2: Sodium bisulfite conversion (Zymo Research, USA) 
Graphics illustrating the process of sodium bisulfite conversion. “Template” in the 
diagram represents a DNA sequence before sodium bisulfite conversion and “Bisulfite 
Converted” represents the DNA sequence after sodium bisulfite conversion. A, T, G and 
C in the Template and Bisulfite Converted DNA represent the nucleotides adenine, 
thymine, guanosine and cytosine, respectively. Methylated cytosines are represented as 
“C” and unmethylated cytosines are represented as “C”. After bisulfite conversion of the 
template DNA, methylated cytosines remain as it is, whereas the unmethylated cytosines 




Up to 500 ng of tumour DNA was bisulfite converted using Zymo Gold EZ-DNA 
kit (Zymo Research, USA) following the manufacturer’s instructions. Briefly, 130 μl of 
CT Conversion Reagent were added to 20 μl of tumour DNA and mixed by pipetting. The 
mixture was incubated using the following protocol in a thermal cycler: 98°C for 10 
minutes, 64°C for 2.5 hours and a hold step at 4°C (for up to 20 hours). Following 
incubation, the total volume was transferred to a Zymo-Spin™ IC Column, placed into a 
collection tube containing 600 μl of M-binding buffer and mixed properly by inverting. 
The tube was centrifuged at full speed for 30 seconds and the flow through discarded. 
The Zymo-Spin™ IC Column was washed with 100 μl of M-wash buffer. To the column, 
200 μl of M-Desulphonation buffer were added and left to incubate at room temperature 
for 15-20 minutes. The column was washed twice using 200 μl of M-wash buffer and 
placed into a clean 1.5 ml microfuge tube. The bisulfite-converted DNA was eluted in M-
Elution Buffer. The bisulfite converted DNA was stored at -20 °C. 
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2.5.3 DNA restoration 
DNA restoration is carried out to repair the degraded FFPE DNA. For DNA 
restoration, the Infinium HD FFPE Restore kit (Illumina, USA) was used and the 
restoration was performed according to the manufacturer’s instructions. Briefly, to 8 μl 
of bisulfite converted tumour DNA, 4 mL of freshly prepared 0.1N NaOH were added 
and incubated at room temperature for 10 minutes. After incubation, 34 μl of Primer Pre-
Restore Reagent and 38 μl of Amp Mix Restore Reagent were added to the mixture and 
mixed thoroughly by inversion followed by a centrifuge at 280 rcf for 1 minute and an 
incubation at 37°C for 1 hour. After incubation, the mixture was centrifuged at 280 rcf 
for 1 minute and 7 volumes (560 μl) of Zymo DNA Binding Buffer were added to each 
volume of DNA and mixed by pipetting. The mixture was transferred to a Zymo-Spin™ 
I-96 Plate (Zymo Purification Kit) mounted on a collection plate and centrifuged at 2250 
rcf for 2 minutes and the flow through was discarded from the collection plate. The Zymo-
Spin I-96 plate was mounted on a new collection plate and to the DNA sample well, 600 
mL of Zymo Wash Buffer (with 100% ethanol added) was dispensed. The plate was 
centrifuged at 2250 rcf for 2 minutes and the flow through was discarded from the 
collection plate. A clean 0.8 ml 96-well plate was prepared with the Zymo-Spin I-96 plate 
mounted on it. To each sample well, 13 μl of Elution Restore Buffer Reagent were 
dispensed directly and the plate was incubated at room temperature for 5 minutes. The 
sample plate assembly was centrifuged at 2250 rcf for 1 minute to elute the DNA. The 
plate containing approximately 10 μl of eluted DNA was sealed with an adhesive foil seal 
and incubated for 2 minutes at 95°C on a heat block. Immediately after incubation, the 
sample plate was transferred to an ice bucket and incubated for 5 minutes (making sure 
that the bottom of the wells was in contact with ice). Keeping the sample plate on ice, 10 
μl of Convert Master Mix Reagent were added to each sample well and the plate was 
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vortexed for 1 minute at 1600 rpm and centrifuged at 280 rcf for 1 minute followed by an 
incubation at 37°C for 1 hour. After incubation, the plate was centrifuged at 280 rcf for 1 
minute and 7 volumes (140 μl) of Zymo DNA Binding Buffer were added to each volume 
of DNA in the sample plate. The sample mixture was mixed by pipetting and then 
transferred to another Zymo-Spin I-96 Plate mounted on a collection Plate. The Zymo-
Spin I-96 Plate was centrifuged at 2250 rcf for 2 minutes and the flow through in the 
collection plate was discarded. To the sample well of the Zymo-Spin I-96 Plate, 600 μl 
of Zymo Wash Buffer (with 100% ethanol added) were added and the assembly was again 
centrifuged at 2250 rcf for 2 minutes and the flow through discarded. A new 0.8 ml 96-
well microtiter plate was prepared, and the Zymo-Spin I-96 Plate was mounted on the 
sample plate. To each well of the Zymo-Spin I-96 Plate column matrix, 12 mL of 
nuclease-free water was dispensed directly, and the plate was incubated at room 
temperature for 5 minutes. After incubation, the plate assembly was centrifuged at 2250 
rcf for 1 minute to elute the DNA. 
2.5.4 Bisulfite specific qPCR 
After bisulfite conversion and restoration, the samples underwent a final quality 
check before the methylation assay. The QC was performed using bisulfite-specific PCR 
assay designed in-house (Wong et al., 2015). 
 
For the qPCR assay, bisulfite converted DNA specific Forward Primer: 5′ tAA 
GGT AtA ATt AGA GGA TGG GAG GGA t  and Reverse Primer: 5′ aaC AAA CTC 
Aaa TAa AAT TCT TCC TC were designed (Wong et al., 2015). Lower-case letters in 
the primer sequences correspond to bisulfite converted cytosines. The primers were 
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designed to amplify a 134 bp region (hg19: chr17:41,277,493-41,277,626) within the 
promoter of the BRCA1 gene (GenBank: L78833.1). 
 
For the assay, a 10 μl reaction was prepared using 5 μl FastStart SYBR Green dye 
(Roche Diagnostics, Switzerland), 0.3 μl each of forward and reverse primers (10μM) 
(Integrated DNA technologies, USA) and 3 μl of diluted restored bisulfite converted DNA 
(1:6 in nuclease-free water). The reaction volume was equilibrated to 10 μl with nuclease-
free water. A non-bisulfite converted; high molecular weight genomic DNA isolated from 
the U266 multiple myeloma cell line sourced from the Peter MacCallum Cancer Centre 
was used as a negative control. The following qPCR cycling conditions were used for the 
assay: initial polymerase activation at 95°C for 5 minutes followed by 40 cycles of DNA 
denaturation at 95°C for 10 seconds, primer annealing at 60°C for 30 seconds and 
extension at 72°C for 90 seconds. All the samples and controls were assayed in duplicate 
and the average Cq value (number of quantification cycle) was obtained for each sample. 
To determine the presence and bisulfite-conversion efficiency, ΔCq was calculated by 
subtracting the average Cq value for each sample DNA from the average Cq value of the 
negative control. Restored and bisulfite-converted tumour-derived DNA samples with a 
ΔCq value of ≥ 4 were progressed to the Infinium HM450K assay. 
2.5.5 Loading samples on the HM450K BeadChip 
The HM450K assay design included the following controls: i) the multiple 
myeloma cell line (U266) DNA that was included as an internal control and ii) one 
technical replicate from restored bisulfite converted FFPE tumour-enriched DNA to test 
for reproducibility. Each technical replicate was placed on a different BeadChip to test 
for possible effects on data generated on two different BeadChips. 
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Before loading the samples on the HM450K array, 4 μl of bisulfite converted and 
restored DNA sample were denatured by mixing with freshly prepared 0.1N NaOH and 
neutralized using the Random Primer Mix followed by an incubation for 20-24 hours at 
37°C where the denatured DNA was isothermally amplified. After 24 hours incubation, 
the amplified DNA was fragmented using a controlled enzymatic process. The 
fragmented DNA was precipitated using 100% 2-propanol and centrifuged at 3000 rcf at 
4°C for 20 minutes to collect the DNA. After centrifugation, the supernatant was 
discarded by inversion (taking care to not disturb the DNA pellet) and left uncovered and 
inverted on a tube rack for 1 hour at room temperature to air-dry the DNA pellet. 
 
The precipitated DNA was resuspended in 23 μl RA1 and incubated for 1 hour at 
48°C. The resuspended DNA was incubated at 95°C for 20 minutes to denature the DNA 
and then left at room temperature for 30 minutes to cool down. The BeadChips (Illumina, 
USA) were removed from 4°C storage and hybridisation chambers (Illumina, USA) were 
prepared as per manufacturer’s instructions. The BeadChip was placed in the 
hybridisation chamber insert containing 400 μl of humidifying buffer, PB2. Prior to 
loading the BeadChip, a sample sheet was prepared and BeadChip barcode and chip 
position was recorded for each sample. Using a multichannel pipette, 15 μl of each DNA 
sample were dispensed in the sample inlet on the BeadChip at assigned positions. The 
hybridisation chamber inserts containing the BeadChip was placed in the Illumina 
hybridisation chamber and incubated at 48°C in the Illumina Hybridisation Oven (with 
the rocker function on) for 20-24 hours. After incubation, the BeadChip was washed with 
PB1 to remove any unhybridized and non-specifically hybridised DNA. The flow-
through chamber assembly was prepared and proceeded to the extension and staining step 
which was performed on the TECAN liquid handler (Tecan, Switzerland). Post-staining 
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and extension, the BeadChip was washed with 310 ml of PB1 and 310 ml of XC4 and 
dried under vacuum (675 mm Hg) for 50-55 minutes. The underside of the beadchip was 
wiped to remove any excess XC4 and scanned on Illumina iScan. 
2.6 Methylation data pre-processing and normalisation 
Raw intensity files (.IDAT files) for all the samples were imported in the R 
programming software (version 3.6.1) using the Bioconductor package minfi (Aryee et 
al., 2014) and a standard workflow was followed for pre-processing and normalising the 




Figure 2.3: DNA methylation data pre-processing and normalisation workflow. 
Flowchart illustrating the DNA methylation data pre-processing and normalisation 
workflow. Intensity signals from both red and green channels were read from the raw 
intensity files (.IDAT files) and stored in a RGChannelSet object. Detection P-values 
were obtained, and poor-quality samples (detection P-value > 0.01) were removed from 
further analysis. The filtered RGChannelSet object was then normalised using the 
functional normalisation method. The normalised data stored in the MethylSet object was 
checked for poor quality probes and the probes with mean detection P-value > 0.05 were 
removed from further analysis. Filtered and normalised data were used to calculate the 
RatioSets (M values and beta-values) for the samples. The M values and beta-values were 
annotated to the hg19 human genome and were used for further analyses. 
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The data quality was first evaluated by assessing the detection P-value. Detection 
P-value is an indicative factor for the quality of the signals and in minfi, it is calculated 
by comparing the total signal (Methylated+Unmethylated) for each probe to the 
background signal level (estimated from the negative control probes). Samples with a 
mean detection P-value of more than 0.01 were deemed poor quality and were removed 
from further analysis. 
 
Functional normalisation (FNORM) method was used to normalise the methylation 
data. This normalisation method corrects for both within array (technical bias between 
type I and type II probes) as well as between array unwanted variations (Fortin et al., 
2014). It also applies a background adjustment method, “noob” that corrects for any dye-
bias (Triche et al., 2013). FNORM also corrects for potential batch effect and thus no 
further batch correction was performed on the data. After normalisation, CpG probes with 
a mean detection P-value of more than 0.05 in one or more samples were considered 
unreliable and were removed from further analyses. No further filtering was performed 
on the data. M-values and beta-values were calculated from the normalised and filtered 
data. For all statistical analyses, M-value was used and the beta-value was mainly used 
for data exploration and visualisation as suggested in (P Du et al., 2010). Methylation 
level (beta-value) of more than 0.50 was defined as hypermethylated and beta-value of 
less than 0.50 was defined as hypomethylated. 
2.7 Tumour purity estimation 
Tumour purity was estimated using the R tool InfiniumPurify  (Qin et al., 2018) that 
takes methylation beta-values of the tumour samples and uses the methylation levels of 
pre-selected informative differentially methylated CpG sites (iDMCs) identified from 
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TCGA data (when normal data is not available) to estimate tumour purity for each tumour 
sample by density evaluation of Gaussian kernel. Tumour purity estimate was obtained 
as the proportion of tumour cells in each sample. 
2.8 The Cancer Genome Atlas data 
Raw DNA methylation data (.IDAT files) for 659 breast cancer cases (168 ILBC 
and 491 IDBC), were downloaded from TCGA legacy database (Study Accession: 
phs000178) using the R package TCGABiolink (Colaprico et al., 2016). The methylation 
data was pre-processed and normalised similarly as the study set and methylation values 
(beta-values and M-values) were obtained for all cases at 440,380 CpG positions across 
the genome. Survival data was retrieved for 159/168 (95%) ILBC cases. Gene expression 
data in the form of normalised counts (RNA sequencing-Illumina Hi-Seq) was retrieved 
for 159/168 (95%) ILBC cases. 
2.9 Statistical analyses 
2.9.1 Differential methylation analysis 
Differentially methylated positions (DMPs) between the comparison groups were 
identified by a probe-wise differential methylation analysis using the Limma 
Bioconductor package (Smyth, 2005). A linear regression model was implemented on the 
M value matrix of the samples to obtain moderated t-statistics and associated P-values 
for each CpG position. The P-values were corrected for multiple testing using Bonferroni 




Differentially methylated regions (DMRs) were identified using the DMRcate 
package in R (Peters et al., 2015). To calculate the DMRs, a gaussian smoothing estimate 
was applied to group the adjacent DMPs within 1000 bp window. The smoothed test 
statistics was modelled using the Satterthwaite method and P-values were computed 
based on this model (Satterthwaite, 1946). The P-values were corrected using a fdr cut-
off of 0.01. The consecutive significant CpG sites (1000 bp from each other) were 
agglomerated together and the regions were defined as DMRs. 
2.9.2 Variable methylation analysis 
Variable methylation analysis was performed using the DMRcate (Peters et al., 
2015) package in R. To identify the variably methylated regions (VMRs), the variance of 
M values was computed across the samples and gaussian smoothing was applied to the 
resulting per-CpG-site test statistics using the default DMRcate options. DMRcate uses 
the method of Satterthwaite to smooth test statistics and derive respective P-values 
(Satterthwaite, 1946). Nearby significant CpG sites were collapsed in clusters using a 
bandwidth of 1000 bp. The clusters that showed the highest variability in DNA 
methylation (i.e., regions with a minimum adjusted P-value (minfdr) of less than 10-8) 
were defined as VMRs. 
2.9.3 Gene set enrichment analysis 
Gene set enrichment analysis was performed using a web-based tool Metaspace 
using the default settings (Yingyao Zhou et al., 2019). Pathway and gene set enrichment 
analysis were carried out using the following ontology sources: Kyoto Encyclopedia of 
Genes and Genomes (KEGG) Pathway (Kanehisa et al., 2017), Gene Ontology 
(Ashburner et al., 2000) and Reactome Gene Sets (Croft et al., 2010). All genes in the 
genome were used as the enrichment background. Pathways and biological terms with a 
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P-value < 0.01, a minimum count of 3 genes, and an enrichment factor > 1.5 (the ratio 
between the observed counts and the counts expected by chance) were collected and 
grouped into clusters. 
2.9.4 Survival analysis 
Survival analysis was performed using the Survival package in R (Therneau, 
2014). Cox proportional hazards regression models were used to calculate the HRs and 
95% CI for the association between DNA methylation levels (M values) and risk of death. 
Survival curve were constructed using the Kaplan-Meier estimator, and survival 
difference were compared using the log-rank test. Information on death in the MCCS 
cohort, was collected from the following sources: Victorian Birth, Death and Marriages 
(Birth Deaths and Marriages Victoria, 2020) and notified death recorded in Victorian 
Cancer Registry (Victorian Cancer Registry, 2020). For kConFab and ABCFR, 
information on death data collection and linkage was not available. For the MCCS that 
made up to ~90% of the sample size in this study, the latest linkage was done on 31 March 
2017 and was considered to be complete up to 31 December 2016. Overall survival was 
defined as the time (in years) elapsed between breast cancer diagnosis and death (from 
breast cancer or any other cause) or end of follow-up. Follow-up started at the date of 
diagnosis and ended at the date of death or end of follow-up (31 December 2016), 
whichever came first. 
2.9.5 Unsupervised cluster analysis 
Unsupervised cluster analysis was performed based on the methylation levels (M 
values) of the samples across 449,005 CpG positions and the Euclidean distance was 
estimated using ward.D2 minimum variance method (Murtagh & Legendre, 2014). The 
samples were grouped based on the similarity in their methylation levels. In this method, 
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the clustering begins with all samples as individual clusters. A dissimilarity matrix is 
formed which is the squared Euclidean distance between the cluster means. The clusters 
are repeatedly merged into a pair of clusters such that when merged; there is a minimum 
increase in total within-cluster variance (bottom up). The merging of clusters continues 
until a single group including all samples (the top of the tree) is defined. 
2.9.6 Statistical tests for testing associations 
Pearson's chi-square tests the association between categorical variable, whereas 
t.test and ANOVA were used to test the association with continuous variables. A P-value 
of < 0.05 was considered significant. 
2.10 Whole-exome sequencing 
Whole-exome sequencing (WES) was performed for somatic mutation profiling of 
a subset of selected ILBC cases. Libraries for WES were prepared using SureSelect XT 
low input library preparation kit (Agilent, USA) as per manufacturer’s instructions and 
SureSelect clinical research exome v2 (CRE v2) (Agilent, USA) was used as the target 
capture. 
2.10.1 NGS FFPE QC qPCR 
Prior to library preparation, the quality and amplifiable DNA quantity of tumour 
DNA and germline DNA samples were assessed using the NGS FFPE qPCR QC assay 
(Agilent, USA), as per manufacturer’s instructions. The workflow for this assay is 





Figure 2.4: NGS FFPE QC qPCR assay workflow (Agilent, USA). 
Flowchart illustrating the NGS FFPE qPCR QC assay and the data analysis workflow. 
The DNA samples to be assessed were serial diluted to 125 pg/μl. The diluted samples 
were then amplified with Primer set A and Primer set B. Standard curve analysis was used 
to calculate the amplifiable DNA quantity and the DNA quality was determined by 





Briefly, the initial DNA concentration was estimated for each sample using the 
Qubit dsBR assay kit (Thermo Fisher Scientific, USA) (as described in section 2.4). The 
DNA sample was serial diluted to 125 pg/μl as instructed in the protocol and the dilution 
factor (final volume/sample volume) was recorded for each sample. For the qPCR 
reaction, two sets of reaction mix were prepared, one for Primer Set A that targets a single-
copy DNA region of the human genome and produces a 42 bp amplicon and another for 
Primer Set B that targets the same DNA region but produces a 123 bp amplicon. Each 
qPCR reaction (for 1 sample) contained 10 μl of 2× Brilliant III SYBR Green qPCR 
Master Mix, 1 μl of Primer Set A or Primer Set B, 0.3 μl diluted reference dye (freshly 
prepared, 1:500 dilution) and 4 μl of DNA sample. The volume was equilibrated to 20 μl 
using the nuclease-free water. 
 
The reaction plate was set in such a way that the pre-diluted DNA standards: DNA 
standard 1 (2500 pg/μl); DNA standard 2 (625 pg/μl); DNA standard 3 (156.25 pg/μl); 
DNA standard 4 (39.06 pg/μl); and DNA standard 5 (9.77 pg/μl) were only amplified 
with Primer Set A to generate a standard curve for each qPCR run. Sample DNA and a 
positive control DNA were amplified using both Primer Set A and Primer Set B. All the 
reactions were set up in triplicate. QuantStudio 7 Flex qPCR system (Thermo Fisher 
Scientific, USA) was used for the assay and the run was set for real-time detection of 
SYBR Green fluorescence at the annealing and extension steps, reporting of 
quantification cycle (Cq), and subsequent standard curve analysis. The qPCR thermal 
cycling profile was as follows: 95°C for 3 minutes and 40 cycles of DNA denaturation at 




The quantity of amplifiable DNA present in a DNA sample was determined by 
the standard curve analysis. A standard curve was generated (plot of initial DNA quantity 
versus Cq), using the DNA standards amplified using Primer Set A (Figure 2.5). It was 
verified that the standard curve has an R2 value > 0.98 and an amplification efficiency 
between 85% and 110%. The concentration of amplifiable DNA was calculated by 
dividing the amplifiable DNA quantity by 4 μl (volume of sample DNA added to each 
qPCR reaction) and then multiplied by the dilution factor recorded for each sample. 
 
 
Figure 2.5: Standard curve. 
Standard curve showing five points of a 4-fold dilution series of DNA standards (1-5), 
performed in triplicate, amplified using the Primer Set A. The standard curve was 
generated by plotting the threshold cycle (CT) values (on the y-axis) against relative input 






The DNA quality was estimated by assessing the relative amplification of the 
sample DNA using Primer Set A, compared with Primer Set B and the amplification of 
the reference DNA by Primer Set A and Primer Set B. For each sample and the reference 
DNA, integrity score or ΔCq was calculated by subtracting the Cq values from reaction 
B from the Cq values from reaction A for each sample. A normalised DNA integrity score 
or ΔΔCq was calculated for each DNA sample by subtracting the reference DNA ΔCq 
from the sample ΔCq as, ΔΔCq = ΔCqSample - ΔCqRef. 
2.10.2 Shearing the DNA using Covaris 
Before library preparation, tumour DNA and germline DNA were sheared to a 
target fragment size of 150-200 bp by mechanical shearing using the Covaris sonicator 
(Covaris, USA). For this, 200 ng of sample DNA was normalised to a final volume of 50 
μl in 1X Low TE Buffer. The Covaris tank was filled with MilliQ water to the appropriate 
level and the degas process was initiated in the SonoLAB software (Covaris, USA). The 
chiller temperature was set to 2-5°C. The instrument was left to degas for at least 30 
minutes before use. After 30 minutes, 50 μl of sample DNA was loaded in the Covaris 
microtube (130 μl, pre-slit snap cap) using a normal pipette tip through the pre-split septa 
of the cap. It was ensured that no bubbles were introduced into the bottom of the tube. 
The microtube was secured in the Covaris tube holder and the FFPE and genomic DNA 
were sheared using settings provided in protocol with different treatment times for FFPE 
(240 seconds) and genomic DNA (2x 120 seconds). Once the shearing was complete, the 
sheared DNA from the microtube was transferred to a fresh 1.5 ml microfuge tube and 
kept on ice. 
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2.10.3 Library Preparation 
Library preparation for WES was performed using the using the SureSelect XT 
Low Input library preparation kit (Agilent, USA) as per the manufacturer’s instructions. 
SureSelect CRE v2 (Agilent, USA) was used as the target capture. 
 
Input DNA quantity for library preparation was determined based on the DNA 
integrity score, ΔΔCq as determined in the NGS FFPE qPCR QC assay (section 2.10.1). 
For samples with ΔΔCq ≤ 1, the Qubit-based quantity estimate was used and for the 
samples with ΔΔCq ≥ 1, qPCR-based quantity estimate was used to determine the input 
DNA quantity. 
The library preparation workflow is illustrated in Figure 2.6. Briefly, to the 
sheared DNA, dA-tail and end-repairing were performed. A unique molecular barcode 
sequence that are short random nucleotides also called unique molecular index (UMI) 
was ligated into each DNA fragment and were used to mitigate the PCR errors in this 
study. The adaptor ligated library was purified using 80 μl of homogeneous AMPure XP 
beads. For this, AMPure beads and the library were mixed well by pipetting and incubated 
at room temperature for 5 minutes. The mixture was kept on a magnetic separator device 
and left for 5-10 minutes for the solution to clear. Keeping the mixture plate on the 
magnetic stand and without touching the beads, the cleared solution was removed and 
discarded. To each well, 200 μl of freshly prepared 70% ethanol were dispensed, and any 
disturbed beads were allowed to settle for 1 minute. The ethanol was removed and 





Figure 2.6: Library preparation workflow. 
The flow diagram illustrating the whole-exome sequencing (WES) library preparation 
workflow. The input DNA quality and quantity were estimated using NGS qPCR QC 
assay (Agilent, USA). The DNA was fragmented using Covaris mechanical shearing and 
sequencing adaptors were ligated to each library in the dA tailing and adaptor ligation 
step. The adaptor ligated library was purified using the AMPure XP beads and was PCR 
amplified. The quality and quantity of the pre-capture library was assessed using the 
TapeStation and D1000 ScreenTape. Hybridisation reaction was performed, and the 
captured library was PCR amplified. The captured and amplified library was purified 
using the AMPure XP beads to give the final sequencing library. 
Sample DNA
NGS FFPE QC qPCR
Covaris DNA shearing
(150-200 bp)
Molecular barcoded, Adaptor ligated library
AMPure XP beads purification
PCR amplification using index primers




Pre-capture library (500-1000 ng)




AMPure XP beads purification
AMPure XP beads purification
PCR amplificationHybridisation and capture on 
Dynabeads Streptavidin 
magnetic beads
200 ng input DNA
Chapter 2 
85 
After the plate was dry, 35 μl of nuclease-free water were added, vortex mixed 
and incubated at room temperature for 2 minutes. The plate was transferred to the 
magnetic rack and left for 5 minutes or until the magnetic beads were completely bound 
to the magnet. The cleared supernatant (adaptor ligated library) was transferred to a fresh 
PCR plate and amplified using the SureSelect XT Low Input Index Primers. For FFPE 
DNA samples, 11 PCR cycles were performed, whereas for all high molecular weight 
DNA samples, 8 PCR cycles were performed. Unique indexing primers were ligated to 
the library at this stage. 
 
Once the PCR was complete, the library was purified using 50 μl of AMPure XP 
beads following the steps mentioned earlier. After the bead purification, the amplified 
adaptor ligated library was eluted in 15 μl of nuclease-free water. The quality and quantity 
of the pre-capture library was assessed on the 4200 TapeStation (Agilent, USA) using the 
D1000 ScreenTape (Agilent, USA). Library concentration was calculated by integrating 
the area under the peak as instructed in the TapeStation analysis protocol. The 
electropherogram for all the libraries were verified for the expected profile and DNA 
fragment peak. Library prepared from a high-quality DNA was expected to have a peak 
positioned between 300-400 bp, whereas for a low-quality DNA the peak was expected 
to range from 200-400 bp. 
 
After the pre-capture library quality and quantity assessment, 500-1000 ng 
(calculated based on the TapeStation assessment) of pre-capture library was prepared in 
12 μl nuclease-free water. Thermal cycler was programmed on the SureCycler (Agilent, 
USA) and the hybridisation reaction was performed as instructed in the protocol. The 
hybridisation mixture was transferred to a plate containing 200 μl of washed streptavidin 
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beads and mixed well by pipetting. The plate was incubated on a plate mixer at 1400-
1800 rpm at room temperature for 30 minutes. After incubation, the plate was kept on the 
magnetic separator to collect the beads and the supernatant was removed and discarded. 
The beads were then resuspended in 200 μl of pre-warmed SureSelect Wash Buffer 2 and 
put on the magnetic separator to collect the beads. This wash was repeated and a total of 
six washes were performed. After the last wash, 25 μl of nuclease-free water were added 
to the library and the beads were resuspended by pipetting. The enriched DNA library 
was PCR amplified using the post-capture PCR thermal cycling program as instructed in 
the protocol and nine PCR cycles were performed as instructed in the protocol. Once the 
PCR amplification program was complete, the plate was kept on the magnetic stand and 
the supernatant (approximately 50 μl) was removed to a fresh 96-well PCR plate. The 
beads were discarded this time. The amplified captured library was purified using 50 μl 
of AMPure XP beads as described earlier. After purification, the final library was eluted 
in 25 μl of nuclease-free water. The quality and quantity of the final library were assessed 
on 4200 TapeStation (Agilent, USA) using high-sensitivity D1000 ScreenTape assay. 
Figure 2.7 shows a schematic diagram of the final sequencing library. 
 
 
Figure 2.7: A schema showing the SureSelect XT Low Input sequencing library 
(Agilent, USA). 
Content of SureSelect library sequence with sequencing adaptors and barcode ligated to 
5’ and 3’ ends. Each fragment contains one target insert (blue) surrounded by the Illumina 
paired-end sequencing elements (black), the sample index (red), the molecular barcode 
(green) and the library bridge PCR primers (yellow). 
Chapter 2 
87 
2.10.4 Library pooling and sequencing 
For multiplex sequencing, the FFPE DNA and germline DNA libraries were 
pooled in a of 4:1 ratio based on the data output requirement, which was a mean target 
depth of coverage of 150X and 50X for FFPE DNA and germline DNA samples, 
respectively. Starting with different concentrations, the following formula was used to 
determine the amount of each indexed library to be added in the pool. 
 
Volume	of	Index	 = 	V(f) 	∗ 	C(f)	/	number	of	libraries	 ∗ 	C(i) 
 
where, V(f) is the final desired volume of the pool, C(f) is the final concentration (pg/μl) 
of all the libraries in the pool and C(i) is the initial concentration of each indexed library. 
The sequencing was performed on NovaSeq 6000 (Illumina, USA) on a single lane of S4 
flow cell to generate 150 bp paired end reads.  
2.11  Sequencing data processing and somatic variant calling 
A WES somatic variant calling pipeline was implemented for processing the 
sequencing data and for identifying the somatic variants in tumour-normal analysis mode 
(Figure 2.8). Raw sequencing data was obtained as fastq files and an initial QC was 
performed using FASTQC (Andrews S, 2010) to generate a quality report that included 
basic metrics such as per base sequence quality, per base GC content and adapter content. 
After the initial QC, UMI tags were added using fgbio 
(https://github.com/fulcrumgenomics/fgbio) to get UMI annotated unmapped bam files. 
Multiple sequencing reads from PCR duplicates with identical UMI-tags were identified 
after read alignment and were collapsed together to generate a single consensus read thus, 
getting rid of the PCR duplicates. Adapter sequences were marked and removed and the 
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unmapped bam files were mapped to the reference genome (hg19) to get aligned bam 
files using BWA mem (H Li, 2013). 
 
 
Figure 2.8: Whole-exome sequencing data processing and somatic variant calling. 
Flowchart illustrating the whole-exome sequencing and somatic variant calling workflow.  
 
 
Somatic variant calling was performed using VarDict (Lai et al., 2016) in paired 
tumour-normal analysis mode. VarDict default filters were used, which are as follows: 
Mean base quality > 22.5, Mean mapping quality > 0, Variant depth > 3, Total depth > 5, 
Allele frequency > 0.01 and P-value < 0.05. The variants satisfying the above criteria 















variant and reference alleles and based on the allele frequency difference the variants 
were classified as the following if both the tumour and germline samples had coverage: 
i) Germline- variants detected in both tumour and matching germline sample; ii) 
StrongSomatic- variants detected in tumour sample only; iii) StrongLOH- variants 
detected in germline sample only, opposite of StrongSomatic. For regions where only one 
sample had coverage, variants were classified as: i) SampleSpecific- detected in tumour 
sample, but no coverage in germline sample and ii) Deletion- detected in germline sample, 
but no coverage in tumour sample. Single nucleotide variants (SNVs) that were 
exclusively detected in the tumour and not in the germline DNA (tagged as 
“StrongSomatic”) and had passed all the default VarDict filters (tagged as “PASS”) were 
considered somatic SNVs (SSNVs) and selected for further analyses. The following post-
filtering was performed on the SSNVs where a minimum read depth of 30X and minimum 
variant allele frequency of 0.2 cut-offs were applied. 
2.12  Mutation signature analysis 
Mutational signatures were generated using the SSNVs identified in the tumour 
samples using the R package deconstructSigs (Rosenthal et al., 2016). The somatic 
signature profiles of tumour samples were generated using the predefined mutational 
signatures COSMIC (version3) (http://cancer.sanger.ac.uk/cosmic/signatures). The 
weights of each mutational signature contributing to the total mutational catalogue of the 
tumour samples were calculated by applying multiple linear regression model. The weight 
for each signature in deconstructSigs was calculated through an iterative approach which 
was then normalised between 0 and 1. Mutational signatures with a weight 0.06 or higher 
were considered significant as described in deconstructSigs (Rosenthal et al., 2016).
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Chapter 3 Genome-wide DNA methylation 
profile of Invasive Lobular Breast Cancer 
 
3.1 Introduction 
ILBC has been increasingly recognised as a distinct breast cancer subtype with 
unique morphological features, clinical presentation and response to therapy (section 1.5). 
However, the underlying biological explanation for many of these differences in clinical 
behaviour is still unknown and their impact on current clinical decision-making is limited. 
 
Examination of expression profiles of breast cancers has advanced work in 
molecular subtyping. Recent studies have highlighted the differentiating molecular 
features between ILBC and non-ILBC by investigating the molecular features of the 
tumours. The somatic genomic alterations unique to ILBC tumourigenesis has been 
reviewed in detail in section 1.5.4. ILBC has also been shown to display a distinct gene 
expression profile. Comparing the transcriptomic profiles of ILBC (n=21), IDBC (n=38), 
two samples with lymph node metastasis and three normal breast samples, Zhao et al., 
(2004) reported that ILBC showed differential expression at genes involved in cell 
adhesion and mobility, lipid and fatty acid transport and metabolism, immune response 
and electron transport (Zhao et al., 2004). A similar difference in transcriptomic profiles 
of ILBC and IDBC was also reported by (Bertucci et al., 2008). Oliveira et al., (2016) 
compared the proteomic profiles of ILBC and IDBC and reported a differential protein 
levels that involved structural proteins, metabolic enzymes, molecular chaperones/heat-
shock proteins, binding and transport proteins (Oliveira et al., 2016). Identifying unique 
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molecular alterations related to ILBC tumourigenesis and progression, presents 
opportunities for precision, prevention and precision medicine. 
 
In contrast to the attention put to expression profiling approaches to breast cancer 
subtyping, DNA methylation alterations specific to ILBC are not well characterised. 
Studies focusing on ILBC-specific DNA methylation alterations are mainly based on 
candidate gene approaches and have reported gene-specific methylation alterations 
(section 1.8). To the best of our knowledge, there is no study that has investigated the 
genome-wide DNA methylation differences between ILBC and non-ILBC tumours. 
There has also been a growing interest in the promising applicability of tumour DNA 
methylation in breast cancer prognostication (section 1.7.1). However, there is no study 
that has specifically investigated the DNA methylation profiles of ILBC tumours and its 
association with disease prognosis. 
 
Given this gap in knowledge, we sought to study the tumour DNA methylation 
landscape of ILBC in detail. We first used a candidate gene approach to assess the 
methylation patterns of ILBC at the genes that have previously been reported to have an 
altered methylation pattern in ILBC that is presented in Part I: Candidate gene approach. 
Secondly, we investigated the genome-wide DNA methylation profiles of ILBC tumours 
and tested the following hypotheses: i) ILBC have a distinct genome-wide DNA 
methylation profile as compared to non-ILBC, that is presented in the section Part II: 
Genome-wide DNA methylation pattern of ILBC and ii) Genome-wide variation in DNA 
methylation patterns within ILBC reflect different tumour biologies and can be used as a 
prognostic biomarker, as presented in the section Part III: Association of variably 
methylated tumour DNA regions with overall survival for ILBC. 
Chapter 3 
92 
3.2 Method overview 
3.2.1 Study participants and data 
Analyses in this chapter included 492 invasive breast cancer samples. Details of 
the samples and data being used in this chapter and the corresponding sections in the 
thesis where detailed information is available are summarised in Table 3.1.
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Table 3.1: Study participants and data. 




pattern of ILBC 
Part III: Association 
of variably methylated 
tumour DNA regions 
with overall survival 
for ILBC 
Sample 
ILBC (n = 151) 
Non-ILBC (n = 341) 
Adjacent normal breast 
samples (n = 13) 
ILBC (n = 151) 
Non-ILBC (n = 341) 
ILBC (n = 130) 
ILBC, TCGA dataset  
(n = 168) 
Total Tumour (n = 492) Normal (n = 13) Tumour (n = 492) 
Tumour MCCS (n = 130) 
Tumour TCGA (n = 168) 
 
A detailed clinical and pathological description of the study participants is 
presented in Table 2.1 (section 2.1) of the thesis. Details of TCGA data 










 A description of the study design is presented in section 2.1 of the thesis. 
Sample 
type 
FFPE Tumour enriched DNA and adjacent normal DNA (Details of sample 
preparation is presented in section 2.3.1. Data from normal adjacent DNA has 
been previously described in (Wong et al., 2016). 
Data 
information 
Genome-wide DNA methylation using Illumina HM450K array (Details of the 
methylation assay is presented in section 2.5). 
 
Gene expression data (Normalised counts, RNA sequencing-Illumina Hi-Seq) 
was downloaded from TCGA (Details presented in section 2.8). 
ILBC: Invasive lobular breast cancer. Non-ILBC: Non-lobular invasive breast cancer. MCCS: 
Melbourne Collaborative cohort Study. kConFab: The Kathleen Cuningham Foundation 
Consortium for Research into Familial Breast Cancer. ABCFR: Australian Breast Cancer Family 
Registry. TCGA: The Cancer Genome Atlas. FFPE: Formalin-fixed paraffin embedded. 
HM450K: Illumina HumanMethylation 450K array.
Chapter 3 
94 
3.2.2 Statistical analyses specific to part III. 
3.2.2.1 Endpoints 
Incidences of cancer cases and deaths in the MCCS participants are regularly 
updated by linkage to the Victorian and National cancer and death registries, which are 
considered to be virtually complete. The latest linkage was completed on 31 March 2017 
and death data were considered to be complete up to 31 December 2016. Overall survival 
was defined as the time (in years) from breast cancer diagnosis to death (from any cause) 
or end of follow-up. 
3.2.2.2 Survival analysis 
Survival analyses were undertaken for the ten most variably methylated regions 
identified across the MCCS ILBC samples. Follow-up started at the date of diagnosis and 
ended at the date of death or end of follow-up, whichever came first. Cox proportional 
hazards regression models were used to calculate HRs and 95% CI for the association 
between DNA methylation levels (M values) and risk of death. Three models were fitted: 
i) univariable, with DNA methylation as a crude predictor; and multivariable ii) with 
additional adjustment for age at diagnosis and iii) with adjustment for age at diagnosis 
and tumour stage. For each VMR, the methylation level was defined as the average 
methylation value across all CpG sites covering the VMR. The same analysis was carried 
out using the 168 ILBC samples from TCGA. Survival analyses were undertaken using 
the R package Survival (Therneau, 2014). HRs from the two individual studies were then 
pooled using fixed-effects meta-analysis with inverse variance weights. 
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3.2.2.3 Association with gene expression 
To test if DNA methylation correlated with gene expression at the ten strongest 
VMRs (identified in the MCCS) we assessed the correlation between average methylation 
levels (average M-values for all CpGs covering a VMR) and gene expression levels using 
Pearson’s correlation; we used matching gene expression and DNA methylation data 
available in the TCGA dataset for nine of the ten strongest VMRs. The correlations with 
gene expression were also assessed for individual CpG sites of each VMR. 
3.3 Results 
3.3.1 Methylation data pre-processing and normalisation 
Genome-wide DNA methylation was measured in 502 invasive breast cancer 
cases. DNA methylation data was pre-processed and normalised using the Functional 
normalisation (FNORM) method (section 2.6). The data quality was first evaluated by 
assessing the detection P-value. After normalisation, CpG probes with a mean detection 
P-value of more than 0.05 in one or more samples were considered unreliable and were 
removed from further analysis. After filtering out the poor-quality probes, we were left 
with a total of 449,005 CpG probes. Ten samples with mean detection P-value of more 
than 0.01 were considered poor quality and were removed at this stage and we were left 




Figure 3.1: Mean detection P-value. 
Plot showing mean detection P-value distribution for all the breast cancer samples. The 
samples are shown on the x-axis and the mean detection P-value is shown on the y-axis. 
Red line represents the mean detection P-value cut-off of 0.01. 
 
 
Figure 3.2 shows the density distribution of beta-value before and after data 






Figure 3.2: Beta-value density plots a) before data normalisation b) after data 
normalisation. 
Density plots showing the density distribution of methylation levels (beta-value) on the 
x-axis and density on the y-axis. The individual samples are represented by the line in the 
plots. 
 
3.3.2 Tumour purity 
The tumour purity ranged from 37% to 88% across the ILBC samples with 88% of 
the samples showing a tumour purity of > 50%. For non-ILBC samples, the tumour purity 
ranged from 16% to 90% with 84% of the samples showing a tumour purity of > 50%. 
Part I: Candidate gene approach 
We investigated the methylation pattern of ILBC tumours at six genes; CDH1, 
APC, RASSF1, ADAM33, TWIST1 and DAPK1, which have been previously reported to 
have aberrant methylation patterns in ILBC and in breast cancer overall. We also 
investigated the methylation pattern of ILBC tumours at the breast cancer predisposition 
genes; BRCA1 and BRCA2. Non-ILBC samples (n=341) and the matching adjacent 




The methylation pattern was studied across different genomic regions in relation to 
the gene, which are: TSS200 - the region from transcription start site (TSS) to -200 
nucleotides upstream of TSS; TSS1500 - the region from -200 to -1500 nucleotides 
upstream of TSS; 5 prime UTR (5’UTR) - the region within 5 prime untranslated region 
between the TSS and the ATG start site; 1st Exon; gene body - the region between the 
ATG and the stop codon and 3 prime UTR (3’ UTR) - region between the stop codon and 
poly A signal. 
3.3.3 CDH1 
Dysfunction of CDH1 is considered a hallmark of lobular histological subtype of 
breast cancer and a complete loss of the e-cadherin protein expression has been reported 
in ~90% of ILBC tumours (Reed et al., 2015). Studies have reported CDH1 promoter 
methylation as one of the mechanisms for the loss of protein expression in ILBC tumours 
(Droufakou et al., 2001; Sarrió et al., 2003). 
 
We investigated the methylation pattern of ILBC tumours at 20 CpG positions 
across the genomic region, chr16:68,770,613-68,869,013, covering the CDH1 gene. 
ILBC tumours showed a hypomethylation pattern across the CDH1 promoter associated 
regions (TSS1500, TSS200, 5 prime UTR, 9 CpGs) with average methylation level 
ranging from 0.09 to 0.25 (mean = 0.15) across this region (Figure 3.3a). On the other 
hand, ILBC tumours were hypermethylated across the gene body and 3 prime UTR 
regions of CDH1 with average methylation level ranging from 0.43 to 0.61 (mean = 0.52) 
(Figure 3.3a). 
A variability in the DNA methylation levels (as indicated by the boxed region in 
(Figure 3.3a), was observed across a small region (3 CpG positions) located in the gene 
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body of CDH1. The methylation level across this region ranged from 0.11 to 0.71 across 
the ILBC samples. Across this region, the adjacent normal breast samples showed a lower 
methylation level (mean beta-value = 0.22) compared with the ILBC samples (mean beta-
value = 0.34) however, the difference was not statistically significant (t.test, P-value = 
0.20) (Figure 3.3b). Comparing the methylation patterns of ILBC, non-ILBCs and the 
adjacent normal samples across CDH1 promoter associated regions, we did not observe 
a significant difference in their methylation levels (mean beta-value, ILBC = 0.15 versus 
non-ILBC = 0.14, t.test, P-value = 0.89; mean beta-value, ILBC = 0.15 versus adjacent 


































































































































Figure 3.3: DNA methylation pattern at CDH1. 
Graphics showing a) the methylation pattern of ILBC (n=151) across CDH1 and b) the 
mean methylation patterns of ILBC (n=151), non-ILBC (n=341) and adjacent normal 
samples (n=13) across CDH1. The CpG positions sorted by genomic positions are shown 
on the x-axis and the corresponding genomic regions are marked as indicated in the 
legend at the bottom. The methylation level (beta-value) of the samples is shown on the 
y-axis. The points in plot a represent individual ILBC samples and the different colour 
lines in plot b represent the mean methylation levels of ILBC, non-ILBC and adjacent 
normal samples as indicated in the legend on the right. The region of variable methylation 
pattern is indicated by the boxed area. P-value (t.test) assessing significant difference in 

























































































































































































































































(ILBC vs normal adjacent,
P-value = 0.20)
TSS200- region from transcription start site (TSS) to 200 nucleotides (nt) upstream of TSS.
TSS1500- region from 200 to 1500 nt upstream of TSS.
5’UTR- region within 5 prime untranslated region, between the TSS and the ATG start site
Gene body- region between the ATG and stop codon.




APC is a well-recognised tumour-suppressor gene and frequently reported to be 
hypermethylated in cancers including breast cancer (Virmani et al., 2001). Two distinct 
promoters have been identified for APC, promoter 1A (Genbank accession number: 
U02509) and promoter 1B (accession number D13981), of which, promoter 1A is the 
major APC promoter and is reported to be most commonly active (Horii et al., 1993). 
 
We investigated the methylation pattern of ILBC tumours at 38 CpG positions 
across the genomic region, chr5:112,041,847-112,160,748 that spanned the two 
promoters of APC as indicated in Figure 3.4. ILBC tumours showed a substantial 
variability across APC promoter 1A (16 CpGs) with average methylation level (beta-
value) ranging from 0.05 to 0.82 across this region and 66/151 (44%) ILBC tumours 
showing hypermethylation (Figure 3.4). On the other hand, the methylation pattern across 
APC promoter 1B (20 CpGs) was less variable with average methylation level ranging 
from 0.19 to 0.34 and no ILBC tumour showing hypermethylation across this region 













































































































































































































































































































































































































































































































































































Promoter 1B Promoter 1A
P-value =0.003)
(P-value =6.6x10-11)
TSS200- region from transcription start site (TSS) to 200 nucleotides (nt) upstream of TSS.
TSS1500- region from 200 to 1500 nt upstream of TSS.
5’UTR- region within 5 prime untranslated region, between the TSS and the ATG start site
Gene body- region between the ATG and stop codon.
3’ UTR- region between the stop codon and poly A signal.
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Figure 3.4: DNA methylation pattern at APC. 
Graphics showing a) the methylation pattern of ILBC (n=151) across APC and b) the 
mean methylation patterns of ILBC (n=151), non-ILBC (n=341) and adjacent normal 
samples (n=13) across APC. The CpG positions sorted by the genomic positions are 
shown on the x-axis and the corresponding genomic regions are marked and indicated in 
the legend at the bottom. The methylation levels (beta-value) of the samples are shown 
on the y-axis. The points in plot a represent individual ILBC samples and the different 
colour lines in plot b represent the mean methylation levels of ILBC, non-ILBC and 
adjacent normal samples as indicated in the legend on the right. The regions associated 
with the two APC promoters are indicated. P-value (t.test) assessing significant difference 





















The methylation patterns of non-ILBC and adjacent normal samples were similar 
to ILBC at APC promoter 1B with average methylation level ranging from 0.09 to 0.38 
in non-ILBC and 0.26 to 0.30 in adjacent normal breast samples across this region and no 
significant difference in their mean methylation levels (mean beta-value, ILBC = 0.28 
versus non-ILBC = 0.28, t.test, P-value = 0.99; mean beta-value, ILBC versus adjacent 
normal breast samples = 0.29, P-value = 0.91) (Figure 3.4b). However, at APC promoter 
1A, ILBC tumours showed significantly higher methylation level compared with the non-
ILBC tumours (mean beta-value, ILBC = 0.40 versus non-ILBC = 0.30, t.test, P-value = 
0.003; mean beta-value, ILBC versus adjacent normal samples = 0.13, t.test, P-value = 
6.6x10-11) (Figure 3.4b). ILBC tumours were also more frequently methylated at APC 
promoter 1A compared with the non-ILBC tumours (66/151, 44% of ILBC tumours 
versus 97/341, 28% of non-ILBC tumours). 
3.3.5 RASSF1 
RASSF1 is a putative tumour suppressor gene that controls tumour growth by 
inhibiting the Ras pathway (Vos et al., 2000). It is one of the most frequently methylated 
gene in cancer including breast cancer (Hesson et al., 2007). Eight different transcripts 
RASSF1A-RASSF1H are known for RASSF1, of which transcript A and C are the most 
common (Agathanggelou et al., 2005). Two CpG islands are associated with the 
promoters of RASSF1. The smaller CpG island spans the promoter region of RASSF1A 
(indicated as CpG island A in Figure 3.5 and the second CpG island spans the promoter 
region of RASSF1B and RASSF1C (indicated as CpG island B in Figure 3.5) 































































































































































































































































































Genomic position (chr3: 50,367,341-50,379,334)
CpG Island A CpG Island B
a)
TSS200- region from transcription start site (TSS) to 200 nucleotides (nt) upstream of TSS.
TSS1500- region from 200 to 1500 nt upstream of TSS.
5’UTR- region within 5 prime untranslated region, between the TSS and the ATG start site
Gene body- region between the ATG and stop codon.
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Figure 3.5: DNA methylation pattern at RASSF1. 
Graphics showing a) the methylation pattern of ILBC (n=151) across RASSF1 and b) the 
mean methylation patterns of ILBC (n=151), non-ILBC (n=341) and adjacent normal 
samples (n=13) across RASSF1. The CpG positions sorted by the genomic position are 
shown on the x-axis and the corresponding genomic regions are marked as indicated in 
the legend at the bottom. The methylation levels (beta-value) of the samples are shown 
on the y-axis. The points in plot a represent individual ILBC samples and the different 
colour lines in plot b represent the mean methylation level of the ILBC, non-ILBC and 
adjacent normal samples as indicated in the legend on the right. The regions associated 
with the two RASSF1 CpG islands are indicated. P-value (t.test) assessing significant 
difference in mean methylation level of ILBC and adjacent normal samples is indicated 





























We investigated the methylation pattern of ILBC tumours at 51 CpG positions 
across the genomic region, chr3:50,367,341-50,379,334 that spanned the two CpG islands 
associated with RASSF1, indicated as CpG island A (10 CpGs) and CpG island B (21 
CpGs) (Figure 3.5). The average methylation level (beta-value) ranged from 0.09 to 0.87 
at CpG island A and 80/151 (53%) of ILBC tumours were hypermethylated across this 
region. On the other hand, the average methylation level ranged from 0.05 to 0.32 at CpG 
island B (21 CpGs) and no sample was found to be hypermethylated across this region 
(Figure 3.5a). 
The methylation patterns of non-ILBC and adjacent normal samples were similar 
to ILBC tumours across CpG island B with no significant difference in their mean 
methylation levels (mean beta-value, ILBC = 0.14 versus non-ILBC = 0.10, t.test, P-value 
= 0.41; mean beta-value, ILBC = 0.14 versus adjacent normal breast = 0.11, P-value = 
0.48) (Figure 3.5b). However, across CpG island A the tumour samples (both ILBC and 
non-ILBC) showed a significantly higher methylation level compared with the adjacent 
normal breast samples (mean beta-value, ILBC = 0.49 versus adjacent normal = 0.27, P-
value = 0.001) (Figure 3.5b). No difference in the methylation levels of ILBC and non-
ILBC tumours was observed across this region (mean beta-value, ILBC = 0.49 versus 
non-ILBC = 0.46, t.test, P-value = 0.58). However, ILBC tumours were found to be more 
frequently methylated across RASSF1 CpG island A compared with non-ILBC tumours 






ADAM33 is a member of A Disintegrin and Metalloprotease (ADAM) family 
(Yoshinaka et al., 2002) and it is involved in multiple biological functions such as 
proteolysis, adhesion, fusion and signalling (Stone et al., 1999; Primakoff & Myles, 
2000). Promoter methylation of ADAM33 has been proposed to be a potential molecular 
marker for ILBC in a previous study (Seniski et al., 2009). 
 
We investigated the methylation pattern of ILBC tumours at 21 CpG positions 
across the genomic region, chr20: 3,649,247-3,663,421, mostly located in the gene body 
region (17 CpGs) and a small portion (4 CpGs), located in the promoter associated regions 
(TSS1500 and 1st Exon) of ADAM33 (Figure 3.6). The average methylation level across 
the promoter associated regions (4 CpGs), ranged from 0.11 to 0.49 and all the samples 
were found to be hypomethylated (Figure 3.6a). 
 
Non-ILBC and adjacent normal breast samples showed similar methylation 
patterns to ILBC across ADAM33 and no significant difference in their mean methylation 
levels was observed across the promoter associated regions (mean beta-value, ILBC = 
0.31 versus non-ILBC = 0.29, t.test, P-value = 0.91; mean beta-value, ILBC = 0.31 versus 
adjacent normal breast = 0.25, P-value = 0.77) (Figure 3.6b). While none of the ILBC 
tumours were found to be hypermethylated across ADAM33 promoter, 5/341 (1%) non-




































































































































































































































































































































































































TSS200- region from transcription start site (TSS) to 200 nucleotides (nt) upstream of TSS.
TSS1500- region from 200 to 1500 nt upstream of TSS.
5’UTR- region within 5 prime untranslated region, between the TSS and the ATG start site
Gene body- region between the ATG and stop codon.
3’ UTR- region between the stop codon and poly A signal.
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Figure 3.6: DNA methylation pattern at ADAM33. 
Graphics showing a) the methylation pattern of ILBC (n=151) across ADAM33 and b) 
the mean methylation patterns of ILBC (n=151), non-ILBC (n=341) and adjacent normal 
samples (n=13) across ADAM33. The CpG positions sorted by the genomic position are 
shown on the x-axis and the corresponding genomic regions are marked as indicated in 
the legend at the bottom. The methylation level (beta-value) of the samples are shown on 
the y-axis. The points in plot a represent individual ILBC samples and the different colour 
lines in plot b represent the mean methylation level of the ILBC, non-ILBC and adjacent 

































TWIST1 is a transcription factor, which is overexpressed in many epithelial 
cancers including breast cancer and is known to promote metastasis (Yang et al., 2004). 
 
The methylation patterns of ILBC tumours were investigated at 27 CpG positions 
across the genomic region, chr7:19,155,785-19,158,747 that mostly covered TWIST1 
promoter associated regions (TSS1500, 1st exon, 24 CpGs) and the 3 prime UTR (3 CpGs) 
(Figure 3.7). The average methylation level across TWIST1 promoter regions (24 CpGs) 
ranged from 0.20 to 0.64 and 24/151 (16%) of ILBC tumours were found to be 
hypermethylated (Figure 3.7a).  
 
Non-ILBC and adjacent normal breast samples showed similar methylation 
patterns to ILBC across TWIST1 with no significant difference in their mean methylation 
levels across the promoter region (mean beta-value, ILBC = 0.41 versus non-ILBC = 
0.38, t.test, P-value = 0.45; mean beta-value, ILBC = 0.41 versus adjacent normal = 0.32, 
P-value = 0.08) (Figure 3.7b). ILBC tumours were found to be more frequently 
methylated at TWIST1 promoter compared with the non-ILBC tumours (24/151, 16% of 


























































































































































































































































































































































































































































TSS200- region from transcription start site (TSS) to 200 nucleotides (nt) upstream of TSS.
TSS1500- region from 200 to 1500 nt upstream of TSS.
5’UTR- region within 5 prime untranslated region, between the TSS and the ATG start site
Gene body- region between the ATG and stop codon.
3’ UTR- region between the stop codon and poly A signal.
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Figure 3.7: DNA methylation pattern at TWIST1. 
Graphics show a) the methylation pattern of ILBC (n=151) across TWIST1 and b) the 
mean methylation patterns of ILBC (n=151), non-ILBC (n=341) and adjacent normal 
samples (n=13) across TWIST1. The CpG positions sorted by the genomic position are 
shown on the x-axis and the corresponding genomic regions are marked as indicated in 
the legend at the bottom. The methylation level (beta-value) of the samples are shown on 
the y-axis. The points in plot a represents individual ILBC samples and the different 
colour lines in plot b) represent the mean methylation level of the ILBC, non-ILBC and 

































The DAPK1 gene is a pro-apoptotic gene that is downregulated by promoter 
hypermethylation in many cancers including breast cancer (Mittag et al., 2006; Jia et al., 
2016; Loginov et al., 2017; Shawky et al., 2019). Promoter methylation of DAPK1 has 
been reported to be more frequent in lobular subtype compared with ductal breast cancer. 
A significant difference in DAPK expression level has also been reported between the 
two subtypes (Lehmann et al., 2002). 
 
The methylation patterns of ILBC tumours were investigated at 28 CpG positions 
across the genomic position, chr9:90,112,101-90,321,326 that covered the promoter 
associated regions (TSS1500, TSS200 and 5’UTR) and the gene body region of DAPK1 
Figure 3.8. The average methylation across DAPK1 promoter region (9 CpGs) ranged 
from 0.12 to 0.62 and 4/151 (3%) of ILBC tumours were found to be hypermethylated 
across this region (Figure 3.8a). Non-ILBC and adjacent normal breast samples showed 
similar methylation patterns to ILBC across DAPK1 promoter region with no significant 
difference in their mean methylation level (Figure 3.8b) (mean beta-value, ILBC = 0.30 
versus non-ILBC = 0.25, t.test, P-value = 0.71; mean beta-value, ILBC = 0.30 versus 
adjacent normal = 0.24, P-value = 0.65). The analysis found 14/341 (4%) non-ILBC 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































TSS200- region from transcription start site (TSS) to 200 nucleotides (nt) upstream of TSS.
TSS1500- region from 200 to 1500 nt upstream of TSS.
5’UTR- region within 5 prime untranslated region, between the TSS and the ATG start site
Gene body- region between the ATG and stop codon.






Figure 3.8: Methylation at DAPK1. 
Graphics showing a) the methylation pattern of ILBC (n=151) across DAPK1 and b) the 
mean methylation patterns of ILBC (n=151), non-ILBC (n=341) and adjacent normal 
samples (n=13) across DAPK1. The CpG positions sorted by the genomic position are 
shown on the x-axis and the corresponding genomic regions are marked as indicated in 
the legend at the bottom. The methylation level (beta-value) of the samples are shown on 
the y-axis. The points in plot a represents individual ILBC samples and the different 
colour lines in plot b represent the mean methylation level of the ILBC, non-ILBC and 
































3.3.9 BRCA1 and BRCA2 
BRCA1 and BRCA2 are breast cancer predisposition genes involved in several 
cellular pathways such as cell-cycle, transcriptional regulation, apoptosis and DNA repair 
mechanism (Roy et al., 2012). The increased risk of breast cancer associated with BRCA1 
and BRCA2 pathogenic variant has been estimated to be OR= 5.91 (95% CI:5.25-6.67) 
and OR= 3.31 (95% CI: 2.95-3.71), respectively (Kurian et al., 2017). 
 
Methylation patterns of ILBC tumours were investigated at 47 CpG positions 
across the genomic region, chr17:41,197,783-41,278,906 that covered BRCA1 gene body 
and promoter associated regions (TSS1500 and 5 prime UTR) (Figure 3.9a). The 
promoter associated region of BRCA1; 5 prime UTR (11 CpGs) and TSS1500 (29 CpGs) 
showed different methylation patterns (Figure 3.9a). The average methylation level across 
5 prime UTR was found to be consistent and hypomethylated, ranging from 0.03 to 0.60 
with only one sample found to be hypermethylated across this region. The 
hypermethylated sample was grade III ILBC tumour with mixed lobular-ductal 
morphology (ICD-O code- 8522) and was negative for ER. TSS1500 on the other hand, 
was found to be hypermethylated across 96/151 (64%) of ILBC tumours with average 
methylation level ranging from 0.34 to 0.77 across this region (Figure 3.9a). 
 
Non-ILBC tumours and adjacent normal breast samples showed similar 
methylation profiles to ILBC tumours across BRCA1 promoter associated regions with 
no significant difference in their mean methylation levels across 5 prime UTR (mean 
beta-value, ILBC = 0.08 versus non-ILBC = 0.07, t.test, P-value = 0.61; mean beta-value, 
ILBC = 0.08 versus adjacent normal = 0.08, P-value = 0.79) and TSS1500 (mean beta-
value ILBC = 0.52 versus non-ILBC = 0.52, P-value = 0.96; mean beta-value, ILBC = 
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0.52 versus adjacent normal breast = 0.52, P-value = 0.98) (Figure 3.9b). The analysis 
found 3/341 non-ILBC tumours to be hypermethylated across BRCA1 5 prime UTR and 
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Figure 3.9: Methylation at BRCA1. 
Graphics showing a) the methylation pattern of ILBC (n=151) across BRCA1 and b) the 
mean methylation patterns of ILBC (n=151), non-ILBC (n=341) and adjacent normal 
samples (n=13) across BRCA1. The CpG positions sorted by the genomic position are 
shown on the x-axis and the corresponding genomic regions are marked as indicated in 
the legend at the bottom. The methylation level (beta-value) of the samples are shown on 
the y-axis. The points in plot a represents individual ILBC samples and the different 
colour lines in plot b represent the mean methylation levels of the ILBC, non-ILBC and 
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TSS200- region from transcription start site (TSS) to 200 nucleotides (nt) upstream of TSS.
TSS1500- region from 200 to 1500 nt upstream of TSS.
5’UTR- region within 5 prime untranslated region, between the TSS and the ATG start site
Gene body- region between the ATG and stop codon.
3’ UTR- region between the stop codon and poly A signal.
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Investigation of the methylation patterns of ILBC tumours at 18 CpG positions   
across the genomic region, chr13:32,889,023- 32,973,072 that spanned the BRCA2 gene 
body (3 CpGs), 3 prime UTR (1 CpG) and promoter associated regions (TSS1500, 
TSS200 and 5’UTR, 14 CpGs) (Figure 3.10). 
 
The average methylation level across BRCA2 promoter associated regions (14 
CpGs) ranged from 0.08 to 0.22 and all the ILBC tumours were found to be 
hypomethylated (Figure 3.10a). Non-ILBC and adjacent normal breast samples showed 
a similar methylation pattern to ILBC with no significant difference in the methylation 
levels across BRCA2 promoter associated regions (mean beta-value, ILBC = 0.14 versus 
non-ILBC = 0.13 t.test, P-value = 0.87; mean beta-value, ILBC = 0.14 versus adjacent 
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Figure 3.10: Methylation at BRCA2. 
Graphics showing a) the methylation pattern of ILBC (n=151) across BRCA2 and b) the 
mean methylation pattern of ILBC (n=151), non-ILBC (n=341) and adjacent normal 
samples (n=13) across BRCA2. The CpG positions sorted by the genomic position are 
shown on the x-axis and the corresponding genomic regions are marked as indicated in 
the legend at the bottom. The methylation level (beta-value) of the samples are shown on 
the y-axis. The points in a) represents individual ILBC samples. The different colour lines 
in b) represent the mean methylation levels of the ILBC, non-ILBC and adjacent normal 
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TSS200- region from transcription start site (TSS) to 200 nucleotides (nt) upstream of TSS.
TSS1500- region from 200 to 1500 nt upstream of TSS.
5’UTR- region within 5 prime untranslated region, between the TSS and the ATG start site
Gene body- region between the ATG and stop codon.
3’ UTR- region between the stop codon and poly A signal.
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Part II: Genome-wide DNA methylation pattern of ILBC 
 
To identify the genome-wide differences in DNA methylation levels between ILBC 
(n = 151) and non-ILBC (n = 341) tumours, a probe-wise differential methylation analysis 
was performed between the two groups as described in section 2.9.1. 
3.3.10 Differential DNA methylation between ILBC and non-ILBC 
The analysis identified 53,898 CpG positions genome-wide that were 
differentially methylated between ILBC and non-ILBC tumours (adjusted P-value < 
0.01). The differentially methylated CpG positions (DMPs) were defined as the CpGs 
where the change in mean methylation levels (M values) of ILBC and non-ILBC differed 
significantly (adjusted P-value < 0.01). Of the DMPs, 30,869/53,898 (57%) were 
hypermethylated, with a positive log fold change (logFC), where logFC is the change in 
the average M value between the comparison groups. 23,029/53,898 (42%) of DMPs 
were found to be hypomethylated, with a negative logFC in ILBC in comparison with the 
non-ILBC tumours. 
 
The DMPs corresponded to 13,763 genes and 8,456 intergenic regions. The most 
significant DMPs (adjusted P-value < 0.01) and the genes overlapping these DMPs were 
cg05968270 (chr1:65,533,502, P-value = 2.5x10-37), cg08052428 (RALGDS, P-value = 
3x10-36), cg11658047 (AGPAT1, P-value = 6.5x10-36), cg13286318 (IMPAD1, P-value = 
1.2x10-35), and cg04402633 (CDKN1C, P-value = 1x10-34). The methylation levels of 




Figure 3.11: Five most significant differentially methylated CpG positions (by P-
value) between ILBC and non-ILBC tumours. 
Graphics showing the most significant differentially methylated CpG positions (DMPs); 
a) cg05968270, b) cg08052428, c) cg11658047, d) cg13286318 and e) cg04402633 
between ILBC and non-ILBC tumours. Sample groups are shown on the x-axis and the 
methylation levels (beta-value) is shown on the y-axis. P-values assessing difference in 



















































































































































To characterise the functional genomic location of differential methylation, the 
observed versus expected frequencies of the DMPs overlapping a functional region in the 
genome were evaluated. The hypermethylated DMPs were found to be enriched in CpG 
island (commonly associated with the gene promoter regions) by 1.64-fold. An 
enrichment by 1.12-fold for N-shore (up to 2 kb upstream from CpG island) and by 1.26-
fold for S-shore region (up to 2 kb downstream from CpG island), in the hypermethylated 
DMPs was also observed (Figure 3.12a). On the other hand, the hypomethylated DMPs 
were found to be enriched in N-Shelf (2-4 kb upstream from CpG island) and S-shelf (2-
4 kb downstream from CpG island) regions by 1.78-fold and 1.81-fold, respectively. A 
small enrichment (1.18-fold) in the open sea (region more than 4 kb away from the CpG 
island) was also observed in the hypomethylated DMPs (Figure 3.12a). 
 
In relation to the gene, hypermethylated DMPs were enriched in the promoter 
associated regions; TSS200 by 1.87-fold, TSS1500 by 1.47, 5 prime UTR by 1.35-fold 
and in 1st exon by 1.65-fold. On the other hand, the hypomethylated DMPs were enriched 





Figure 3.12: Genomic distribution of differentially methylated positions. 
Bar plots showing the distribution of 53,898 differentially methylated positions (DMPs); 
30,869 hypermethylated and 23,029 hypomethylated between ILBC and non-ILBC 
tumours a) relative to CpG islands, shores (0-2 kb from island), shelves (2-4 kb from 
island) and open sea and b) in relation to the gene, TSS1500 (the region from -200 to -
1500 nt upstream of TSS), TSS200 (region from transcription start site (TSS) to -200 
nucleotides upstream of TSS), 5’UTR (region within 5 prime untranslated region between 
the TSS and the ATG start site), 1st Exon, Gene body (region between the ATG and the 
stop codon), 3’UTR (region between the stop codon and poly A signal) and region 
associated with enhancers. Different genomic locations are shown on the x-axis and the 
fold change measured as a ratio between the frequency of hypermethylated or 
hypomethylated DMPs overlapping a genomic location over the expected frequency if 












Island N-shelf N-shore Open Sea S-shelf S-shore
Hypermethylated DMPs
Hypomethylated DMPs

























































TSS1500 TSS200 5' UTR 1st Exon Gene body 3' UTR Enhancer
Hypermethylated DMPs
Hypomethylated DMPs





























































Differentially methylated regions (DMRs) were identified using the DMRcate 
(Peters et al., 2015) package in R as described in section 2.9.1. The DMPs (n = 53,898) 
collapsed into 9,543 DMRs (75% hypermethylated and 25% hypomethylated). Many 
significant DMRs overlapped with genes previously reported in breast cancer including 
PTEN (15CpGs, P = 4.5x10-148, rank = 16), MYC (11CpGs, P = 9.4x10-129, rank = 24), 
TP53 (9CpGs, P = 5.4x10-93, rank = 104) and APC (6CpGs, P = 2.7x10-67, rank = 438), 
whereas many DMRs were overlapping genes that are not already known to be involved 
in breast cancer development. The ten most significant DMRs (P < 0.01) between ILBC 
and non-ILBC are summarised in Table 3.2.
Chapter 3 
127 
Table 3.2: Ten most significant (by P-value) differentially methylated regions between ILBC and non-ILBC. 






Protein Function Reported relevance to cancer 
progression/ etiology 
Reference 
chr6:32937267-32942358 0 36 BRD2 Transcription factor involved in cyclin 
gene transcription 




chr6:31632722-31635946 7.1x10-239 21 Y_RNA.248, 
CSNK2B, 
GPANK1 
CSNK2B- Wnt signalling pathway, 
Regulation of TP53 activity. 
GPANK1- Nucleic acid binding. 
- - 
chr6:30710373-30712559 1.8x10-238 21 IER3, FLOT1 PI3K/AKT pathway activation - - 
chr6:30687942-30690567 9.2x10-199 19 TUBB Structural molecule activity Hypermethylation of TUBB is 




chr6:28889996-28893092 5.9x10-193 17 TRIM27 Negative regulation of interleukin-2 
secretion 
Promotes breast tumour growth (Xing et al., 
2020) 
chr6:33385325-33387188 8.2x10-174 17 SYNGAP1, 
CUTA 
SYNGAP1- Inhibitory regulator of the Ras-
cAMP pathway; CUTA- Enzyme binding 
 
- - 
chr6:30613282-30616867 9.6x10-170 15 C6orf136 Uncharacterised protein - - 
chr6:28863395-28864820 1.7x10-161 17 HCG14 RNA gene - - 
chr6:31865274-31866286 3.1x10-161 15 EHMT2 Histone H3-K27 methylation, negative 
regulation of G0 to G1 transition. 
Promotes metastasis in breast 
cancer. 
(K Kim et 
al., 2018) 
chr5:180670343-180671419 9.9x10-159 15 GNB2L1 Ribosomal protein involved in translation. Promotes invasion and metastasis 
in breast cancer. 
(Fan et al., 
2019; Buoso 
et al., 2020) 
a Differentially methylated region. * P-value computed using Stouffer’s method (Stouffer et al., 1949) assessing the significance of methylation difference. † RefSeq gene name.
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Next, the distribution of DMRs (both hypermethylated and hypomethylated) on 
the chromosomes were investigated to know if the DMRs were randomly distributed. A 
positive correlation was observed between the total number of DMRs and the 
chromosome length for both hypermethylated (R = 0.64, P-value = 0.0007) and 
hypomethylated DMRs (R = 0.43, P-value = 0.04) (Figure 3.13a). In terms of gene density 
(number of genes per chromosome), chromosome 1 and 6 with lower gene densities had 
a higher proportion of both hypermethylated (11% on chromosome 1 and 7% on 
chromosome 6) and hypomethylated DMRs (8% on chromosome 1 and 10% on 
chromosome 6) (Figure 3.13b). Overall, chromosomes 19, 17 and 16 had the highest 
densities of both hypermethylated and hypomethylated DMRs, whereas it was lower for 










































Figure 3.13: Relation between number of differentially methylated regions and 
chromosome length and gene density. 
Graphics showing the relation between a) the number of hypermethylated differentially 
methylated regions (DMRs), n = 6,274 and b) the number of hypomethylated DMRs, n = 
2,265, identified between ILBC and non-ILBC samples and chromosome length (Mbp) 
and gene density (number of genes per chromosome).
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To further check for any hotspots of differential methylation, the DMR density 
using a 5 Mb sliding window was calculated. The DMRs were distributed across the 
genome with dense clusters at some chromosomal locations such as chromosome 19 that 
had hypermethylated clusters, whereas chromosome 16 and 17 showed hypomethylated 
DMR clusters. Chromosome 6 had intense clusters of both hypermethylated and 






Figure 3.14: Differentially methylated regions between ILBC and non-ILBC. 
Rainfall plot illustrating the genomic distribution of differentially methylated regions (DMRs) between ILBC and non-ILBC and also shows 
localized clusters of hypermethylated (n = 6,274) and hypomethylated (n = 2,265) DMRs. Four tracks are shown for each chromosome (from top 
to bottom): i) chromosome number; ii) rainfall plots for hypermethylated (shown in red dots) and hypomethylated (shown in blue dots) DMRs; iii) 
genomic density for hypermethylated (pink density plot) and hypomethylated (purple density plot) DMRs, and iv) ideograms. Each dot in the 
rainfall plot represents a DMR. The x-axis shows the genomic coordinate, and the y-axis shows the minimal distance (log transformed) of the DMR 
to its two neighbouring DMRs and the genomic density of the DMRs (defined as the fraction of a genomic window that is covered by DMRs).
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3.3.11 Gene set enrichment analysis of DMRs 
Gene set enrichment analysis was performed on the 1,000 most significant DMRs 
using Metaspace as described in section 2.9.3. The genes associated with the DMRs were 
enriched for 386 terms (FDR-adjusted P <0.05) with stronger evidence for metabolism of 
RNA (R-HSA-8953854), mRNA processing (GO:0006397), RNA splicing (GO:0008380), 
cell cycle (R-HSA-1640170) and DNA repair (GO:0006281). 
3.3.12 Luminal A ILBC versus Luminal A non-ILBC 
DNA methylation pattern is known to be influenced by the hormone receptor and 
HER2 expression status of breast tumours (Widschwendter et al., 2004). To minimise the 
molecular subtype driven heterogeneity and to better identify methylation signatures 
specific to ILBC an analysis limited to only luminal A samples was conducted, 
representing 65% of ILBC (n = 98) and 54% of non-ILBC (n = 185) cases. The samples 
were classified into intrinsic subtypes using immunohistochemistry (IHC) status of ER, 
PR and HER2. The definition reported by the St Gallen International Expert Consensus 
that defines luminal A as ER and/or PR positive and HER2 negative was used (Goldhirsch 
et al., 2011). There were 36 ILBC cases for whom no IHC information was available and 
hence were not included in the analysis. 
 
In the subset of only luminal A samples, 10,973 DMPs were identified out of 
which, 8,630 (79%) were hypermethylated and 2,343 (21%) were hypomethylated in 
luminal A ILBC compared with luminal A non-ILBC samples. The DMPs (n = 10,973) 
further clustered into 1,569 DMRs. The analysis found 498/1,569 (32%) of DMRs to be 
common between the two comparisons (ILBC versus non-ILBC and luminal A ILBC 
versus luminal A non-ILBC). Many significant DMRs in ILBC versus non-ILBC 
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comparison also ranked highly in luminal A ILBC versus luminal A non-ILBC 
comparison including, BRD2 (P-value = 1.3x10-44, rank = 10), TUBB (P-value = 8.3x10-
42, rank = 13), TRIM27 (P-value = 1.4x10-41, rank = 15), EHMT2 (P-value = 2.3x10-49, 
rank = 7), GNB2L1 (P-value = 2.4x10-50, rank = 5) and IER3 (P-value = 1.0x10-39, rank= 
22). 
Pathway enrichment analysis of the 1,000 most significant DMRs identified 
between luminal A ILBC and luminal A non-ILBC showed an enrichment for 567 terms 
(FDR-adjusted P <0.05). Of these, 283 (50%) overlapped with pathways identified in 
ILBC versus non-ILBC DMRs. Most significant pathways identified in ILBC versus non-
ILBC DMRs were also found to be significant (P <0.05) in luminal A ILBC versus 
luminal A non-ILBC DMRs including metabolism of RNA (R-HSA-8953854), mRNA 
processing (GO:0006397), RNA splicing (GO:0008380), cell cycle (R-HSA-1640170) 
and DNA repair (GO:0006281). 
Part III: Association of variably methylated tumour DNA 
regions with overall survival for ILBC 
Tumour DNA methylation profiling has shown potential to refine disease subtyping 
and improve the diagnosis and prognosis prediction of breast cancer. Here, the genome-
wide variability of DNA methylation levels across a subset of ILBC tumours was 
investigated and the association between methylation levels at the variably methylated 
regions and overall survival in women with ILBC was assessed. In order to maintain the 
data uniformity, this analysis only included the participants from the MCCS (n = 130) 
and was replicated using data retrieved from TCGA for 168 ILBC cases. 
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3.3.13 Study participants 
The median age at breast cancer diagnosis in the MCCS was 65 years with 
tumours being diagnosed at stage 1A/1B (65/130, 50%), 2A/2B (48/130, 37%) and 
3A/3C/4 (17/130, 13%). There were 37 deaths observed during follow-up (median 
[interquartile range]: 13 [9-18] years). The tumours were mainly ER positive, PR positive 
and HER2 negative (47%). In TCGA data, the median age at diagnosis was 62 years. In 
both datasets, older women (aged 60 years or older at diagnosis) formed the majority of 
the cases (65% in the MCCS and 58% in TCGA). There was a higher proportion of young 
women at diagnosis (age less than 50 years: 21%) in TCGA compared with the MCCS 
(5%). The proportion of later stage tumours (3A/3B/3C/4) was also higher in TCGA 
(33%) compared with the MCCS (13%). A total of 14 deaths were recorded during the 
follow up (median [interquartile range]: 2 [1.5-5] years) in TCGA dataset. The clinical 
and pathological features of the study participants in the MCCS and TCGA and a 
comparison of the two studies is summarised in Table 3.3.
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Table 3.3: Clinical and pathological features of the study participants from the 
Melbourne Collaborative Cohort Study and The Cancer Genome Atlas. 
Sample characteristics MCCSa (n=130) TCGAb (n=168) P-value* 
Median age at diagnosis, years  
[interquartile range] 
65 [25%; 58] 62 [25%; 51] 0.02 


































Overall deaths, n (%) 37 (28) 14 (8) 4.7x10-06 
Median follow-up time, years 13 2 2.2x10-16 
















































































a Melbourne Collaborative Cohort Study. b The Cancer Genome Atlas. ER: Estrogen receptor, PR: 
Progesterone receptor, HER2: Human epidermal receptor 2, *P-values are for chi-square tests 
and T-tests for categorical and continuous variables, respectively. 
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3.3.14 Variably methylated regions in ILBC 
Across the genome, 2,771 regions showed substantially variable methylation (P < 
10-8) across ILBCs in the MCCS. These VMRs corresponded to 2,208 genes and 563 
intergenic regions. The most significant regions (P < 10-8) and the genes associated with 
these regions were chr20:13199787-13201844 (ISM1, 29 CpGs), chr5:112073348-
112074043 (APC, 16 CpGs), chr17:42091713-42093050 (TMEM101, 16 CpGs), 
chr11:2290953-2293552 (ASCL2, 41 CpGs), chr10:134598496-134602228 (NKX6, 39 
CpGs) and chr1:228644750-228647248 (HIST3H2A/HIST3H2BB, 28 CpGs). The 
average methylation level (beta-values) ranged between 0.09 and 0.63 at ISM1, 0.08 and 
0.82 at APC, 0.15 and 0.83 at TMEM101, 0.15 and 0.77 at ASCL2, 0.07 and 0.70 at NKX6, 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.15: Methylation pattern of ILBC samples. 
Heatmaps show the methylation patterns of invasive lobular breast cancer (ILBC) 
samples in the Melbourne Collaborative Cohort Study (MCCS) across the ten most 
significant variably methylated regions (VMRs): a ISM1, b APC, c TMEM101, d ASCL2, 
e NKX6, f HIST3H2A, g HCG4P3, h HES5, i CELF2 j EFCAB4B. Annotation of CpGs 
by genomic position and location in the context of gene are marked on the maps. 
Annotation of samples by age at diagnosis and tumour characteristics are shown in the 
colour bars as indicated in the legend on the top-right. The methylation beta-value of the 
CpG positions shown in the heatmap is indicated in the colour key on the top-right corner.
Chapter 3 
145 
The number of CpGs included in each VMR was wide-ranging (between 11 and 





Figure 3.16: Relation between the number of CpGs related to each variably 
methylated region and their ranking. 
The graphic shows the distribution of total number of CpG positions related to the 
variably methylated regions (VMRs), n=2,771, identified within ILBC samples in the 
Melbourne Collaborative Cohort Study (MCCS). The ranks of the VMRs are shown on 
the x-axis and the number of CpG positions related to each VMR is shown on the y-axis 






























A significant enrichment for CpG-island associated regions compared to all 
probes included in the HM450K array was identified (Figure 3.17a). Gene annotation also 
showed that 62% of the VMRs were located in gene promoter regions (1st Exon, 5 prime 
UTR, TSS1500 and TSS200) compared with 20% in gene body regions and 23% in 




Figure 3.17: Genomic distribution of the variably methylated regions. 
Bar plots show the distribution of 2,771 variably methylated regions (VMRs) identified 
within ILBC samples in the Melbourne Collaborative Cohort Study (MCCS) a) relative 
to CpG islands, shores (0-2 kb from island), shelves (2-4 kb from island) and open sea 
and b) in relation to the gene. Different genomic locations are shown on the x-axis and 
the percentage of CpG positions related to the VMRs is shown on the y-axis. The 
distribution of the HM450K probes relative to each CpG context is also indicated. P-
values (Chi-square test) assessing significant enrichment in a given category relative to 
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The pathway enrichment analysis showed that the genes associated with the 
VMRs were enriched for 1,973 terms (FDR-adjusted P <0.05) including 54 KEGG 
pathways with stronger evidence for neuroactive ligand-receptor interaction (hsa04080), 
breast cancer (hsa05224), pathways in cancer (hsa05200), hippo signalling pathway 
(hsa04390), Rap1 signalling pathway (hsa04015) and PI3K-Akt signalling pathway 




Figure 3.18: Twenty most significantly enriched KEGG pathways. 
Bar plot shows twenty most significantly enriched KEGG pathways in the variably 
methylated region (VMRs) identified within ILBC samples in the Melbourne 
Collaborative Cohort Study (MCCS). The enriched terms are shown on the y-axis and the 
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Replication of the VMR analysis in TCGA dataset (n=168), identified 2,760 
VMRs, of which 763 (28%) overlapped with the MCCS. The ten most significant VMRs 
identified in the MCCS ranked highly in the TCGA dataset (Table 3.4). Pathway 
enrichment analysis of the 763 overlapping VMRs resulted in 416 enriched functional 
terms (FDR-adjusted P <0.05) including nine enriched KEGG pathways. Of these, 369 
overlapped with pathways identified for all MCCS VMRs; neuroactive ligand-receptor 
interaction (hsa04080) and hippo signalling pathway (hsa04390) were among the KEGG 




Table 3.4: Ten most significant variably methylated regions identified in the Melbourne Collaborative Cohort Study and their respective 
ranking in The Cancer Genome Atlas dataset. 
MCCSa TCGAb 
Genomic location of the 
VMRc (hg19) 




Genomic location of the VMRs in 
relation to the corresponding genes 
minfdr* Rank in 
TCGA 
chr20:13199787-13201844 5x10-181 29 ISM1 TSS1500 1x10-120 10 
chr5:112073348-112074043 5x10-181 16 APC Body, 1st exon, TSS200, TSS1500 3x10-170 4 
chr17:42091713-42093050 4x10-172 16 TMEM101 TSS1500, TSS200, 5’UTR, 1st exon 3x10-92 20 
chr11:2290953-2293552 2x10-152 41 ASCL2 3’UTR, 1st exon, 5’UTR, TSS200, TSS1500 1x10-90 23 
chr10:134598496-134602228 1x10-142 39 NKX6 Body, 1stExon, TSS1500 6x10-118 12 
chr1:228644750-228647248 1x10-131 28 HIST3H2A/ 
HIST3H2BB 
TSS1500, TSS200 2x10-196 2 
chr6:29973557-29976071 4x10-124 52 HCG4P3/HLA-J Body 2x10-194 3 
chr1:2460621-2462364 1x10-110 11 HES5 3’UTR, Body, TSS200, TSS1500 3x10-90 24 
chr10:11059290-11060652 2x10-109 14 CELF2 TSS1500, TSS200, 5’UTR, 1st exon 9x10-130 7 
chr12:3862221-3862810 6x10-104 13 EFCAB4B 1stExon, 5’UTR, TSS200, TSS1500 7x10-198 1 
a Melbourne Collaborative Cohort Study. b The Cancer Genome Atlas. c Variably methylated region. * minimum adjusted P-value. † RefSeq gene name. TSS200 is the region 
from the transcript start site (TSS) to 200 nucleotides upstream of TSS; TSS1500 is the region from 200 to 1500 nucleotides upstream of TSS; 5’ UTR is the region within 5 
prime untranslated regions, between the TSS and the ATG start site; Body is the region between the ATG and stop codon; 3’ UTR is between the stop codon and poly A signal.
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3.3.15 VMRs and association with overall survival 
In the MCCS, higher tumour methylation showed association with shorter overall 
survival for APC (HR = 1.28, 95% CI: 1.07-1.53), HIST3H2A/HIST3H2BB (HR = 1.28, 
95% CI: 1.02-1.62), CELF2 (HR = 1.30, 95% CI: 1.07-1.58) and TMEM101 (HR = 1.21, 
95% CI: 1.00-1.48). Weak evidence of association was also observed for ISM1 (HR = 
1.34, 95% CI: 0.97-1.85), NKX6 (HR = 1.25, 95% CI: 0.98-1.60) and HCG4P3 (HR = 
1.24, 95% CI: 0.93-1.67). After adjusting for age at diagnosis and tumour stage, the 
association remained consistent for APC (HR = 1.24, 95% CI: 1.04-1.49), TMEM101 (HR 
= 1.22, 95% CI: 0.99-1.51) and HCG4P3 (HR = 1.25, 95% CI: 0.91-1.72) (Table 3.5). As 
shown in Table 3.5, all VMRs had an average methylation level below 0.5 and the 
direction of association was positive (gains in methylation associated with shorter 
survival). 
In TCGA dataset, the crude HRs were all positive, consistent with the MCCS 
dataset, albeit generally greater, in particular for ISM1 (HR = 1.48, 95% CI: 0.91-2.41), 
ASCL2 (HR = 1.28, 95% CI: 0.74-2.20), NKX6 (HR = 2.06, 95% CI: 1.32-3.21), 
HIST3H2A/HIST3H2BB (HR = 1.35, 95% CI: 1.00-1.83), HCG4P3 (HR = 2.04, 95% CI: 
1.32-3.15), CELF2 (HR = 1.50, 95% CI: 1.06-2.12) and EFCAB4B (HR = 1.41, 95% CI: 
1.05-1.89). Associations remained consistent after adjustment for age at diagnosis and 
tumour stage for all VMRs except those located at APC and HES5. The pooled HRs after 
adjustment for age at diagnosis and tumour stage showed that methylation was associated 
with overall survival for four genes: APC (HR = 1.18, 95% CI: 1.02-1.36), TMEM101 
(HR = 1.23, 95% CI: 1.02-1.48), HCG4P3 (HR = 1.37, 95% CI: 1.05-1.79) and CELF2 




Table 3.5: Hazard ratios for the association between the methylation levels at the ten most significant variably methylated regions and 
overall survival in the Melbourne Collaborative Cohort Study and The Cancer Genome Atlas dataset. 
MCCSa TCGAb 
 Adjusted for age Adjusted for age 
and stage 







P HR (95% 
CI) 





P HR (95% 
CI) 
P HR (95% CI) P 
APC 39.1 1.28 (1.07-1.53) 0.01 1.24 (1.04-1.47) 0.02 1.24 (1.04- 1.49) 0.01 35.9 1.16 (0.89-1.51) 0.28 1.12 (0.86-1.44) 0.41 1.06 (0.82- 1.38) 0.63 
TMEM101 39.6 1.21 (1.00-1.48) 0.06 1.19 (0.98-1.44) 0.08 1.22 (0.99- 1.51) 0.06 39 1.13 (0.77-1.66) 0.52 1.12 (0.78-1.60) 0.54 1.27 (0.87- 1.85) 0.21 
ISM1 22.8 1.34 (0.97-1.85) 0.07 1.02 (0.76-1.38) 0.89 0.90 (0.65- 1.26) 0.54 19.2 1.48 (0.91-2.41) 0.11 1.38 (0.80-2.37) 0.25 1.48 (0.86- 2.54) 0.15 
ASCL2 44.4 1.16 (0.81-1.65) 0.42 0.93 (0.66-1.31) 0.69 0.99 (0.71- 1.38) 0.95 44.6 1.28 (0.74-2.20) 0.38 1.17 (0.68-2.02) 0.57 1.44 (0.81- 2.57) 0.22 
HIST3H2A 20.1 1.28 (1.02-1.62) 0.03 1.08 (0.86-1.35) 0.53 1.03 (0.82- 1.29) 0.78 20.1 1.35 (1.00-1.83) 0.05 1.28 (0.94-1.73) 0.12 1.23 (0.90- 1.68) 0.18 
NKX6 29 1.25 (0.98-1.60) 0.07 1.06 (0.83-1.35) 0.63 1.01 (0.79- 1.29) 0.91 30.2 2.06 (1.32-3.21) 0.00
1 
1.88 (1.21-2.92) 0.01 2.01 (1.28- 3.17) 0.002 
HCG4P3 29.1 1.24 (0.93-1.67) 0.14 1.13 (0.84-1.53) 0.41 1.25 (0.91- 1.72) 0.16 31.1 2.04 (1.32-3.15) 0.00
1 
1.80 (1.13-2.85) 0.01 1.69 (1.05- 2.72) 0.03 
HES5 19 1.11 (0.88-1.40) 0.38 1.11 (0.88-1.40) 0.37 1.13 (0.89- 1.42) 0.29 20.9 1.26 (0.88-1.80) 0.21 1.15 (0.80-1.65) 0.45 1.13 (0.76- 1.68) 0.53 
CELF2 33.4 1.30 (1.07-1.58) 0.01 1.12 (0.93-1.36) 0.23 1.13 (0.93- 1.36) 0.21 35 1.50 (1.06-2.12) 0.02 1.44 (1.01-2.05) 0.04 1.51 (1.07- 2.13) 0.02 
EFCAB4B 32.8 1.01 (0.83-1.23) 0.88 0.96 (0.80-1.15) 0.63 0.99 (0.83- 1.19) 0.99 34.5 1.41 (1.05-1.89) 0.02 1.32 (0.98-1.78) 0.07 1.25 (0.93- 1.67) 0.14 
a Melbourne Collaborative Cohort Study. b The Cancer Genome Atlas. † Gene associated with the variably methylated regions (VMRs), most of the VMRs were located in the 
promoter region of the genes, RefSeq gene name * Average methylation level (beta-value) of the samples across the VMRs, HR: Hazard ratio, CI: Confidence interval.
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Table 3.6: Pooled hazard ratios for the association between methylation levels at the 
ten most significant variably methylated regions and overall survival: Meta-analysis 
of the Melbourne Collaborative Cohort Study and The Cancer Genome Atlas 
results. 
  Adjusted for age Adjusted for age and stage 
Gene† HR (95% CI) P HR (95% CI) P HR (95% CI) P 
APC 1.24 (1.07-1.44) 0.004 1.20 (1.04-1.39) 0.01 1.18 (1.02-1.36) 0.03 
TMEM101 1.19 (1.00-1.42) 0.05 1.17 (0.99-1.39) 0.06 1.23 (1.02-1.48) 0.03 
ISM1 1.38 (1.05-1.80) 0.02 1.09 (0.84-1.42) 0.50 1.03 (0.77-1.36) 0.83 
ASCL2 1.19 (0.88-1.61) 0.24 0.99 (0.74-1.33) 0.96 1.08 (0.81-1.45) 0.57 
HIST3H2A 1.30 (1.08-1.57) 0.004 1.15 (0.95-1.37) 0.14 1.09 (0.91-1.31) 0.33 
NKX6 1.40 (1.13-1.74) 0.002 1.21 (0.98-1.50) 0.08 1.18 (0.95-1.46) 0.13 
HCG4P3 1.45 (1.13-1.85) 0.003 1.30 (1.00-1.67) 0.04 1.37 (1.05-1.79) 0.02 
HES5 1.15 (0.95-1.40) 0.15 1.12 (0.92-1.36) 0.25 1.13 (0.92-1.38) 0.23 
CELF2 1.34 (1.13-1.60) 0.0006 1.18 (1.00-1.40) 0.05 1.21 (1.02-1.43) 0.02 
EFCAB4B 1.12 (0.95-1.32) 0.17 1.05 (0.89-1.22) 0.57 1.05 (0.90-1.23) 0.49 
† Gene associated with the variably methylated regions (VMRs) most of the VMRs were located in the 
promoter region of the genes. † RefSeq gene name. HR: Hazard ratio. CI: Confidence interval. 
 
3.3.16 Correlation with gene expression 
A negative correlation between DNA methylation and gene expression was 
observed for six of the nine tested VMRs in TCGA (Figure 3.19). These included 
EFCAB4B (R = -0.5, P-value = 1.4x10-10), CELF2 (R = -0.25, P-value = 0.001), 
HIST3H2A (R = -0.41, P-value = 1x10-7), ASCL2 (R = -0.24, P-value = 0.002), ISM1 (R 
= -0.24, P-value = 0.002) and HES5 (R = -0.15, P-value = 0.04) (Figure 3.19a). No or 
slightly positive correlation between DNA methylation and gene expression levels was 
observed for APC, TMEM101 and NKX6 (Figure 3.19b). The feature-by-feature analysis 
of correlations with gene expression was very consistent with the analysis using average 
methylation, virtually all associations being in the same direction, with only moderate 







Figure 3.19: Correlation between methylation levels and gene expression. 
Graphics showing the correlation between average DNA methylation (beta-value) on the 
x-axis and gene expression (normalised count) on the y-axis of ILBC cases at the 
corresponding genes associated with nine of ten strongest variably methylated regions 
(VMRs) with available gene expression data in The Cancer Genome Atlas (TCGA) in the 
ILBC cases in TCGA dataset. Corresponding gene names are marked on the top-right and 




This chapter presents the findings of the investigation of DNA methylation 
alterations in ILBC tumours based on a candidate gene approach and a genome-wide 
approach. Comparison of genome-wide DNA methylation levels of ILBC and non-ILBC 
tumours identified differentially methylated genes and provided some evidence that ILBC 
display a unique genome-wide DNA methylation profile compared with non-ILBC 
tumours. Methylation markers predictive of patient outcome that supported the 
hypothesis that tumour DNA methylation levels can be used as a prognostic biomarker 
for women with ILBC were also identified. 
 
Investigating the methylation pattern of ILBC tumours using a candidate gene 
approach, a higher rate of promoter methylation in ILBC compared with non-ILBC 
tumours at APC (44% of ILBC versus 28% of non-ILBC), RASSF1 (53% of ILBC versus 
48% of non-ILBC), TWIST1 (16% of ILBC versus 13% of non-ILBC) and BRCA1 (64% 
of ILBC versus 58% of non-ILBC) was identified. No hypermethylation was observed at 
the promoter associated regions of CDH1, ADAM33 and BRCA2, which was inconsistent 
with previous reports suggesting a frequent ADAM33 promoter methylation in ILBC 
compared with non-ILBC tumours (Seniski et al., 2009). CDH1 promoter methylation 
has also been reported as an alternative method for CDH1 silencing reported in 40-80% 
of ILBC tumours (Droufakou et al., 2001; Sarrió et al., 2003; Caldeira et al., 2006). 
However, no hypermethylation was observed at CDH1 promoter in this study. One of the 
reasons for this discrepancy could be the difference in technology. While Illumina 
HM450K assay was used to in this study, all the studies mentioned above have used 
methylation-specific PCR for measuring the methylation levels. 
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A distinct methylation pattern was observed across the two APC promoters, 
promoter 1A and promoter 1B. While promoter 1B showed hypomethylation across all 
the ILBC tumours, a substantial variability in methylation level was observed across 
promoter 1A. APC promoter 1A methylation has previously been reported in breast 
cancer. Liu et al., (2007) reported promoter 1A hypermethylation in 28/76 (37%) of breast 
cancer cases compared with normal breast tissue (0%) (P-value < 0.05). They also 
reported a negative correlation between promoter 1A hypermethylation and APC protein 
expression (measured by immunohistochemistry) (R= -0.368, P-value < 0.05), suggesting 
a functional role of promoter 1A methylation in APC gene regulation (Liu et al., 2007). 
A higher frequency of APC promoter 1A methylation in ILBC tumours compared with 
non-ILBC and a lack of methylation in the normal adjacent breast samples indicates its 
potential applicability in early diagnosis of ILBC and should further be investigated. 
 
Studying the methylation pattern at individual genes revealed that different 
genomic regions associated with the gene show distinct pattern of methylation. While 
methylation level across the gene body region was found to be higher at all the genes, the 
different genomic regions associated with the gene promoter showed varied methylation 
patterns. For instance, within the promoter associated region of BRCA1, the 5 prime UTR 
region was hypomethylated across all the samples except one, whereas the TSS1500 
region was hypermethylated in 96/151 (64%) of ILBC tumours (Figure 3.9). This may 
suggest that different regions associated with a gene promoter may have different 
functional control in gene expression regulation. This has previously been suggested in a 
study that reported that methylation level at the 1st exon is tightly linked to the gene 
expression (Brenet et al., 2011). The one sample hypermethylated at the 5 prime UTR of 
BRCA1 was grade III tumour of mixed lobular-ductal morphology that was found to be 
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negative for ER expression. This may suggest that methylation at 5 prime UTR could be 
an indicator of an aggressive tumour behaviour and future study investigating the 
association between 5 prime UTR methylation in relation to BRCA1 gene expression 
could unravel any possible link. This analysis again points towards the heterogeneous 
nature of ILBC tumours and reiterates the importance of investigating the histological 
subtypes for a precise understanding of their molecular nature. Future studies 
investigating the methylation profile of different well-defined histological subtypes of 
ILBC at genome-wide scale or at specific breast cancer genes will shed more light on this 
and would suggest approaches of using methylation level information for treating ILBC 
with precision. 
 
Comparing the genome-wide DNA methylation patterns of ILBC and non-ILBC 
tumours, revealed regions of differential methylation between the two tumour types. The 
DMRs were significantly enriched in pathways such as metabolism of RNA (R-HSA-
8953854), mRNA processing (GO:0006397), RNA splicing (GO:0008380), cell cycle (R-
HSA-1640170) and DNA repair (GO:0006281). Many of the genes involved in these 
pathways have been found to be dysregulated in cancer suggesting the involvement of 
DMRs in cancer initiation and progression. Limiting the analysis to only luminal A ILBC 
and luminal A non-ILBC tumours, a similar differential methylation pattern was observed 
and the most significant DMRs in ILBC versus non-ILBC comparison remained 
significant in luminal A ILBC versus luminal A non-ILBC comparison also. 
 
The genome-wide DNA methylation pattern of ILBC tumours, with the aim of 
identifying methylation markers predictive of patient outcome was investigated. Scanning 
of the ILBC methylome revealed regions of variable methylation in ILBC tumours. The 
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VMRs were primarily located in CpG island regions and were significantly enriched in 
pathways such as breast cancer (hsa05224), pathways in cancer (hsa05200), hippo 
signalling pathway (hsa04390), Rap1 signalling pathway (hsa04015) and PI3K-Akt 
signalling pathway (hsa04151). These pathways have previously been found to be 
dysregulated in cancer tissue suggesting the involvement of the identified VMRs in 
cancer initiation and progression (Bailey et al., 2009; Hall et al., 2010; McSherry et al., 
2011; Yin & Zhang, 2011; N Li et al., 2017; X-L Ma et al., 2019). Some of the key genes 
involved in the enriched pathways included APC, DAPK1, BMP2 and CCND2. DAPK1 
is an important regulator of cell apoptotic pathways (Gozuacik et al., 2008) and DAPK1 
promoter hypermethylation has previously been reported in ILBCs with a potential role 
in tumour progression (Lehmann et al., 2002; Tserga et al., 2012). BMP2 is a member of 
the TGF-ß superfamily and is involved in cell proliferation and differentiation during 
tumour formation (Thawani et al., 2010). Promoter methylation of BMP2 has been 
associated with breast cancer progression and drug resistance (M Du et al., 2014). 
CCND2 promoter methylation was previously reported to be a common event in breast 
cancer and have prognostic value (Hung et al., 2018). A similar DNA methylation 
variability profile was observed in TCGA dataset, in particular for the VMRs showing 
strongest variability in the MCCS. Several previous studies have reported tumour DNA 
methylation to have prognostic value in cancer (Buffart et al., 2008; Ellinger et al., 2008; 
CY Hu et al., 2014; Sailer et al., 2017; Guo et al., 2018; de Almeida et al., 2019). 
Methylation at many gene promoters has been reported to have independent prognostic 
value in breast cancer including HOXA11 (Xia et al., 2017), ESR1 and PITX2 (Sheng et 
al., 2017), HOXD13 (Zhong et al., 2015) CDH22 (Martín-Sánchez et al., 2017) BRCA1 
and RASSF1 (Jiang et al., 2012; Wu et al., 2013). Tumour DNA methylation and its 
prognostic significance has also been investigated for certain breast cancer subtypes, in 
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particular gene expression-based subtypes. Thomas et al., (2017) used hierarchical 
clustering based on DNA methylation to further segregate luminal A tumours into two 
subgroups and found that the subgroup with lower relative methylation showed better 
prognosis (Fleischer et al., 2017), similar to the findings of this study. Another study 
using whole-genome methylation sequencing stratified triple-negative breast cancers into 
three methylation-defined clusters and found the hypomethylated cluster to show better 
prognosis compared with the other two highly methylated clusters (Stirzaker et al., 2015), 
also consistent with results of this study. However, to our knowledge, no study has 
reported on the overall tumour methylation variability in ILBC and tested the potential 
for the variably methylated regions to be used as prognostic markers. The assessment of 
VMRs was genome-scale but only the highest ranking VMRs were tested for their 
association with survival. Although many of the tested VMRs showed a significant 
association with overall survival, there could be other VMRs or individual CpG sites for 
which methylation is associated with survival. Promoter hypermethylation at APC, 
TMEM101 and HCG4P3 was found to be associated with shorter overall survival in the 
MCCS after adjustment for age and tumour stage. The results in TCGA were largely 
consistent with the MCCS, although associations generally appeared stronger; this might 
suggest that the prognostic value of these DNA methylation markers is greater for women 
with more advanced ILBC. In the pooled analysis, DNA methylation at four genes (APC, 
TME101, HCG4P3 and CELF2) was associated with shorter overall survival. All the 
highest ranking VMRs had an average methylation level below 0.5 and the direction of 
association with survival was virtually always positive, which indicates that methylation 
gains (i.e., loss of the normal hypomethylation state) were associated with worse survival. 
While a low correlation between methylation and gene expression was observed for APC, 
TMEM101 and NKX6, six of the nine VMRs tested showed a strong inverse correlation. 
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This could suggest that the VMRs tend to overlap with the promoter regions for the 
corresponding genes and the hypermethylation may be involved in repression of these 
genes. APC is a well-known tumour suppressor gene, and this finding is in agreement 
with previous reports (K He et al., 2016; Debouki-Joudi et al., 2017). Debouki et al., 
(2017) found a significant correlation between APC promoter methylation and aggressive 
behaviour of both non-familial and familial breast cancer in the Tunisian population 
(Debouki-Joudi et al., 2017). The association of APC promoter methylation with reduced 
survival has also been reported for other cancer types, such as non-small cell lung cancer 
(Brabender et al., 2001) and prostate cancer (Henrique et al., 2007; Richiardi et al., 2009). 
CELF2, an RNA binding protein involved in alternative splicing, has also been reported 
to be involved in breast cancer growth and progression. Piqué et al., (2019) found that 
CELF2 promoter methylation led to a loss of CELF2 expression that had a growth 
promoter effect in breast tumours. They also found that CELF2 promoter methylation 
was associated with worse patient outcome (Piqué et al., 2019). In TCGA data, a strong, 
negative correlation between CELF2 promoter methylation and the gene expression 
levels was found. TMEM101 is a transmembrane protein that has been shown to activate 
NF-kappa-beta signalling pathways. There is to our knowledge no previous literature 
suggesting a role of TMEM101 promoter methylation in relation to cancer 
progression/survival. HCG4P3 is also known as HLA complex group 4 pseudogene 3 and 
there is to our knowledge no record of this gene being involved in cancer. 
 
One of the main limitations of the candidate gene and genome-wide comparison of 
ILBC tumours with non-ILBC and adjacent normal samples was the selection of control 
samples.  Although all are breast tissues, the cellular composition of the non-ILBC, ILBC 
and adjacent normal tissue is likely to be somewhat different and therefore likely to have 
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different methylation profiles. The most ideal control sample for identifying DNA 
methylation specific to ILBC will one that had the same types of cells as the ILBC 
samples, which is challenging to achieve given the variation in normal breast and breast 
cancer histopathological features. Another factor that may have an impact on the results 
of ILBC and non-ILBC comparison at the genome-wide methylation level is tumour 
purity. Although more than 80% of the samples in both ILBC and non-ILBC tumour 
sample groups showed a tumour purity of more than 50%, the samples showed a range of 
purity values that could have impacted the DNA methylation signals for samples with 
low tumour purity. No significant bias (P.value, t.test= 0.13) was observed between ILBC 
and non-ILBC samples in terms of tumour purity (Table 2.1). The main limitation of the 
VMR study was the relatively small sample size that limited the analysis to all-cause 
death as an endpoint. The MCCS and TCGA data had different characteristics in terms of 
their study design and sample characteristics. The two studies had different follow-up 
times and TCGA data had more young women and generally higher tumour stage (Table 
3.3). These differences in the studies could in part account for the low concordance (28%) 
between the VMRs identified between the MCCS and TCGA. The findings for both the 
VMR and survival analysis were nevertheless consistent across the two studies. The main 
factors that we thought could impact methylation profiles in tumours and ILBC survival 
were considered, i.e., age and stage. Factors such as smoking, alcohol consumption or 
diabetes, and perhaps family history (via underlying genetic sequence) likely play some 
role, but it is presumably less important, so were not included in the analysis. These 
variables are not systematically collected with precision (questionnaires) in the clinical 
setting. In this context, this study identified methylation biomarkers and it is likely that 
many factors worthy of investigation (genetic and lifestyle and environmental) play a role 
in explaining the observed associations. Finally, while a large number of regions across 
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the ILBC genome that showed substantial variable methylation pattern were identified, 
only the strongest ten VMRs were tested for association with survival to minimise the 
multiple testing burden. If replicated by other studies, the methylation markers identified 
in our study may contribute to the development of molecular signatures for enhanced 
prediction of ILBC survival. Using TCGA dataset for validation, we were able to show 
that the VMRs identified in the MCCS were also consistently variably methylated across 
TCGA dataset. Although HRs in the two datasets show some variation, (including their 
statistical significance), they are consistent in terms of the direction of the association. 
Differences between the two studies, MCCS and TCGA in terms of study design and 
clinical characteristics of participants may in part account for the observed variation in 
association. This work warrants further validation in a larger dataset with less sample 
variation. 
3.5 Summary 
The analyses involving candidate gene approach in Part I of this study indicated 
that ILBC tumours were more frequently methylated at APC, RASSF1, TWIST1 and 
across the TS1500 region of BRCA1 compared with the non-ILBC tumours. Based on the 
genome-wide comparison of ILBC and non-ILBC tumours, genes that differed in their 
methylation patterns between ILBC and non-ILBC tumours were identified. Many of 
these genes were found to be enriched for pathways related to mRNA processing. Further 
investigation is required to find out the effect of these methylation alterations on the 
expression level of corresponding genes. This study also indicated that methylation levels 
at the most variable regions across the genome may explain differences in tumour 
prognosis within the ILBC subtype. APC, TMEM101, HCG4P3 and CELF2 promoter 
methylation were identified as possibly relevant prognostic biomarkers for women with 
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Chapter 4 Sub-classifying Invasive Lobular 




Heterogeneity within a breast cancer subtype is regarded as a major challenge in 
personalised cancer medicine. ILBC also presents as a heterogeneous disease showing 
varying morphological features, genetic makeup, clinical presentation and patient 
outcome (section 1.5) of the thesis. However, they are routinely regarded as a single entity 
while making treatment decisions. 
 
Gene expression profile-based subtyping has highlighted the heterogeneity of 
breast cancer and has enabled further subtyping. In their analysis, Sørlie et al., (2001) 
included 78 breast tumours, out of which only five were ILBC tumours (Sørlie et al., 
2001). Out of the five ILBCs, two were classified as luminal A and one each as luminal 
B, basal and normal-like subtype. West et al., (2001) used the expression levels of 7,129 
genes and identified similar subgroups as the intrinsic subtypes in 49 breast cancer 
samples that were all IDBC (West et al., 2001). In another study, Van’t Veer et al., (2002), 
used gene expression profiling of 98 primary breast cancer samples and identified a 70 
gene signature for poor prognosis however, in this study the histological information of 
samples was not reported (Van't Veer et al., 2002). ILBC was poorly represented in the 
foundation work that subtyped breast cancer and a better stratification is required to 
identify subtype-specific diagnostic and prognostic markers for a more precise treatment 
regime for ILBC. 
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DNA methylation is known to be a crucial regulator of gene expression and tumour 
methylation profiling has been shown to be a robust tool to accurately identify disease-
specific subtypes in many cancer types including breast cancer (Toyota et al., 1999; 
Noushmehr et al., 2010; Barreau et al., 2013; Conway et al., 2014). DNA methylation 
profiling is less technically challenging compared with gene-expression profiling as DNA 
is more stable than RNA and DNA methylation is detectable in tumour tissue thus making 
it a more applicable tool for clinical purposes (Kit et al., 2012). 
 
Several studies have used DNA methylation levels to further stratify breast cancer. 
However, these studies have primarily been focused on the intrinsic subtypes or more 
aggressive breast cancer subtype, TNBC. DiNome et al., (2019) used genome-wide DNA 
methylation profiles and identified four epitypes within TNBC that showed differences 
in survival and their gene expression and mutation profiles (DiNome et al., 2019). Zhang 
et al., (2018) identified nine subgroups within the intrinsic subtypes including two further 
subtypes within the basal-like group with prognostic significance (S Zhang et al., 2018). 
In another study, Fleischer et al., (2017) used hierarchical clustering based on tumour 
DNA methylation levels to further segregate luminal A tumours into two subgroups and 
found that the subgroup with lower relative methylation showed better prognosis 
(Fleischer et al., 2017). Stefansson et. al., (2015) using DNA methylation profiling of 40 
tumours and 17 normal breast samples defined two DNA methylation-defined subtypes; 
Epi-LumB and Epi-Basal associated with poor outcome (Stefansson et al., 2015). 
 
No study has yet attempted to subtype ILBC based on tumour DNA methylation 
profiling. In Chapter 3, it was demonstrated that a substantial variability in tumour DNA 
methylation exists within ILBC and some of this variability is associated with prognosis. 
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This finding points towards the potential of using tumour DNA methylation to stratify 
ILBC into further subgroups. In this study, we hypothesised that subgroups of ILBC may 
be identified using genome-wide tumour DNA methylation data. We aimed to identify 
subgroups of ILBC via unsupervised cluster analysis using genome-wide tumour DNA 
methylation profiling of 151 ILBC and 341 non-ILBCs. 
4.2 Method overview 
4.2.1 Study participants and data 
Analyses in this chapter included 492 invasive breast cancer samples. Details of 
the study resources are provided in Table 4.1. 
 
Table 4.1: Study participants and data. 
Study Breast cancer type 
 ILBC Non-ILBC 
MCCS
a
 (n=471) 130 341 
kConFab
b
 (n=6) 6 0 
ABCFR
c
 (n=15) 15 0 
Details of the study design is presented in the Methods section 2.1. 
Total 151 341 
Sample type 
FFPE tumour enriched DNA 
Details of sample preparation from FFPE is presented in the 
Method section 2.3.1. 
Data information 
Genome-wide DNA methylation using Illumina HM450K 
array (Details of the methylation assay is presented in the 
Methods section 2.5). 
ILBC: Invasive lobular breast cancer. Non-ILBC: Non-lobular invasive breast cancer. a Melbourne 
Collaborative cohort Study. b The Kathleen Cuningham Foundation Consortium for Research into Familial 
Breast Cancer. c Australian Breast Cancer Family Registry. FFPE: Formalin-fixed paraffin-embedded. 
HM450K: Illumina HumanMethylation 450K array. 
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4.3 Results 
4.3.1 Unsupervised cluster analysis 
To further subclassify ILBC, an unsupervised cluster analysis was performed 
(section 2.9.5), using the genome-wide tumour DNA methylation levels (M-values) of all 
ILBC (n=151) and non-ILBC breast cancer cases (n=341). 
 
The clustering divided the breast cancer samples into two main groups; group A 
and group B, based on the overall similarity in their DNA methylation patterns. The main 
groups further separated into many small groups (Figure 4.1). The pattern of clustering 
and length of branches in the dendrogram shows the relatedness of the samples by their 
genome-wide DNA methylation profiles (Figure 4.1). Group A contained 115/151 (76%) 
of the ILBC samples, whereas a smaller proportion, 36/151 (31%) of ILBCs clustered 
into group B. ILBC samples in group A formed close clusters (samples were in close 
proximity), whereas this was not observed in group B (Figure 4.1). Based on the 
clustering of ILBC samples in group A, subgroups of ILBC were defined such that, 
samples that stemmed from the same branch and formed a close cluster were assigned to 
the same subgroup. Based on this criterion, three main subgroups of ILBC were defined; 
Subgroup 1 (n = 28), Subgroup 2 (n = 27) and Subgroup 3 (n = 21), shown in the boxes 
in the dendrogram (Figure 4.1).
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Figure 4.1: Unsupervised cluster analysis of breast cancer samples (ILBC, n=151 and non-ILBC, n=341) based on their genome-wide DNA 
methylation profiles. 
Dendrogram showing the unsupervised clustering of all breast cancer samples (n = 492) including ILBC, n = 151 and non-ILBC, n = 341, based 
on their genome-wide DNA methylation profiles. Each leaf of the dendrogram represents a breast cancer sample and the length of the branches 
show the Euclidean distance between the two clusters (y-axis). Higher distance on the dendrogram represents more dissimilar clusters and vice-
versa. The colour bar “Subtype” indicates the two breast cancer histological subtypes; i.e., ILBC (shown in red) and non-ILBC (shown in turquoise). 
The colour bars “ER”, “PR” and “HER2” indicate the estrogen, progesterone and human epidermal growth factor receptor 2 expression status, 
respectively of the breast tumours. Hormone receptor positive tumours are shown in “yellow” and hormone receptor negative tumours are shown 
in “blue” colour. The three ILBC subgroups defined based on the clustering are numbered and marked in black boxes.
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As hormone receptor expression status has been known to significantly influence 
the DNA methylation patterns in breast tumours (Holm et al., 2010), we further tested 
whether the clustering was driven by the ER, PR and HER2 expression status (as 
measured by immunohistochemistry) of the tumours. The majority of the samples in all 
three ILBC subgroups were ER and PR positive and HER2 negative and a strong 
clustering based on the hormone receptor expression status was not observed for the ILBC 
samples (Figure 4.1). As the breast cancer samples included in this analysis were sourced 
from three different studies (Table 4.1), any influence of the variation in study design on 
the clustering was also tested. No significant association was observed between the 
clustering and the studies from which the samples were sourced (chi-square test, P-value 
= 0.28). 
4.3.2 Differential methylation between the ILBC subgroups 
To further investigate the differences in DNA methylation between the ILBC 
methylation-defined subgroups and to find the CpG positions that were differentially 
methylated (hypermethylated or hypomethylated) between the subgroups, a differential 
methylation analysis was performed as described in section 2.9.1 of the thesis. 
 
Between Subgroup 1 and Subgroup 2, 27,675 significantly (P-value < 0.01) 
differentially methylated positions (DMPs) were identified. Of these, 8,647 (31%) were 
hypermethylated and 19,028 (69%) were hypomethylated in Subgroup 1 compared with 
Subgroup 2 (Figure 4.2a). Between Subgroup 1 and Subgroup 3, 13,067 DMPs were 
identified, of which 4,758 (36%) were hypermethylated and 8,309 (64%) were 
hypomethylated in Subgroup 1 compared with Subgroup 3 (Figure 4.2b). Between 
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Subgroup 2 and Subgroup 3, 65 DMPs were identified and all 65 DMPs were 
hypomethylated in Subgroup 2 compared with Subgroup 3 (Figure 4.2c).
Chapter 4 
 





























DMPs between Subgroup 1 and Subgroup 2 DMPs between Subgroup 1 and Subgroup 3





     174 
Figure 4.2: Differentially methylated positions between ILBC methylation-defined subgroups. 
Volcano plots showing the differentially methylated positions (DMPs) between the ILBC methylation-defined subgroups a) between Subgroup 1 
and Subgroup 2; b) between Subgroup 1 and Subgroup 3 and c) between Subgroup 2 and Subgroup 3. logFC (change in the average M value 
between the comparison subgroups) is shown on the x-axis and P-value (log transformed) of the DMPs is shown on the y-axis. DMPs between the 
comparison subgroups are represented by the dots where blue colour dots represent the DMPs with an absolute logFC of greater than 2 and the 
grey colour dots represent the DMPs with an absolute logFC of less than 2 between the comparison subgroups.
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The differential methylation analysis revealed that Subgroup 1 was 
hypomethylation at most of the DMPs, whereas Subgroup 3 was hypermethylation at 
most of the DMPs identified between these two subgroups. The average methylation level 
of Subgroup 1 across the DMPs was found to be significantly different from the remaining 
two subgroups (Subgroup 1 and Subgroup 2- ANOVA, P-value = 2.7x10-13, Subgroup 1 
and Subgroup 3- ANOVA, P-value = 7.1x10-12), whereas the methylation profiles of 
Subgroup 2 and Subgroup 3 were more similar (ANOVA, P-value = 0.33). Figure 4.3 
shows the difference in average methylation levels between the ILBC methylation-
defined subgroups across the DMPs between the subgroups (Figure 4.3a) and across all 
CpG positions genome-wide (Figure 4.3b). 
 
 
Figure 4.3: Average methylation levels (beta-value) of the ILBC methylation-defined 
subgroups. 
Box plots illustrating the difference in average methylation levels (beta-value) between 
the ILBC methylation-defined subgroups; Subgroup 1, Subgroup 2 and Subgroup 3 
(shown on the x-axis) across a) the differentially methylated positions (DMPs) between 
the subgroups and b) all CpG positions genome-wide. ANOVA, P-values indicating the 
significance of the difference in average methylation levels between the subgroups in 
different comparisons and the overall comparison of the three subgroups are marked on 
the plots. 
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Subgroup 1 was found to cluster alongside the TNBC cases on the dendrogram. 
Although, the TNBC cases were clustered into a separate branch (group B) than Subgroup 
1 (Figure 4.1), the global methylation profile (average methylation beta-value across all 
CpG positions genome-wide) of Subgroup 1 was found to be more similar to TNBC 
(ANOVA, P-value = 0.37) than to Subgroup 2 (ANOVA, P-value = 3.9x10-6) and 
Subgroup 3 (ANOVA, P-value = 9.4x10-10) (Figure 4.4). 
 
 
Figure 4.4: Average methylation level (beta-value) of ILBC methylation-defined 
subgroups and the triple negative breast cancer cases alongside Subgroup 1. 
Box plots illustrating the average methylation level (beta-value), shown on the y-axis at 
all CpG positions genome-wide, of the ILBC methylation-defined subgroups; Subgroup 
1, Subgroup 2 and Subgroup 3 and the triple negative breast cancer (TNBC) cases that 
were found to cluster alongside ILBC on the cluster dendrogram (shown on the x-axis). 
ANOVA P-values indicating the significance of the difference in average methylation 
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In terms of the genomic locations, the DMPs between Subgroup 1 and Subgroup 
2 and between Subgroup 1 and Subgroup 3 were found to be largely distributed in the 
CpG island and the open sea region (region more than 4 kb away from the CpG island), 
whereas a smaller proportion was associated with the shore (up to 2 kb away from the 
CpG island) and the shelf (2-4 kb away from the CpG island) regions of the genome 
(Figure 4.5). The DMPs between Subgroup 2 and Subgroup 3 were predominantly 
associated with the CpG island region (85%) and a small proportion of DMPs were 
located in the shore (12%) and open sea region (3%) of the genome (Figure 4.5). 
 
 
Figure 4.5: Genomic distribution of the differentially methylated positions. 
Bar plot showing the distribution of the differentially methylated positions (DMPs) 
between the ILBC methylation-defined subgroups (shown on the y-axis) across different 
genomic regions; CpG island (region commonly associated with gene promoters), Shore 
(region up to 2 kb from the CpG island), Shelf (region up to 2-4 kb from the CpG island) 
and Open Sea (region more than 4 kb away from the CpG island). The x-axis shows the 
proportion of the DMPs in different genomic regions, represented by different bar colours 
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The consecutive (located within 1000 bp of each other) methylated CpG positions 
or differentially methylated regions (DMRs) were identified between the ILBC 
methylation-defined subgroups as described in section 2.9.1 of the thesis. The DMPs 
between Subgroup 1 and Subgroup 2 clustered into 3,740 DMRs, of which 1,441 (39%) 
were overlapping with gene promoters and 2,299 (61%) were present in the intergenic 
regions. Between Subgroup 1 and Subgroup 3, 1,276 DMRs were identified, of which 
498 (39%) were overlapping with gene promoters and 778 (61%) were present in the 
intergenic region. No DMRs were identified between Subgroup 2 and Subgroup 3 
possibly due to the smaller number of DMPs between these two subgroups. 
 
Table 4.2: Differentially methylated positions and differentially methylated regions 
identified in between the ILBC methylation-defined subgroups. 
ILBC methylation-defined 
subgroup Number of DMP Number of DMR 
Subgroup 1 and 2 27,675 3,740 
Subgroup 1 and 3 13,067 1,276 
Subgroup 2 and 3 65 0 




The DMRs identified in Subgroup 1 were overlapping the genes that were mainly 
transcription factors and genes related to protein kinases activity. Among the most 
significant DMRs (P-value < 0.01), were the microRNAs such as MIR433, MIR127, 
MIR136, MIR431 and MIR432 and also included the genes related to immune response 
such as TAP1, SOCS1, CD81, PSMB9, and TRIM27. Gene ontology analysis performed 
on the top 10% (by P-value) of the DMRs between the subgroups showed that the genes 
overlapping the DMRs between Subgroup 1 and Subgroup 2 were significantly enriched 
(FDR-adjusted P < 0.05) for functional categories such as Regulation of cytokine 
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production involved in inflammatory response (GO:1900015), Positive regulation of 
inflammatory response (GO:0050729), Regulation of leukocyte migration (GO:0002685), 
Cytokine secretion (GO:0050663) and Regulation of CD4-positive, alpha-beta T cell 
activation (GO:2000514). Among the significantly enriched (FDR-adjusted P < 0.05) 
functional categories in the genes overlapping the DMRs between Subgroup 1 and 
Subgroup 3 were Metabolism of RNA (R-HSA-8953854), mRNA Splicing (R-HSA-
72172), Processing of Capped Intron-Containing Pre-mRNA (R-HSA-72203), RNA 
splicing via transesterification reactions (GO:0000375) and Ribonucleoprotein complex 
biogenesis (GO:0022613). The ten most significant DMRs (by P-value) identified 
between the subgroups are summarised in Table 4.3 (between Subgroup 1 and Subgroup 
2) and Table 4.4 (between Subgroup 1 and Subgroup 3). Table 4.5 summarises the ten 
most significant DMPs (by P-value) identified between Subgroup 2 and Subgroup 3.
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Table 4.3: The ten most significant (by P-value) differentially methylated regions between ILBC methylation-defined Subgroup 1 and 
Subgroup 2. 






Protein Function Reported relevance to 
cancer progression/etiology 
Reference 
chr17:1956958-1958162 1.4x10-67 8 HIC1 Positive regulation of 
DNA damage 
response, signal 
transduction by p53 
class mediator 
Tumour suppressor function in 
several cancers including breast 
cancer. 
(Cheng et al., 
2014; Y Wang et 
al., 2018) 
chr7:66368242-66369611 8.6x10-58 7 RP11-458F8.4 Long non-coding RNA - - 
chr6:32036449-32038027 3x10-57 7 NA - - - 
chr6:32184410-32185984 6.4x10-57 7 NA - - - 
chr14:67999752-67999935 1.3x10-56 7 PLEKHH1, 
TMEM229B 
- - - 








Downregulation of TAP1 
promotes immune evasion and 
associated with poor outcome. 
(Pedersen et al., 
2017) 





MIR433, MIR127, MIR136, 
MIR431- tumour suppressive 
role in breast cancer. 
(S Wang et al., 
2014; M Yan et 
al., 2016; X Hu et 
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MIR431, 
RTL1, MIR432 
 al., 2018; W 




6.1x10-55 7 SOCS1 Negative regulation of 
cytokine signalling. 
Oncogenic role in TNBCb. (Qian et al., 2018) 
chr6:31853565-31855709 6.3x10-55 7 EHMT2 Histone H3-K27 
methylation, negative 
regulation of G0 to G1 
transition. 
Promotes metastasis in breast 
cancer. 
(K Kim et al., 
2018) 
chr7:75701033-75703958 1.2x10-54 7 AC005077.14-
001 
Pseudogene - - 
a Differentially methylated region. * P-value computed using Stouffer’s method (Stouffer et al., 1949). † RefSeq gene name. NA: DMR not annotated to any 
gene. b Triple negative breast cancer.
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Table 4.4: The ten most significant (by P-value) differentially methylated regions between ILBC methylation-defined Subgroup 1 and 
Subgroup 3. 






Protein Function Reported relevance to 
cancer progression/ etiology 
Reference 
chr11:2397773-2398533 1.0x10-56 7 CD81 Class I MHC mediated 
antigen processing and 
presentation, positive 
regulation of T-helper 2 cell 
cytokine production. 
Increased expression is 
associated with poor patient 
prognosis in breast cancer. 
(N Zhang et 
al., 2018) 
chr6:31597034-31599537 9.2x10-54 7 PRRC2A Regulation of pre-mRNA 
splicing. 
- - 
chr16:88940941-88943452 4.1x10-48 6 NA - - - 
chr6:28890887-28892849 7.9x10-48 6 TRIM27 Negative regulation of 
interleukin-2 secretion 
Promotes breast tumour growth (Xing et al., 
2020) 
chr7:66368242-66369525  4.3x10-47 6 RP11-
458F8.4 
Long non-coding RNA - - 
chr11:67260775-67262993 2.2x10-42 5 PITPNM1 Phosphatidylinositol 
biosynthetic process. 
Promotes epithelial to 
mesenchymal transition. 
(Keinan et al., 
2014) 
chr14:67999752-67999927 1.1x10-41 5 PLEKHH1, 
TMEM229B 
- - - 
chr7:35734160-35734978 1.1x10-41 5 HERPUD2, 
RP11-
379H18.1 
Cellular response to unfolded 
protein. 
- - 
chr6:33422190-33422529 1.4x10-41 5 ZBTB9 Transcription regulation. ER-alpha target gene. (Lin et al., 
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2007) 
chr6:32820577-32822017 7.4x10-40 5 TAP1, 
PSMB9 
TAP1-Antigen processing 
and presentation of 
exogenous peptide antigen 
via MHC class I, TAP-
dependent. 
PSMB9- immunoproteasome 
Downregulation of TAP1 
promotes immune evasion and 
associated with poor outcome. 
(Pedersen et 
al., 2017) 
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Table 4.5: The ten most significant (by P-value) differentially methylated positions between Subgroup 2 and Subgroup 3. 
DMPa P-value* Associated 
gene† 
Protein Function Reported relevance to cancer 
progression/ etiology 
Reference 
cg11715828 2.4x10-6 RNF220 Protein ubiquitination, positive regulation 
of canonical Wnt signalling pathway. 
Role in Wnt-related tumourigenesis such 
as colon cancer. 
(P Ma et al., 
2014) 
cg01656394 2.2x10-5 NA - - - 
cg15289658 2.2x10-5 PSAT1 Pyridoxal phosphate binding Associated with response to endocrine 
therapy in breast cancer. 
(Martens et al., 
2005) 
cg12796383 4.9x10-5 NA - - - 
cg18529845 5.8x10-5 SRD5A2 Metabolism of steroid hormones Regulates progesterone metabolism in 
breast cancer. 
(Lewis et al., 
2004) 
cg16896847 6.0x10-5 MAFA DNA binding and transcription factor 
activity 
- - 
cg22674412 1.1x10-4 RPRML p53 dependent arrest of the cell cycle. Tumour suppressor activity, inhibits cell 
migration and invasion. 
(Buchegger et al., 
2016) 
cg04974587 1.1x10-4 ARHGAP20 GTPase activator activity. - - 
cg14305313 1.2x10-4 NA - - - 
cg24879335 1.3x10-4 TF Iron binding protein - - 
a Differentially methylated position. * P-value calculated using moderated t.test. † RefSeq gene name.  NA: DMP not annotated to any gene.
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4.3.3 Correlation with clinicopathological features 
To further investigate any possible association between the ILBC methylation-
defined subgroups and the clinicopathological features of the tumour samples, the 
subgroups were evaluated using available clinical and pathological data and 
epidemiological information (including family history). A detailed comparison of the 
ILBC methylation-defined subgroups based on tumour characteristics and family history 
data are shown in Table 4.6. The associations were tested using Pearson’s chi-square test 
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(n = 28) 
Subgroup 2 
(n = 27) 
Subgroup 3 
(n = 21) 
P-
value* 
Median age at diagnosis, years 
[interquartile range] 
67 [25%; 60] 62 [25%; 59] 60 [25%; 51] 0.36 
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Median tumour Purity, % 
[interquartile range] 
56 [25%, 50] 54 [25%, 52] 58 [25%, 55] 0.73 
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Parity and lactation history, n (%) 
Nulliparous 
Parous, lactated 























































































































ILBC: Invasive lobular breast cancer. * P-values are for chi-square test and ANOVA test for 
categorical and continuous variables, respectively. a Melbourne Collaborative Cohort Study. b The 
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. c 
Australian Breast Cancer Family Registry. d New Zealand. ER: Estrogen receptor. PR: 
Progesterone receptor. HER2: Human epidermal growth factor receptor 2. † International 
Classification of Diseases for Oncology (8520- Invasive lobular breast cancer, 8522- Infiltrating 
ductal and lobular carcinoma), ER, PR and HER2 expression status was determined using 
immunohistochemistry as described in (Blows et al., 2010).
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The median age of women at cancer diagnosis was 67 years for Subgroup 1, 62 
years for Subgroup 2 and 60 years for Subgroup 3. The women were primarily of 
Australian/New Zealand ethnic background (64% in Subgroup 1, 82% in Subgroup 2 and 
62% in Subgroup 3). As previously observed in the unsupervised cluster analysis (Figure 
4.1), the clustering of ILBCs was not significantly driven by the ER, PR and HER2 
receptor expression status of the tumour and the majority of samples in all three subgroups 
were ER and PR positive and HER2 negative (Figure 4.6). This was consistent with what 
is known for ILBC (Ciriello et al., 2015; Reed et al., 2015). There was no ER negative 
case in Subgroup 1, whereas in Subgroup 2, 3/27 (11%) samples were ER negative and 
in Subgroup 3, 1/21 (5%) sample was ER negative. Subgroup 1 was enriched for ER 
positive/PR negative tumours, 8/28 (29%) compared with Subgroup 2, 4/27 (15%) and 
Subgroup 3, 4/21 (19%) however it was not statistically significant. There were 2 triple-
negative breast tumours, both in Subgroup 2. Out of the two triple-negative tumours in 
Subgroup 2, one was associated with DCIS and the woman was premenopausal. Both 
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Figure 4.6: Distribution of hormone receptor and human epidermal growth factor 
receptor 2 expression status across the ILBC methylation-defined subgroups. 
The bar plots showing the distribution of hormone receptor expression status measured 
using immunohistochemistry a) Estrogen receptor (ER); b) Progesterone receptor (PR) 
and c) Human epidermal growth factor receptor 2 (HER2) in the ILBC methylation-
defined subgroups (shown on the x-axis). The sample count is shown on the y-axis. 
Respective colours representing the hormone receptor expression status are marked in the 
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Grade II was the most frequently observed tumour grade across the three 
subgroups: 16/28 (57%) of cases in Subgroup 1, 18/27 (67%) of cases in Subgroup 2 and 
13/21 (62%) of cases in Subgroup 3 (Figure 4.7a). Four cases of grade III tumour were 
recorded in Subgroup 1 compared with three cases in Subgroup 2 and one case in 
Subgroup 3. Tumour stage was recorded as stage 1A/1B, 2A/2B, 3A/3C and stage 4 with 
stage 1A/1B being the most frequently observed across the subgroups (Figure 4.7b). In 
Subgroup 2, 15/27 (56%) of cases and in Subgroup 3, 10/21 (48%) of cases were stage 
1A/1B tumour compared with 9/28 (32%) of cases in Subgroup 1. Advanced stage 
tumours (3A/3C and stage 4) were relatively rare with five cases of tumour stage 3A/3C 
in Subgroup 1 (2/5 cases showed mixed lobular/ductal morphology, ICDO-code 8522), 
two cases each in Subgroup 2 and one case in Subgroup 3 (all showing classic ILBC 
morphology, ICDO-code-8520). There was one case of stage 4 tumour that clustered in 
Subgroup 2 (ICDO-code-8520). 
 
The size of the tumour at diagnosis ranged from 5 mm to more than 40 mm across 
the ILBC subgroups with most cases showing tumour sizes ranging from 10 mm to 20 
mm (10/28, 36% in Subgroup 1; 13/27, 48% in Subgroup 2 and 8/21, 38% in Subgroup 
3) (Figure 4.7c). Five cases had large size tumours (>40 mm), out of which, two cases 
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Figure 4.7: Distribution of tumour features across the ILBC methylation-defined 
subgroups. 
Bar plots showing the distribution of tumour features a) Tumour grade; b) Tumour stage; 
c) Tumour size and d) Tumour laterality in ILBC methylation-defined subgroups (shown 
on the x-axis). The sample count is shown on the y-axis. Respective colours depicting 











Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 1 Subgroup 2 Subgroup 3











Subgroup 1 Subgroup 2 Subgroup 3
P-value = 0.71 P-value = 0.39
P-value = 0.52 P-value = 0.51
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ILBCs are known to be more frequently bilateral and multifocal compared with 
other breast cancer types (Arpino et al., 2004). Across the ILBC methylation-defined 
subgroups, Subgroup 1 had equal proportion of women with tumour in left and right 
breasts, whereas Subgroup 2 and Subgroup 3 had higher proportion of women with 
tumours in the right breast compared to the left breast (Figure 4.7d). There was one 
bilateral case that clustered in Subgroup 2. There was an enrichment of multifocal 
tumours in Subgroup 2 (11/27, 41%) compared with Subgroup 1 (4/28, 14%) and 
Subgroup 3 (5/21, 24%) (Figure 4.8). No significant association was observed between 
ILBC methylation subgroups and any of the tumour features discussed above (tumour 
grade, P-value = 0.71; tumour stage, P-value = 0.39; tumour size, P-value = 0.52; tumour 
laterality, P-value = 0.51 and multifocality, P-value = 0.11). 
 
 
Figure 4.8: Distribution of tumour focality status across the ILBC methylation-
defined subgroups. 
The bar plot shows the distribution of tumour focality status in the ILBC methylation-
defined subgroups (shown on the x-axis) and the sample count shown on the y-axis. 
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Factors such as use of oral contraceptive, hormone replacement therapy, age at 
menarche and parity status are well known risk factors for breast cancer (Clavel-Chapelon 
& Gerber, 2002). In terms of oral contraceptive pill usage, Subgroup 2 and Subgroup 3 
showed a significant enrichment (P-value = 0.02) for women who had a history of oral 
contraceptive pills usage (19/27, 70% in Subgroup 2 and 13/21, 62% in Subgroup 3) 
compared with Subgroup 1 where 8/28 (29%) of the women had used or had been using 
oral contraceptive pills (Figure 4.9a). In terms of hormone replacement therapy (HRT), 
Subgroup 2 was again found to be slightly enriched for women who have taken HRT 
(12/27, 44%) compared with Subgroup 1 (9/28, 32%) and Subgroup 3 (6/21, 29%), 
however, this association was not statistically significant (P-value = 0.51) (Figure 4.9b). 
 
 
Figure 4.9: Distribution of women reproductive history and other breast cancer risk 
factors across the ILBC methylation-defined subgroups. 
Bar plots showing the distribution of reproductive history and other breast cancer risk 
factors a) Oral contraceptive usage and b) Hormone replacement therapy (HRT) across 
the ILBC methylation-defined subgroups (shown on the x-axis). The sample count is 
shown on the y-axis. Respective colours depicting the different factors are shown in the 















b)P-value = 0.02 P-value = 0.51
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A complex crosstalk exists between genetic variations and epigenetic patterns in 
tumours (You & Jones, 2012). Genetic variations are known to alter the DNA methylation 
patterns (Kerkel et al., 2008; Bell et al., 2011). Therefore, we were interested to know if 
any inherited genetic factor was driving the ILBC subgroups and to find out more, the 
subgroups were evaluated for the family history data of the women in the three ILBC 
methylation subgroups. Subgroup 3 was found to have a significant enrichment (P-value 
= 0.03) for women who had a mother with history of cancer (any kind) (Figure 4.10a). 
Looking at the data specific for breast cancer, Subgroup 2 and Subgroup 3 showed an 
enrichment for women who had a female relative with breast cancer (9/27, 33% of women 
in Subgroup 2 and 6/21, 28% of women in Subgroup 3) compared with Subgroup 1 (3/28, 
11%) however, the difference was not statistically significant (P-value = 0.22) (Figure 
4.10c). No significant association was found between the subgroups and women who had 
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Figure 4.10: Distribution of family history information of women across the ILBC 
methylation-defined subgroups. 
The bar plots show the distribution of the family history information of women with ILBC 
a) history of mother with cancer; b) history of father with cancer and c) history of a female 
relative with breast cancer across the ILBC methylation-defined subgroups (shown on the 
x-axis. The sample count is shown on the y-axis. Respective colours depicting the 































Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 1 Subgroup 2 Subgroup 3
Subgroup 1 Subgroup 2 Subgroup 3




     197 
4.3.4 Methylation subgroups differ in their overall survival 
As information on breast cancer specific survival was not available, difference in 
overall survival was tested among the ILBC methylation-defined subgroups. During the 
median follow-up period of 13 years, there were 17 confirmed deaths recorded in the 
sample set. Kaplan-Meir survival curves stratified according to the ILBC methylation-
defined subgroups are shown in the Figure 4.11a. The survival probability of the three 
subgroups were compared using a log-rank test that showed that Subgroup 1, with a 
relatively hypomethylated profile among the three subgroups, showed a poor overall 
survival in comparison with Subgroup 2 and Subgroup 3 (Figure 4.11a). While comparing 
the overall survival probability between the two most distinct methylation-defined 
subgroups, i.e., Subgroup 1 (the most hypomethylated) and Subgroup 3 (the most 
hypermethylated), Subgroup 1 showed a significantly reduced overall survival compared 
with Subgroup 3 (log-rank test, P-value = 0.035) (Figure 4.11b). After adjusting for age 
and year of diagnosis, in a multivariable analysis using Cox proportional regression 
hazard model, the association remained consistent, with Subgroup 1 showing a worse 
overall survival compared with Subgroup 2 and Subgroup 3 (Table 4.7). 
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Figure 4.11: Kaplan-Meier plot stratified according to the ILBC methylation-
defined subgroups. 
Kaplan-Meier plots show the overall survival curves of a) the ILBC methylation-defined 
subgroups; Subgroup 1, Subgroup 2 and Subgroup 3 and b) the ILBC methylation-
defined subgroups; Subgroup 1 and Subgroup 3. Total follow-up time (number of years) 
is shown on the x-axis and the survival probability (the probability of patients surviving 
past a specific time) is shown on the y-axis. The survival curves of the three ILBC 
methylation subgroups; Subgroup 1, Subgroup 2 and Subgroup 3 are represented by red, 
green and blue lines, respectively. Vertical lines on the survival curves indicate censored 
data and their corresponding x-values indicate the time at which the censoring occurred. 
Table below the plot shows samples at risk over time. 
 
 
Table 4.7: Hazard ratios for the association between the invasive lobular breast 







Adjusted for age and year 
of diagnosis 
Subgroup 1 





Subgroup 2 0.64 (0.22 -1.86) 0.41 0.59 (0.19-1.79) 0.35 
Subgroup 3 0.22 (0.05-1.05) 0.05 0.16 (0.03-0.88) 0.03 
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4.4 Discussion 
This chapter provides data to support the hypothesis that subgroups of ILBC with 
increased DNA methylation homogeneity can be identified using genome-wide tumour 
DNA methylation measurement. This approach defined three subgroups of ILBC via 
unsupervised cluster analysis that had significantly differentially methylated positions, 
some important differences in epidemiological risk factors and provided some evidence 
for differences in patient prognosis. 
4.4.1 ILBC subgroups associated with a family history of breast cancer 
A strong heritable component for ILBC susceptibility has been reported in 
previous studies. Allen-Brady et al., (2005) reported that relatives of women affected by 
ILBC had an increased risk for ILBC (first-degree relative: familial relative risk (FRR) = 
4.51, 95% CI: 2.8-6.9) and an increased risk for any type of breast cancer (first-degree 
relative: FRR = 2.5, 95% CI: 2.1-2.9) (Allen-Brady et al., 2005). This was supported by 
a recent report from Henry & Cannon‐Albright, (2019) who identified significant familial 
clustering in ILBC with an increased RR for breast cancer of any histology in second-
degree relatives of women with ILBC estimated to be 1.36 (95% CI: 1.25-1.47), P-value 
<0.001 (Henry & Cannon‐Albright, 2019). 
 
In this study, Subgroup 3 showed a significant enrichment (P-value = 0.03) for 
women who had a mother with history of cancer (any kind). Subgroups 2 and 3 were also 
found to be enriched for women who had a female relative with breast cancer. Genetic 
variation is known to influence DNA methylation both at the site of genetic variation and 
in some instances considerable distance from the genetic variation (Kerkel et al., 2008; 
Bell et al., 2011). The mechanisms behind this observation include simple direct 
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disruption (or creation) of the CpG sites, genetic disruption of the methylation machinery 
through to disruption of complex regulatory interactions where the effect is considerably 
distant from the genetic variation (McRae et al., 2014; Taylor et al., 2019). Data from 
this study could suggest that women in Subgroups 2 and 3 carry germline genetic 
variation and/or could have acquired common somatic genetic variation that influences 
the methylation pattern of their ILBC. The germline genetic variation could potentially 
be a rare variant that influences the tumourigenic pathway sufficiently to generate the 
methylation patterns described in the subgroups or could be a reflection of heritable 
common genetic variation that influences the methylation status of the ILBCs. Samples 
from Subgroup 2 and Subgroup 3 should be investigated further for possible association 
with a shared heritable component. This could possibly lead to the identification of 
subgroup-specific novel predisposition genes and or common genetic variation associated 
with ILBC. 
4.4.2 Genome-wide DNA methylation of mixed lobular ductal 
histological subtype 
ILBC can be morphologically challenging to categorise as some ILBC tumours 
also have growth patterns typical of ductal carcinomas. These tumours are classified as 
mixed lobular ductal carcinoma and are defined as having a lobular pattern in at least 50% 
of the tumour and a ductal pattern in 10-50% of the tumour (Lakhani, 2012). Mixed 
lobular ductal subtype (ICDO-code, 8522) constituted 17/76 (22%) of the ILBC tumours 
in the three methylation subgroups. The ILBC cases with mixed lobular ductal 
morphological features were found to cluster in the three subgroups: 7/28, 25% of cases 
in Subgroup 1, 3/27, 11% of cases in Subgroup 2 and 7/21, 33% of cases in Subgroup 3. 
A higher proportion of grade III tumours were observed in the mixed lobular ductal 
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subtype compared with the classic ILBC subtype (4/17, 24% grade III tumours in mixed 
lobular ductal versus 4/59, 7% in classic ILBC, chi-square, P-value = 0.07). Women who 
had a premenopausal cancer diagnosis showed a higher proportion of mixed lobular 
ductal tumours (3/4, 75% mixed lobular ductal tumour versus 1/4, 25% classic ILBC, chi-
square, P-value = 0.06). Although mixed lobular ductal subtype has been associated with 
more aggressive tumour features (Rakha et al., 2009; Arps et al., 2013), no significant 
difference in age at diagnosis (t.test, P-value = 0.09) and other prognostic features such 
as stage (chi square, P-value = 0.87) and tumour size (t.test, P-value = 0.37) was observed 
between classic ILBC and the mixed lobular-ductal type in this study. Although, a 
separation of mixed lobular ductal tumours into hypermethylated and hypomethylated 
subgroups was expected, the data did not suggest such differences in their methylation 
profiles. Some evidence relating to this is presented in the recent TCGA study where two 
groups of mixed lobular ductal tumours are defined namely “ILC-like” and “IDC-like” 
resembling ILBC and IDBC, respectively at their genomic level (Ciriello et al., 2015), 
which potentially could influence their genome-wide methylation profiles. Further study 
is needed to better characterise and further refine the classification of mixed lobular-
ductal tumours that should include molecular pathology approaches that can consider the 
growth patterns independently (rather than in a single tumour-enriched DNA sample). 
Single cell approaches may be useful here. 
4.4.3 Hypomethylation and Subgroup 1 
Subgroup 1 displayed a distinct methylation profile compared with the other two 
ILBC methylation-defined subgroups. Samples in Subgroup 1 had a hypomethylated 
profile across the DMPs identified between the subgroups as well as across all CpG 
positions genome-wide (global methylation, i.e., average across the genome) Figure 4.3. 
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The clustering of Subgroup 1 in the dendrogram was found to be alongside the TNBC 
cases. The TNBC cases and Subgroup 1 belonged to two separate main branches in the 
dendrogram; Group A and Group B, respectively on Figure 4.1. The global methylation 
profile (average methylation beta-value genome-wide) of Subgroup 1 resembled the 
TNBC cases (ANOVA, P-value = 0.37) compared with Subgroup 2 (ANOVA, P-value = 
3.9x10-6) and Subgroup 3 (ANOVA, P-value = 9.4x10-10) (Figure 4.4). This reveals a 
subset of ILBC cases that may share some features with TNBC. Although, none of the 
samples in Subgroup 1 were TNBC (based on their hormone receptor expression status), 
a higher proportion of ER positive PR negative tumours were found in Subgroup 1 
compared to the other two subgroups (8/28, 29% in Subgroup 1 versus 4/27, 15% in 
Subgroup 2 and 4/21, 19% in Subgroup 3). Although the difference was not statistically 
significant (P-value = 0.41), it may be reflective of a small sample size. PR negative 
tumours are known to be associated with poor patient outcome (Rakha, Reis-Filho, & 
Ellis, 2010) which is consistent with our finding that also associated Subgroup 1 with 
poorer overall survival when compared with Subgroup 2 and Subgroup 3. The proportion 
of stage 3A/3C tumours were higher in Subgroup 1 (5/28, 18% versus 2/27, 7% in 
Subgroup 2 and 1/21, 5% in Subgroup 3, P-value = 0.19), but was not a reflection of the 
distribution of mixed ductal ILBC in these subgroups. We found 3/28 (11%) cases in 
Subgroup 1 showing recurrence (one case of distant and two cases of local recurrences) 
compared with 1/27 (4%) case of distant recurrence in Subgroup 2 and 1/21 (5%) case of 
distant recurrence in Subgroup 3. These features associated with aggressive tumour 
behaviour further suggesting a similarity in clinical behaviour and suggests that Subgroup 
1 may represent an aggressive form of ILBC tumours independent of histology. 
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4.4.4 Implication of the immune response in Subgroup 1 
tumourigenesis 
The DMRs between the subgroups were mainly overlapping with genes that were 
transcription factors and genes related to protein kinase and protein transferase activity. 
The DMRs between Subgroup 1 and Subgroup 2 were mainly enriched in biological 
pathways related to immune system regulation such as Regulation of cytokine production 
involved in inflammatory response (GO:1900015), Positive regulation of inflammatory 
response (GO:0050729), Regulation of leukocyte migration (GO:0002685), Cytokine 
secretion (GO:0050663), Regulation of CD4-positive, alpha-beta T cell activation 
(GO:2000514) and involved genes such as MAPK14, IL17RA, APPL1, GPSM3, ADAM8, 
CD81 and HYAL2. This involvement of immune response related pathways and genes 
differentially methylated between Subgroup 1 and Subgroup 2 might suggest a difference 
at the level of immune regulation that might in part differentiate these subgroups. This 
finding is consistent with the gene-expression based subtypes of ILBC identified in 
previous studies that performed cluster analysis using mRNA gene expression data of 144 
and 106 ILBC samples, respectively (Ciriello et al., 2015; Michaut et al., 2016). Both 
these studies defined one of the ILBC subtypes as “immune related”. Michaut et al., 
(2016) defined this subtype characterised by upregulation of genes associated with 
cytokine/chemokine signalling and showed a higher lymphocytic infiltration. Similarly, 
Ciriello et al., (2015) also defined a subtype of ILBC characterised by overexpression of 
interleukin and chemokine mRNA expression and also showed an overexpression of 
macrophage associated signalling. This suggests that there might be functional difference 
in the immune activity that define the ILBC subgroups and that this subset of ILBC may 
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4.4.5 Limitations of the study 
Despite some promising results, one of the possible limitations of this study is the 
hierarchical clustering approach used to define the methylation subgroups. Clustering 
algorithms work by linking the two most similar samples together first, and then 
successively merging other samples in the order of similarity. Therefore, when new cases 
are added or the sample set is changed, the previous clustering order is revised, and a 
completely new dendrogram is generated. This was observed when clustering was 
performed using the same methylation dataset (methylation at 449,005 CpG positions), 
however limiting the clustering to only ILBC cases (n=151). Additional Figure 1 in the 
appendices shows how the dendrogram changed after the clustering was limited to only 
ILBC cases. Samples from Subgroup 1 (26/28, 92%) (identified in all breast cancer 
clustering, Figure 4.1), clustered in branch A, separate from the rest of the ILBC cases, 
shown in black on the colour bar (Additional Figure 1). Samples from Subgroup 2 and 
Subgroup 3 clustered in the main branch B with some overlapping. Although it was 
reassuring that Subgroup 1 was recognised as the most distinct subgroup, the existence 
of further subgroups in addition to the three defined subgroups and the subjective nature 
of the sample assignment to the subgroups must be acknowledged. We used TCGA DNA 
methylation data of all breast cancer (n = 666) to replicate the clustering. A similar 
clustering pattern of ILBC was observed in the TCGA dataset with ILBC samples 
clustering beside the TNBC cases similar to the pattern observed in the study set (defined 
as Subgroup 1) (shown in black boxes in Additional Figure 2). Since the clustering of 
ILBC samples in TCGA dataset was more dispersed compared to the study set, we were 
unable to clearly assign samples to Subgroup 2 and Subgroup 3. This gives further 
evidence for the similarities of Subgroups 2 and 3 and further challenges the approach of 
distinguishing them as two distinct subgroups (as discussed in section 4.3.2).  Differences 
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in the study set and TCGA dataset some of them being the characteristics of women such 
as age and tumour stage could likely be the cause of the observed differences in the 
clustering pattern. TCGA dataset, for example had on average older women with more 
advanced disease. We could not completely validate the three Subgroups in the TCGA 
dataset by performing the differential methylation analysis and linking the clusters to the 
clinical characteristics because it was challenging to assign samples to subgroups. This 
finding can be validated in larger dataset involving ILBC tumours with more uniform 
clinical characteristics to further assess if subgroups 2 and 3 are indeed one (albeit 
heterogeneous) subgroup. Another factor that could have impacted the methylation data 
is tumour purity. Tumour purity was assessed based on the methylation level information, 
which may be inaccurate without matching normal samples. No significant bias (P.value 
= 0.73, ANOVA) was observed between the subgroups in terms of the DNA methylation-
based tumour purity estimate (Table 4.6). However, comparing these estimates with 
purity values generated by an experienced pathologist would be beneficial. Since tumour 
purity was not assessed as part of the routine histopathology review of the tumour 
material, this could not be achieved in this study. 
4.5 Summary 
Investigating the genome-wide tumour-derived DNA methylation status of ILBC 
tumours provided more evidence to support that there is substantial heterogeneity within 
this breast cancer subtype. This chapter provides data to support the hypothesis that 
subgroups of ILBC with increased homogeneity can be identified using genome-wide 
tumour DNA methylation measurements. As the somatic mutation profiles of ILBC 
methylation-defined subgroups could both provide some direct explanation for the 
methylation differences and some further evidence of heterogeneity (and thus potential 
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for defining more homogeneous ILBC subgroups) the next chapter explores somatic 
events associated with the three ILBC subgroups described in this chapter.
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The molecular landscape of tumour is shaped by both genetic and epigenetic 
somatic events that are interlinked together (You & Jones, 2012). Growing evidence 
suggest that epigenetic modifications, in particular the DNA methylation pattern is 
influenced by the underlying genetic variations along with environmental and stochastic 
disruptions (Kerkel et al., 2008; Bell et al., 2011). DNA sequence variants that associate 
with DNA methylation are known as methylation quantitative trait loci (meQTL) and 
have been identified in different tissues throughout the genome (Gibbs et al., 2010; Bell 
et al., 2011; Drong et al., 2013). The meQTLs are known to impact the DNA methylation 
pattern of local CpGs (cis acting) as well as CpGs located at distant sites (trans acting). 
Conversely, DNA methylation is also known to influence the tumour genome. Methylated 
cytosines are shown to be more prone to random deamination (loss of amino group) than 
unmethylated cytosines resulting in a higher rate of C > T mutations at methylated CpG 
positions in the genome (Ehrlich et al., 1986). The rate of somatic mutation accumulation 
is also influenced by the nearby chromatic structure (among many other factors), which 
in turn is directly influenced by the methylation status of the DNA sequence (Schuster-
Böckler & Lehner, 2012). Epigenetic silencing of DNA repair genes such as MLH1, 
MGMT and BRCA1 has been reported to cause hypermutation during tumourigenesis that 
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Unique combinations of mutation types in a cancer genome are a record of various 
endogeneous and exogeneous processes that have been active during tumour initiation 
and progression and are termed mutational signatures (Ludmil B Alexandrov & Stratton, 
2014). Bioinformatics tools now make it possible to identify the contribution of these 
endogeneous and exogeneous processes in cancer genomes and thus can inform about the 
mechanisms that were disrupted during tumourigenesis (Ludmil B Alexandrov et al., 
2013). The identification of somatically acquired genomic variations provides the 
potential to identify driver mutations in tumours that may provide options for targeted 
therapies. The interpretation of mutational signatures provides additional opportunities to 
identify altered biological pathways that could be utilised in precision medicine 
approaches. For instance, the mutational signature, SBS3 has been associated with 
homologous recombination deficiency (HRD) (Nik-Zainal et al., 2016). Pathogenic 
germline or somatic variation in BRCA1 or BRCA2 and promoter hypermethylation in 
BRCA1 are well-recognised causes of HRD and thus, tumours showing SBS3 can 
potentially benefit from therapies targeting the HRD pathway (Nik-Zainal et al., 2016). 
Large-scale analyses of 4,645 whole genome and 19,184 exome sequences from most 
types of cancers have currently defined 49 single base substitution (SBS), 11 doublet base 
substitution, four clustered base substitution and 17 small insertion and deletion 
signatures that have been attributed to different mutational processes (Ludmil B. 
Alexandrov et al., 2020). 
 
Chapter 4 described three subgroups of ILBC based on an unsupervised cluster 
analysis of the genome-wide DNA methylation data presented in section 4.3.1. Further 
analyses suggested that Subgroup 1 had a distinct methylation profile with a higher 
frequency of hypomethylation across the DMPs compared with the other two subgroups. 
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Subgroup 3 on the other hand, was found to show higher frequency of hypermethylation 
across the DMPs. Genome-wide differences in DNA methylation in the ILBC 
methylation-defined subgroups might be associated with somatic variations that are 
reflected in the mutational signatures. In this chapter, the whole exomes of ILBC tumours 
from the methylation-defined subgroups were investigated and identified the mutational 
signatures with an aim to further characterise the subgroups based on their somatic 
mutation profiles and identify any subgroup-specific mutational processes. 
5.2 Method overview 
5.2.1 Study participants and data 
Analyses in this chapter included a total of 17 ILBC cases. Details of the study 
resources are provided in Table 5.1.
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Table 5.1: Details of the samples and data being used in this chapter. 
Result Part I: Pilot study 
Part II: Whole-exome 
sequencing and 
mutational signatures of 
tumours in the ILBC 
methylation-defined 
subgroups 
Case ILBC (n=2) ILBC (n=15) 
Sample 
type 
Tumour - DNA derived from FFPE tissue 
Germline - DNA derived from GC and WB 
Tumour - DNA derived from 
FFPE tissue  
Germline - DNA derived from 
GC 




(Sample 1-FFPE, Sample 1-FFPE-rep†, 
Sample 2-FFPE, Sample 2-FFPE-rep) 
 
Germline (n=4) 
Sample 1-WB, Sample 1-GC 










Somatic WES data (library preparation using Agilent SureSelect XT low input 
library preparation kit and SureSelect CREv2 exome (Agilent) as capture. 
 
(Details of library preparation and sequencing are presented in the Methods 
section 2.10). 
ILBC: Invasive lobular breast cancer. FFPE: Formalin-fixed paraffin-embedded. † Technical 
replicate are aliquots of DNA extraction from the same tumour sample. GC: Dried blood spots 
stored on Guthrie Cards. WB: Frozen whole blood. a Australian Breast Cancer Family Registry.  
b Melbourne Collaborative Cohort Study. WES: Whole-exome sequencing. CREv2: Clinical 
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Part I: Pilot study 
5.3 Methods specific to part I 
5.3.1 Experiment design 
A pilot study was conducted to assess: i) the effect of input FFPE-derived DNA 
and genomic DNA quantity and quality on the sequencing data quality and ii) the 
suitability of DNA derived from dried blood spots stored on Guthrie Cards, referred to as 
GC-DNA, as an alternative to DNA derived from frozen whole blood, referred to as WB-
DNA, as the matching germline sample. The pilot study data was also evaluated to 
determine the amount of sequencing data required for somatic variant calling and 
mutational signature analysis. 
 
The pilot study included two ILBC cases as shown in Figure 5.1. ILBC case 2 was 
a known carrier of a heterozygous germline variant in BRCA2 
(NM_000059.3:c.8167G>C), which is classified as pathogenic by ENIGMA (Spurdle et 
al., 2012). ILBC case 1 was not known to carry any pathogenic germline variant. As 
shown in Figure 5.1, each ILBC case had two tumour samples, which were DNA 
templates prepared from FFPE tumour material, referred to as Sample 1-FFPE and 
Sample 1-FFPE-rep for case 1 and Sample 2-FFPE and Sample 2-FFPE-rep for case 2. 
The “rep” samples were technical replicates, i.e., aliquots of DNA extraction from the 
same tumour from each ILBC case. Germline samples were prepared for each ILBC case 
from two different DNA sources, one from WB-DNA referred to as Sample 1-WB and 
Sample 2-WB and the other from GC-DNA referred to as Sample 1-GC and Sample 2-
GC for case 1 and case 2, respectively. 
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Figure 5.1: Selection of ILBC cases and library preparation for the pilot study. 
Diagram showing an overview of the pilot study workflow. Libraries were prepared for 
two ILBC cases from DNA derived from formalin-fixed paraffin-embedded (FFPE) 
tumour material. Matching germline libraries were prepared from DNA derived from 
frozen whole blood (WB-DNA) and dried blood spots stored on Guthrie Cards (GC-
DNA). Technical replicates of tumour, which were aliquots of DNA extraction from the 
same tumour are indicated as “rep”. SureSelect XT low input kit (Agilent) was used for 
library preparation and the libraries were enriched using SureSelect Clinical Research 
Exome v2 (CREv2, Agilent). The libraries were pooled and sequenced on a S4 flow cell 
on NovaSeq to generate 150 bp paired end reads. Somatic variant calling was performed 
in paired tumour-normal analysis mode using VarDict (Lai et al., 2016) using WB-DNA 






















(SureSelect XT Low input kit)
(SureSelect Clinical Research ExomeV2- capture)
Sequencing
(NovaSeq-150 bp Paired-end)













     214 
DNA quality, as assessed using the DNA integrity score (ΔΔCq), and amplifiable 
DNA quantity were estimated for both the tumour and germline DNA samples for each 
case using the NGS FFPE qPCR QC assay (Agilent) as described in section 2.10.1 of the 
thesis. The input DNA quantity for library preparation was determined based on the ΔΔCq 
score as per the manufacturer’s instructions. For DNA samples with a ΔΔCq > 1, input 
DNA quantity was calculated based on the qPCR assay results, whereas for samples with 
a ΔΔCq < 1, input DNA quantity was calculated based on the dsHS Qubit assay results 
(Thermo Fisher Scientific). An input DNA quantity of 100 ng was used for library 
preparation for all the samples except for Sample 2-FFPE-rep. An input DNA of 200 ng 
was used for Sample 2-FFPE-rep to test the effect of input DNA quantity on the 
sequencing data quality. Table 5.2 summarises the input DNA quantity and quality of the 
tumour and germline DNA samples in the pilot study. 
 
Table 5.2: Input DNA quantity and quality of the samples in the pilot study. 
ΔΔCq: DNA integrity score measured based on the NGS qPCR QC assay (Agilent). For samples with ΔΔCq 
> 1, input DNA quantity was calculated based on the NGS qPCR QC assay and for samples with ΔΔCq < 
1, input DNA quantity was calculated based on the dsHS Qubit assay. * Input DNA amount calculated 
based on the NGS qPCR QC assay. † Input DNA amount calculated based on the Qubit assay. The replicate 
samples indicated as “rep” are aliquots of DNA extraction from the same tumour. ng: nanogram. 
Sample Input DNA quantity (ng) Input DNA quality (ΔΔCq) 
Tumour   
Sample 1-FFPE 100* 1.19 
Sample 1-FFPE-rep 100* 1.18 
Sample 2-FFPE 100* 1.45 
Sample 2-FFPE-rep 200* 1.3 
Germline   
Sample 1-WB 100† -0.11 
Sample 1-GC 100†  0.31 
Sample 2-WB 100† -0.57 
Sample 2-GC 100† -0.08 
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Libraries were prepared using the SureSelect XT low input library preparation kit 
(Agilent) and enriched using Agilent SureSelect CREv2 as described in section 2.10.3 of 
the thesis. Tumour and germline libraries were pooled for multiplex sequencing as 
described in section 2.10.4 of the thesis. 2.5 nM of tumour libraries and 2.5 nM of 
germline libraries were pooled in a 4:1 (tumour: germline) ratio with the aim to achieve 
a mean target depth of coverage for tumour and germline samples of 150X and 50X, 
respectively. Sequencing was performed on the NovaSeq 6000 (Illumina, USA) using an 
S4 flow cell at the Australian Genome Research Facility (AGRF). All the libraries (n=8) 
were sequenced on a single lane to generate 150 bp paired end reads. 
5.3.2 Sequencing data processing and somatic variant calling 
Raw sequencing data was pre-processed as described in section 2.11 of the thesis. 
Somatic variant calling was performed using VarDict (Lai et al., 2016) for tumour 
samples and their technical replicates in paired tumour-normal analysis mode, using WB-
DNA and GC-DNC as the reference germline and two sets of somatic variant calls were 
generated. Somatic variant calling was performed using VarDict default filters as 
presented in detail in section 2.11 of the thesis. 
5.3.3 Determining thresholds for somatic variant filtering 
Single nucleotide variants (SNVs) that were exclusively detected in the tumour 
and not in the germline DNA (tagged as “StrongSomatic” by VarDict) and had passed all 
the default VarDict filters (tagged as “PASS”) were considered somatic SNVs (SSNVs) 
and selected for further analyses. A detailed description of the VarDict default filters is 
presented in section 2.11 of the thesis. On the SSNVs the following additional filters were 
applied: i) minimum read depth of 30X and ii) minimum variant allele fraction of 0.2. 
These filters were selected considering the mean target depth of coverage and the 
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percentage of target coverage achieved across the samples. For determining the above 
filter cut-offs, the BAM files of tumour and the reference germline samples were 
compared. The concordance level (number of matching genotypes) between the tumour 
and normal reads were assessed using the bcftools (H Li et al., 2009). The tumour and 
normal reads were compared at different allele frequencies and depths considering that a 
lower concordance level mainly represents the presence of sequencing artefacts. 
5.3.4 Variant annotation and mutational signature analysis 
The SSNVs were annotated using the VarSeq software (Golden Helix, Inc., 
Bozeman, MT, www.goldenhelix.com), to add annotations to the somatic and germline 
variants that included RefSeq Genes (O'Leary et al., 2016), COSMIC Mutations (Tate et 
al., 2019) and ClinVar (Landrum et al., 2018). 
 
Mutational signatures were generated using the R package deconstructSigs 
(Rosenthal et al., 2016). The somatic signature profiles of the tumour samples were 
identified using the predefined mutational signatures COSMIC (version3) 
(http://cancer.sanger.ac.uk/cosmic/signatures). Mutational signatures with weight 0.06 
and higher were considered significant as described in deconstructSigs (Rosenthal et al., 
2016). 
5.3.5 Determining the concordance between variant calls identified 
using different reference germline 
The SSNVs identified in the tumour samples using GC-DNA and WB-DNA as 
the reference germline are henceforth referred to as SSNVsGC and SSNVsWB, 
respectively. To determine the concordance between SSNVsGC and SSNVsWB, the two 
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sets of somatic variant calls (.vcf files) were compared at each variant position using the 
-isec option of bcftools (H Li et al., 2009). The function generated output .vcf files 
containing somatic variants that overlapped between SSNVsGC and SSNVsWB as well as 
.vcf files with somatic variants that were unique to SSNVsGC and SSNVsWB variant call 
sets. 
5.4 Results: Part I 
5.4.1 Evaluating the sequencing performance 
In the pilot study, tumour exomes of two ILBC cases (Sample 1-FFPE and Sample 
2-FFPE) were sequenced. Germline exomes from matching GC-DNA (Sample 1-GC and 
Sample 2-GC) and WB-DNA (Sample 1-WB and Sample 2-WB) were used as the 
reference germline. Technical replicates of the tumour samples (Sample 1-FFPE-rep and 
Sample 2-FFPE-rep) were also sequenced to test for technical reproducibility. 
 
The sequencing yielded an average of 138 million unique reads and a mean target 
depth of 56X for the tumour samples. For germline GC-DNA samples, an average of 49 
million unique reads and a mean target depth of 34X were achieved, whereas for germline 
WB-DNA samples an average of 48 million unique reads and a mean target depth of 37X 
were achieved (Figure 5.2a). For tumour samples, over 50% of the target was covered on 
average at a minimum of 30X read depth, whereas for the germline samples over 40% of 
the target was covered on average at a minimum of 30X read depth (Figure 5.2b). The 
mean target depth of coverage achieved in the pilot study was lower than expected for 
both the tumour (~150X) and germline (~50X) samples, as estimated based on the 
allocated data yield capacity of the NovaSeq S4 flow cell (120 Gb) and the targeted data 
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yield for the tumour and germline samples, which were 24 Gb and 6 Gb, respectively as 
recommended by AGRF. The sequencing quality metrics of the tumour and germline 
samples in the pilot study are summarised in Table 5.3. 
 
 
Figure 5.2: Mean target depth of coverage and percentage of target covered at 10X, 
30X and 50X of the tumour and germline samples in the pilot study. 
Graphs showing a) the mean target depth of coverage and b) the percentage of target 
(Clinical Research Exome v2, Agilent) covered at different read depths (10X, 30X and 
50X) for the samples in the pilot study, calculated using Picard tools 
(http://broadinstitute.github.io/picard/). Samples in plot b are represented by different 
colour bars as indicated in the legend in the top-right.
a)
b)
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Table 5.3: Whole-exome sequencing* quality metrics for the tumour and germline samples included in the pilot study. 
Gb: Gigabase. a Reads that are not marked as duplicates. *Clinical Research Exome v2, Agilent, 67.3Mb. † Bases that did not align the target region. Sequencing 
data quality metrics were calculated using Picard tools.








Bases of target 
covered at least at 
30X depth (%) 
Bases of target not 






Tumour        
Sample 1-FFPE 33 122 62 51 2.3 8 41 
Sample 1-FFPE-rep 38 125 76 60 2 8 50 
Sample 2-FFPE 33 137 73 55 2.2 6 36 
Sample 2-FFPE-rep 37 169 87 59 2 6 29 
Germline        
Sample 1-WB 10 48 37 41 3 7 21 
Sample 1-GC 9 48 33 36 3 5 16 
Sample 2-WB 10 48 36 39 3 6 20 
Sample 2-GC 10 50 34 40 3 6 18 
Chapter 5 
220 
To assess if the input DNA quantity has an impact on the sequencing data quality, 
the sequencing performance of Sample 2-FFPE and Sample 2-FFPE-rep were compared, 
which used different input DNA quantities (100 ng and 200 ng, respectively). Sample 2-
FFPE-rep had nominally higher mean target depth of coverage (87X versus 73X in 
Sample 2-FFPE) and percentage of target covered at a read depth of 30X (60% versus 
55% in Sample 2-FFPE), and a lower PCR duplication rate (29% versus 36% in Sample 
2-FFPE) in comparison with Sample 2-FFPE. The percentage of target covered at a read 
depth of 50X was also nominally higher for Sample 2-FFPE-rep (48% versus 43% in 
Sample 2-FFPE) (Figure 5.2b). No difference in the percentage of bases aligned off-target 
was observed between the two samples. The proportion of target bases not covered was 
also similar (~ 2%) for both samples (Table 5.3). 
 
Input DNA quality, as assessed by the ΔΔCq score ranged from 1.18 to 1.45 across 
the tumour samples and from -0.57 to 0.31 across the germline samples (Table 5.2). A 
large variation in the ΔΔCq score was not observed across the same sample type, therefore 
a reliable comparison between DNA quality and the output sequencing data quality could 
not be made. 
5.4.2 Use of Guthrie Card-derived DNA as germline reference 
To assess the suitability of GC-DNA to be used as an alternative to WB-DNA as 
the germline reference sample in tumour-normal paired analysis, the SSNVs (SSNVsGC 
and SSNVsWB) and the mutational signatures identified in the tumour samples including 
their technical replicates, using the two sources of germline DNA were compared. 
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At a minimum read depth of 30X, 33% of the target region was commonly covered 
by both Sample 1-WB and Sample 1-GC and 34% of the target region was commonly 
covered by both Sample 2-WB and Sample 2-GC (Table 5.4). 
 
Table 5.4: Target base coverage for the two sources of germline DNA. 
Sample 
Bases of target* 
covered at least 
at 30X depth 
(%) 
Number of target 
bases uniquely covered 
at a minimum read 
depth of 30X 
Bases of target commonly 
covered by WB-DNA and 
GC-DNA samples at 30X 
depth (%) 
Sample 1-WB 41 2,259 
33 
Sample 1-GC 36 11,444 
Sample 2-WB 39 9,414 
34 
Sample 2-GC 40 6,114 
* Clinical Research Exome v2 (Agilent, 67.3Mb). WB-DNA: DNA derived from frozen whole 
blood. GC-DNA: DNA derived from blood spots stored on Guthrie Cards. 
 
 
The total number of SSNVsGC and SSNVsWB identified in Sample 1-FFPE, 
Sample 2-FFPE and their technical replicates are summarised in Table 5.5. For Sample 
1-FFPE, a concordance level of over 55% between SSNVsGC and SSNVsWB was observed 
with 157 overlapping SSNVs, whereas 239 and 126 SSNVs were unique to the SSNVsGC 
and SSNVsWB call sets, respectively (Figure 5.3a). For Sample 2-FFPE, a concordance 
level of 55% was observed with 215 overlapping SSNVs, whereas 174 and 182 SSNVs 
were unique to the SSNVsGC and SSNVsWB call sets, respectively (Figure 5.3b). For 
Sample 1-FFPE-rep, a lower concordance level of 33% was observed with 199 
overlapping SSNVs, whereas 407 and 219 SSNVs were unique to the SSNVsGC and 
SSNVsWB call sets, respectively (Figure 5.3c). For Sample 2-FFPE-rep, a concordance 
level of over 50% was observed with 279 overlapping SSNVs, whereas 223 and 295 




Table 5.5: Total number of somatic single nucleotide variants identified in the 
tumour samples and their technical replicates using DNA derived from frozen whole 
blood and DNA derived from dried blood spots stored on Guthrie Cards as the 





Tumour SSNVs SSNVs 
Sample 1-FFPE 283 396 
Sample 1-FFPE-rep 418 606 
Sample 2-FFPE 397 389 
Sample 2-FFPE-rep 574 502 
WB-DNA: DNA derived from frozen whole blood. GC-DNA: DNA derived from dried blood spots stored 







Figure 5.3: Comparison of somatic single nucleotide variants calls identified using 
DNA derived from frozen whole blood and DNA derived from dried blood spots 
stored on Guthrie Cards as germline reference. 
Venn diagrams showing the overlap between somatic single nucleotide variants (SSNVs) 
identified in the tumour samples and their technical replicates; a) Sample 1-FFPE, b) 
Sample 2-FFPE, c) Sample 1-FFPE-rep and d) Sample 2-FFPE-rep, using matching DNA 
derived from frozen whole blood sample (WB-DNA) and dried blood spots stored on 
Guthrie Cards (GC-DNA) as the germline reference sample, in the tumour-normal paired 

















To investigate if the source of germline DNA has any impact on mutational 
signature analysis, mutational signatures were generated using the two sets of variant 
calls, SSNVsWB and SSNVsGC. Some mutational signatures were detected from both the 
pairs, whereas some signatures were detected from only one of the pairs. For Sample 1-
FFPE, mutational signatures SBS4 (signature weight = 0.06), SBS6 (0.06) and SBS31 
(0.11) were identified only from SSNVsGC, whereas SBS16 (0.08) was identified from 
SSNVsWB and not from SSNVsGC. Sample 1-FFPE-rep on the other hand, showed more 
concordant signature profile with only two signatures, SBS31 (0.07) and sequencing 
artefacts associated signatures (0.07), uniquely identified from SSNVsGC and not from 
SSNVsWB (Figure 5.4). 
 
In the case of Sample 2-FFPE, with a known heterozygous germline pathogenic 
variant in BRCA2 (NM_000059.3:c.8167G>C), the expected HRD-associated signature 
(Mesman et al., 2019), SBS3 was identified from SSNVsGC as the most predominant 
signature (signature weight=0.26), however SSNVsWB did not identify this signature 
(Figure 5.4). Other signatures that were uniquely identified from SSNVsGC were SBS5 
(0.07), SBS6 (0.08) and SBS13 (0.06). Mutational signatures identified uniquely from 
SSNVsWB were SBS1 (0.07), SBS5 (0.31), SBS24 (0.08) and SBS39 (0.08). Sample 2-
FFPE-rep displayed SBS3 in both the pairs with a signature weight of 0.20 and 0.15, 
respectively (Figure 5.4). No discrepancies were observed in the mutational signatures 
identified from SSNVsGC and SSNVsWB for Sample 2-FFPE-rep, although there were 




Figure 5.4: Mutational signatures identified in the tumour of ILBC cases included 
in the pilot study. 
Heatmap showing the mutational signatures identified in the tumour of ILBC cases 
generated using the somatic single nucleotide variants (SSNVs) with DNA derived from 
frozen whole blood (WB-DNA) and DNA derived from dried blood spots stored on 
Guthrie Cards (GC-DNA) used as matching germline reference sample in a tumour-
normal paired analysis. The mutational signatures identified using the SSNVs with GC-
DNA as the germline reference are marked as “FFPE-GC” and the mutational signatures 
generated using the SSNVs with WB-DNA as the germline reference are marked as 
“FFPE-WB” on the heatmap. Mutational signatures were generated using deconstructSigs 
(Rosenthal et al., 2016). The samples are plotted on the x-axis (as columns) and the 
mutational signatures are plotted on the y-axis (as rows). Signature weights are 

























































































































































































































5.4.3 Concordance between tumour samples and their replicates 
Tumour replicate libraries were prepared from aliquots of DNA extracted from 
the same tumour samples. The library profiles and SSNVs of the tumour samples were 
compared to their replicates to test for technical reproducibility of the assay. 
 
Comparing the post-hybridisation library profiles of the tumour samples and their 
respective technical replicates, Sample 1-FFPE library showed a fragment size peak at 
282 bp (Figure 5.5a) and the profile resembled a typical FFPE DNA sample as 
recommended in the protocol with the expected peak size of 200-400 bp, whereas in the 
case of Sample 1-FFPE-rep, two peaks were observed, one at 279 bp and another one at 
324 bp (Figure 5.5b). In the case of Sample 2-FFPE and its replicate, DNA fragment 
peaks were observed within the expected range at 284 bp and 274 bp, respectively (Figure 




Figure 5.5: Post-hybridisation library profiles of Sample 1-FFPE and its technical 
replicate. 
Electropherograms showing the post-hybridisation library profiles of a) Sample 1-FFPE 
and b) Sample 1-FFPE-rep, separated using the D1000 ScreenTape assay and the 
TapeStation system. The fragment size distribution of the library is shown on the x-axis 
and the library intensity is shown on the y-axis. The lower and upper markers at 25 bp 
and 1500 bp are internal references that are used to determine the molecular weight size 
of the sample. The expected peak size of the library DNA fragment is 200-400 bp 
according to the Agilent SureSelect low input library preparation protocol. The peak size 
of Sample 1-FFPE library was 282 bp. Two library fragment peaks were observed for 
Sample 1-FFPE-rep, one at 279 bp and another at 324 bp. 
G11: post Hyb DNA 288 8987_7
Sample Table
Well Conc. [pg/µl] Sample Description Alert Observations





Assigned Conc. [pg/µl] Peak Molarity [pmol/l] % Integrated Area Peak Comment Observations
25 434 - 26700 - Lower Marker
279 77.3 - 426 39.57
324 118 - 561 60.43
1500 250 250 256 - Upper Marker
Region Table
From [bp] To [bp] Average Size [bp] Conc. [pg/µl]
Region Molarity
[pmol/l]
% of Total Region Comment Color
150 1000 336 262 1270 81.02
High Sensitivity D1000 ScreenTape® Page 9
TapeStation Analysis Software A.02.02 (SR1) © Agilent Technologies, Inc. 2017 Generated: 27-Feb-2019
A11: post Hyb DNA 288 8987_1
Sample Table
Well Conc. [pg/µl] Sample Description Alert Observations





Assigned Conc. [pg/µl] Peak Molarity [pmol/l] % Integrated Area Peak Comment Observations
25 407 - 25100 - Lower Marker
282 884 - 4820 100.00
1500 250 250 256 - Upper Marker
Region Table
From [bp] To [bp] Average Size [bp] Conc. [pg/µl]
Region Molarity
[pmol/l]
% of Total Region Comment Color
150 1000 307 1000 5270 89.90
High Sensitivity D1000 ScreenTape® Page 3






Figure 5.6: Post-hybridisation library profiles of Sample 2-FFPE and its technical 
replicate. 
Electropherograms showing the post-hybridisation library profiles of a) Sample 2-FFPE 
and b) Sample 2-FFPE-rep, separated using the D1000 ScreenTape assay and the 
TapeStation system. The fragment size distribution of the library is shown on the x-axis 
and the sample intensity is shown on the y-axis. The lower and upper markers at 25 bp 
and 1500 bp are internal references that are used to determine the molecular weight size 
of the sample. The expected peak size of the library DNA fragment is 200-400 bp 
according to the Agilent SureSelect low input library preparation protocol. The peak size 
of Sample 2-FFPE and Sample 2-FFPE-rep libraries was observed at 284 bp and 274 bp, 
respectively. The tumour sample and its replicate differed in their input DNA amount 








D11: post Hyb DNA 288 8987_4
Sample Table
Well Conc. [pg/µl] Sample Description Alert Observations





Assigned Conc. [pg/µl] Peak Molarity [pmol/l] % Integrated Area Peak Comment Observations
25 414 - 25500 - Lower Marker
284 925 - 5020 100.00
1500 250 250 256 - Upper Marker
Region Table
From [bp] To [bp] Average Size [bp] Conc. [pg/µl]
Region Molarity
[pmol/l]
% of Total Region Comment Color
150 1000 306 1030 5420 90.29
High Sensitivity D1000 ScreenTape® Page 6
TapeStation Analysis Software A.02.02 (SR1) © Agilent Technologies, Inc. 2017 Generated: 27-Feb-2019
H11: post Hyb DNA 288 8987_8
Sample Table
Well Conc. [pg/µl] Sample Description Alert Observations





Assigned Conc. [pg/µl] Peak Molarity [pmol/l] % Integrated Area Peak Comment Observations
25 455 - 28000 - Lower Marker
274 1560 - 8770 100.00
1500 250 250 256 - Upper Marker
Region Table
From [bp] To [bp] Average Size [bp] Conc. [pg/µl]
Region Molarity
[pmol/l]
% of Total Region Comment Color
150 1000 292 1710 9310 94.41
High Sensitivity D1000 ScreenTape® Page 10





At a minimum read depth of 30X, 59% of the target bases were commonly covered 
by both Sample 1-FFPE and Sample 1-FFPE-rep, whereas 65% of the target bases were 
commonly covered by both Sample 2-FFPE and Sample 2-FFPE-rep. Similar SSNVs call 
sets were expected in the tumour samples and their respective technical replicates given 
that they were aliquots of DNA extraction from the same tumour sample. Comparing the 
SSNVsWB variant call set, Sample 1-FFPE and Sample 1-FFPE-rep showed a concordance 
of 41%, whereas a concordance of 64% was observed between Sample 2-FFPE and 
Sample 2-FFPE-rep (Figure 5.7a, Figure 5.7c). On the other hand, comparing the 
SSNVsGC variant call set, Sample 1-FFPE and Sample 1-FFPE-rep showed a concordance 
of 53%, whereas a concordance of 58% was observed between Sample 2-FFPE and 







Figure 5.7: Comparison of somatic single nucleotide variants identified in the 
tumour samples and their technical replicates. 
Venn diagrams showing the overlap of somatic single nucleotide variants (SSNVs) 
identified in the tumour samples and their respective technical replicates. The SSNVs 
identified using DNA derived from frozen whole blood (WB-DNA) as the germline 
reference sample are referred to as SSNVsWB and the SSNVs identified using DNA 
derived from dried blood spots stored on Guthrie Cards (GC-DNA) as the germline 
reference are referred to as SSNVsGC. Venn diagrams a) and b) show the comparison 
between Sample 1-FFPE and Sample 1-FFPE-rep of SSNVsWB and SSNVsGC variant call 
sets, respectively. Venn diagrams c) and d) show the comparison between Sample 2-

















Part II: Whole-exome sequencing and mutational signatures of 
tumours in the ILBC methylation-defined subgroups 
5.5 Methods specific to part II 
5.5.1 Sample selection 
Five ILBC cases were selected from each ILBC methylation-defined subgroup 
identified in Chapter 4 for WES (Figure 5.8). Table 5.6 summarises the clinical and 
pathological characteristics of the selected ILBC cases. The primary selection criteria for 
the cases from the subgroups was their participation in the MCCS. Samples were selected 





Figure 5.8: Selection of cases from the ILBC methylation-defined subgroups for whole-exome sequencing. 
Dendrogram showing the result of the cluster analysis presented in Chapter 4 where three methylation-defined subgroups were identified (shown 
in black boxes). The colour bar “Subtype” shows ILBC samples in red and non-ILBC samples in turquoise colour. Five cases were selected from 
each ILBC methylation-defined subgroup for whole-exome sequencing.
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with breast cancer* 
Family history of 
colorectal cancer 
8965 1 70 8520 Never II 1A ER+/PR+/HER2- NA NA 
34757 1 83 8520 Never II 2A ER+/PR+/HER2- Yes (Mother) No 
13412 1 67 8520 Never II 1A ER+/PR-/HER2- No No 
10780 1 62 8522 Never II 3A ER+/PR+/HER2+ No NA 
27328 1 57 8520 Never II 2A ER+/PR+/HER2- No No 
34778 2 67 8520 Never II 1A ER-/PR-/NA Yes Yes 
24634 2 60 8520 Never II 3A ER+/PR+/HER2- No No 
29513 2 71 8520 Never II 1A ER+/PR-/HER2- Yes (Aunt) Yes 
27217 2 69 8520 Former II 1A ER+/PR+/HER2- NA No 
38184 2 63 8520 Never III 1A ER+/PR+/HER2- No Yes 
33053 3 69 8522 Never II 3A ER+/PR+/HER2- No Yes 
25911 3 68 8520 Never II 1A ER+/PR+/HER2- Yes (Mother) No 
40384 3 51 8522 Former II 2A ER+/PR-/HER2- No No 
37762 3 51 8522 Current III 1A ER+/PR+/HER2+ Yes (Mother) No 
32623 3 60 8520 Never II 2A ER+/PR+/HER2- Yes (Aunt) Yes 
ER: Estrogen. PR: Progesterone. HER2: Human epidermal growth factor receptor 2, +: Positive. -: Negative. NA: Not available. *Any breast cancer type. ICDO: International 
Classification of Diseases for Oncology (8520- Infiltrating lobular carcinoma, 8522- Infiltrating ductal and lobular carcinoma).
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5.5.2 Library preparation and sequencing 
Tumour and germline libraries were prepared for 15 ILBC cases from DNA 
derived from tumour-enriched FFPE material and GC-DNA, respectively. Library 
preparation was done following the manufacturer’s instructions without any 
modifications, as described in section 2.10.3 of the thesis. An input DNA quantity of 200 
ng (where available) was used for library preparation for both the tumour and germline 
samples as per the manufacturer’s recommendation. Based on the comparison of WB-
DNA and GC-DNA in the pilot study, GC-DNA was found suitable to be used as an 
alternative to WB-DNA as the germline reference and, therefore all germline libraries in 
the main experiment were prepared using GC-DNA. As the mean target depth of coverage 
achieved in the pilot study was lower than expected, additional sequencing was added in 
the main experiment to mitigate the loss of sequencing due to off-target coverage and 
PCR duplication. We aimed for a mean target depth of 150X mapped for tumour and 
40X-50X mapped for the germline samples. The data output for the main experiment was 
estimated based on the pilot study data. In the pilot study for tumour samples, 
35	Gb	raw	data → 138	million	reads	average → 75X	mean	target	depth	of	coverage 
So, to achieve 150X mapped mean target depth of coverage for the tumour samples, 
Required	raw	data = 35 ∗
150
75 = 70	Gb 
For germline samples, 
10	Gb	raw	data → 49	million	reads	average → 35X	mean	target	depth	of	coverage 
So, to achieve 40X-50X mapped mean target depth of coverage for the germline samples, 
Required	raw	data = 10 ∗
40
35 = 10	Gb 
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Although the calculations indicated 70 Gb of raw data per tumour sample and 10 
Gb of raw data per germline sample, the targeted data was considered too high by AGRF. 
Considering the low library complexity of tumour samples, increasing the sequencing 
after a certain point would not result in increase in the target depth of coverage as the 
same DNA template are sequenced rather than sequencing any more unique DNA 
template. So, considering AGRF’s suggestion, we aimed for 44 Gb of raw data per tumour 
sample and 11 Gb of raw data per germline sample. 
5.5.3 Tumour mutation burden 
Tumour mutation burden (TMB) was calculated as the total number of SSNVs per 
megabase of the target region covered. Since the percentage of target region covered at a 
read depth of 30X (minimum read depth used for variant filtering) was different for 
different tumour samples, the effective target region covered of the total 67.3 Mb (target 
capture size-CREv2) for each sample was calculated as below and individual target 
coverage value for each sample was used in the TMB calculation. 
Effective	target	region = %	target	covered	at	a	read	depth	of	30X/67.3	Mb	 
5.5.4 Testing for microsatellite instability 
Microsatellite instability of the tumour samples were investigated using 
MSIsensor (Niu et al., 2014). The reference genome was first interrogated for 
microsatellites (maximum repeat unit length of 5 bp) and homopolymers (at least 5 bp 
length) and the microsatellite sites found in the reference genome were recorded. Aligned 
sequencing reads of both tumour and germline (BAM files) with sufficient coverage (at 
leads 20 reads in both the tumour and germline) were then examined for the available 
microsatellite regions, recorded previously in the reference genome and deletion length 
variation between tumour and germline was identified. A χ2 test was used to identify the 
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loci that were significantly different between tumour and germline and were tagged as 
somatic. The percentage of somatic sites identified based on the χ2 test were represented 
as the MSI score. The samples with MSI score > 3.5 were considered microsatellite 
instable and with MSI score < 3.5 were considered microsatellite stable as described in 
(Niu et al., 2014). 
5.6 Results: Part II 
5.6.1 Evaluating the sequencing performance 
To investigate the mutational signatures in the tumours from the three ILBC 
methylation-defined subgroups, WES was performed on five cases from each subgroup 
using DNA derived from FFPE tumour material and matching germline DNA derived 
from GC-DNA (Figure 5.8). The input DNA quality and quantity and the sequencing data 
metrics of the tumour samples and the germline reference samples are summarised in 
Table 5.7 and Table 5.8, respectively.
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Table 5.7: Input DNA quality and quantity and whole-exome sequencing* data quality metrics of tumour samples from the ILBC 

















Bases of target 
covered at least 
at 30X (%) 
Bases of target 







8965_FFPE 1 200 3.1 149 57 48 2 11 60 
34757_FFPE 1 200 2.8 218 106 59 2 6 56 
13412_FFPE 1 177 4.6 263 116 61 2 7 70 
10780_FFPE 1 200 4.0 119 38 37 2 10 58 
27328_FFPE 1 200 3.3 188 81 51 2 8 58 
34778_FFPE 2 200 0.83 246 158 59 2 5 54 
24634_FFPE 2 200 1.3 175 80 61 2 10 49 
29513_FFPE 2 179 3.7 177 83 57 2 8 57 
27217_FFPE 2 200 1.76 217 107 58 2 5 50 
38184_FFPE 2 200 1.78 214 93 52 2 7 52 
33053_FFPE 3 200 0.99 273 160 65 2 5 54 
25911_FFPE 3 200 2.58 195 99 61 2 7 53 
40384_FFPE 3 200 1.61 234 114 56 2 5 54 
37762_FFPE 3 200 0.04 232 131 58 2 5 53 
32623_FFPE 3 200 2.2 174 64 51 2 13 51 
FFPE: formalin-fixed paraffin embedded. ng: nanogram. a Reads that are not marked as duplicates. *CREv2 (Agilent). ΔΔCq: DNA quality score measured based on the FFPE NGS qPCR QC 
assay. † Bases that did not align the target region.
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Table 5.8: Input DNA quality and quantity and whole-exome sequencing* data quality metrics of the germline samples from the ILBC 






Input DNA  
quantity 
(ng) 









Bases of target 
covered at least 
at 30X (%) 
Bases of target 







8965_GC 1 200 -0.7 70 49 54 2 7 28 
34757_GC 1 200 -0.8 67 46 51 2 7 27 
13412_GC 1 200 0.37 62 42 48 2 7 27 
10780_GC 1 200 -0.63 70 49 54 2 7 28 
27328_GC 1 200 -0.84 76 52 54 2 6 29 
34778_GC 2 200 0.09 62 41 48 2 7 25 
24634_GC 2 200 -0.01 59 38 43 2 7 25 
29513_GC 2 200 -0.35 59 40 48 2 7 25 
27217_GC 2 183 0.59 32 19 22 2 7 18 
38184_GC 2 200 -0.15 41 24 28 2 6 23 
33053_GC 3 200 0.16 56 36 44 2 7 23 
25911_GC 3 200 -0.47 68 45 51 2 7 27 
40384_GC 3 200 0.20 25 15 15 2 7 16 
37762_GC 3 200 -0.39 35 22 26 2 6 21 
32623_GC 3 200 -0.37 67 46 51 2 7 26 
GC-DNA: DNA derived from dried blood spots stored on Guthrie Cards. ng: nanogram. a Reads that are not marked as duplicates. *CREv2 (Agilent). ΔΔCq: DNA quality score measured based 
on the NGS qPCR QC assay. † Bases that did not align the target region.
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The input DNA quality, as measured by the ΔΔCq score, varied across the samples 
in the ILBC methylation-defined subgroups where a lower ΔΔCq score represents a 
sample with more amplifiable DNA. For germline samples, the ΔΔCq scores ranged from 
-0.84 to 0.59 (Table 5.8), whereas across the tumour samples, a wide variation was 
observed with the ΔΔCq scores ranging from 0.04 to 4.6 (Table 5.7). A significant 
negative correlation was observed between the ΔΔCq score and the mean target depth of 
coverage in both the tumour (Pearson correlation, R = -0.59, P-value = 0.02) and germline 
samples (R = -0.58, P-value = 0.04) (Figure 5.9b and Figure 5.10b). While, a significant 
negative correlation between the ΔΔCq score and the number of unique reads was 
observed in the germline DNA samples (R = -0.57, P-value = 0.04) (Figure 5.10a), the 
association was not statistically significant in the tumour DNA samples (R = -0.42, P-
value = 0.12) (Figure 5.9a). The ΔΔCq score was negatively correlated with the 
percentage of target covered at a read depth of 30X in both the tumour and germline 
samples however, the association was not statistically significant for any of the sample 
types (Figure 5.9c, Figure 5.10c). While the ΔΔCq score showed a strong positive 
correlation with the PCR duplication rate (R = 0.74, P-value = 0.002) in the tumour, the 




Figure 5.9: Correlation between the DNA integrity score measured as the ΔΔCq 
score and the sequencing data quality metrics of the tumour samples. 
Scatterplots showing the correlation between the DNA quality measured as ΔΔCq score 
using the Agilent NGS qPCR QC assay (on the x-axis) and whole-exome sequencing 
metrics in the tumour samples (on the y-axis) where low ΔΔCq score represents a sample 
DNA with high amplifiability and vice-versa. The Pearson correlation coefficient, R and 
P-value indicating the strength and significance of correlation between the ΔΔCq score 
and a) Number of unique reads (million), R = -0.42, P-value = 0.12; b) Mean target depth 
of coverage, R = -0.59, P-value = 0.021; c) Percentage target covered at 30X read depth, 
R = -0.42, P-value = 0.12; d) Percent bases off-target, R = 0.42, P-value = 0.12 and e) 
PCR duplication rate, R = 0.74, P-value = 0.0018 are indicated in each plot in the top-
left. 























































































































































































Figure 5.10: Correlation between the DNA integrity score measured as the ΔΔCq 
score and the sequencing data quality metrics of the germline samples. 
Scatterplots showing the correlation between DNA quality measured as ΔΔCq score using 
Agilent NGS qPCR QC assay (on the x-axis) and sequencing data metrics of the germline 
samples (on the y-axis) where low ΔΔCq score represents a sample DNA with high 
amplifiability and vice-versa. The Pearson correlation coefficient, R and P-value 
indicating the strength and significance of correlation between the ΔΔCq score and a) 
Number of unique reads (million), R = -0.57, P-value = 0.042; b) Mean target depth of 
coverage, R = -0.58, P-value = 0.036; c) Percentage target covered at 30X read depth, R 
= -0.53, P-value = 0.064; d) Percent bases off-target, R = 0.44, P-value = 0.13 and e) PCR 
duplication rate, R = -0.62, P-value = 0.024 are indicated in each plot in the top-left. 


















































































































































































The sequencing yielded 57 million unique reads for the germline samples and 205 
million unique reads for the tumour samples on average. Mean target depths of 38X (15X-
52X) and 99X (38X-160X) were achieved for the germline and tumour samples, 
respectively. On average 42% of the target was covered at a read depth of 30X in the 
germline samples, whereas 56% of the target was covered at a read depth of 30X in the 
tumour samples. A higher duplication rate ranging between 49%-70% (average 55%) was 
observed for the tumour samples when compared with the germline samples (16%-29%, 
average 25%). Deeper sequencing in the main experiment based on our findings in the 
pilot study did not seem to improve the target depth of coverage. The mean target depth 
of coverage for both the tumour and germline DNA was lower than the aimed target 
coverage, which were 150X mapped (44Gb of raw data/tumour sample) for the tumour 
and 40X-50X mapped (11Gb of raw data/per germline sample) for the germline samples. 
5.6.2 Mutational signatures of tumours in ILBC methylation subgroups 
A total of 17 different mutational signatures were identified in the ILBC tumours 
(n=15) from the ILBC methylation-defined subgroups (Figure 5.11), that included 





Figure 5.11: Mutational signatures identified in the tumours from the ILBC 
methylation-defined subgroups. 
Heatmap showing the mutational signatures identified in the tumours of ILBC samples 
from the three ILBC methylation-defined subgroups, generated using deconstructSigs 
(Rosenthal et al., 2016). The samples are plotted on the x-axis (as columns) and the 
mutational signatures are plotted on the y-axis (as rows). Signature weights are 
represented by colours in the heatmap as indicated in the colour key in the bottom-right 
corner. Stacked bar plot shows different types of somatic variants identified in the ILBC 
tumours as indicated in the legend in the bottom-left. The colour bar “Subgroup” indicates 
the three ILBC methylation-defined subgroups. The colour bars “Age”, “Grade” and 
“Stage” indicate the age of women at tumour diagnosis, tumour grade and tumour stage, 
respectively. The colour bars “ER”, “PR” and “HER2” indicate the expression status 
(measured by immunohistochemistry) of estrogen receptor, progesterone receptor and 
human epidermal growth factor receptor 2 of the ILBC tumours. The legends on the top-



















































































































































































































































































3 prime UTR variant 5 prime UTR variant
Frameshift variant Inframe InDels
Splice acceptor variant Splice donor variant
Splice region variant Missense variant





Signatures associated with exogeneous environmental exposures were SBS7b, 
associated with ultraviolet light-induced DNA damage (Pfeifer et al., 2005), SBS22, 
associated with exposure to aristolochic acid (Poon et al., 2013) and SBS31 associated 
with platinum drug treatment (Boot et al., 2018) (Table 5.9). SBS6, associated with DNA 
mismatch repair deficiency (MMRd) was the most commonly observed endogeneous 
signature in the ILBC tumours, detected in 4/5 (80%) of the tumours in each ILBC 
subgroups. However, no significant difference in the mean signature weight of SBS6 was 
observed between the ILBC methylation-defined subgroups (ANOVA, P-value = 0.66). 
Other MMRd associated signatures were also displayed by the ILBC tumours that 
included SBS15, observed in 2/5 (40%) of the tumours in Subgroup 2, SBS21, observed 
in 2/5 (40%) of the tumours in Subgroup 3 and SBS26 observed in 2/5 (40%) of the 
tumours in Subgroup 1 (Table 5.9). No significant difference in the cumulative weight of 
MMRd associated mutational signatures SBS6, SBS15, SBS21 and SBS26 was observed 
between the three subgroups (ANOVA, P-value = 0.24). Although, MMRd associated 
signatures were observed ubiquitously in ILBC tumours across all three subgroups, no 
somatic or pathogenic germline variants in the mismatch repair genes MLH1, MSH2, 
MSH3, MSH6, PMS1 and PMS2 were observed in any of these cases according to ClinVar 
(accessed on 2020-01-01). 
 
SBS2 and SBS13, both associated with apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like (APOBEC) cytidine deaminase DNA-editing activity 
endogeneous exposures (Nik-Zainal et al., 2012), were observed in only one tumour from 
Subgroup 1 (Table 5.9). SBS30, associated with base excision repair deficiency was 
observed in 1/5 (20%) of the tumours in Subgroup 1. Several signatures were identified 
in the ILBC tumours for which the etiology is currently unknown that included SBS5, 
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SBS19, SBS23, SBS37 and SBS39. Of these, SBS39 was the most prominent and was 
detected in 14/15 (93%) of the ILBC tumours (Table 5.9). 
 
Table 5.9: Mutational signatures identified in the tumours of the ILBC methylation-
defined subgroups. 











SBS7b-UV exposure 1 (20) 1 (20) 1 (20) 
SBS22-Aristolochic acid 
exposure 
0 (0) 0 (0) 1 (20) 
SBS31-Platinum drug 
treatment 
2 (40) 4 (80) 1 (20) 
Endogeneous 
exposure 
SBS1-Age related 3 (60) 3 (60) 4 (80) 
SBS2 and SBS13-
APOBEC activity 
1 (20) 0 (0) 0 (0) 
SBS6-Mismatch repair 
deficiency 
4 (80) 4 (80) 4 (80) 
SBS15-Mismatch repair 
deficiency 
0 (0) 2 (40) 0 (0) 
SBS21-Mismatch repair 
deficiency 
0 (0) 0 (0) 2 (40) 
SBS26-Mismatch repair 
deficiency 
2 (40) 0 (0) 0 (0) 
SBS30-Base excision repair 
deficiency 
1 (20) 0 (0) 0 (0) 
Unknown 
etiology 
SBS5 1 (20) 0 (0) 2 (40) 
SBS19 0 (0) 0 (0) 1 (20) 
SBS23 0 (0) 0 (0) 1 (20) 
SBS37 1 (20) 1 (20) 1 (20) 




5.6.3 Mismatch repair deficiency and microsatellite instability 
The mismatch repair system plays a key role in repairing the mismatched 
nucleotides and thus, maintain genomic stability and integrity and prevents insertion and 
deletions of DNA at the microsatellite sites (Hsieh & Yamane, 2008). Due to its role in 
genomic stability, some of the downstream consequences of MMRd are microsatellite 
instability, high mutation load and the accumulation of large number of InDel variants in 
tumours (Hsieh & Yamane, 2008). 
 
The MSI-score of the ILBC tumours ranged from 0 to 58 (Table 5.10). Based on 
the MSI-score, 13/15 (87%) of the ILBC tumours were classified as microsatellite 
instable. Comparing the correlation between the cumulative weight of MMRd associated 
signatures SBS6, SBS15, SBS21 and SBS26, and the MSI-score calculated using 
MSIsensor, no significant correlation was observed between the two (Figure 5.12).
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Table 5.10: Percentage of the target region covered at a minimum read depth of 30X and the effective target region used for calculating 







Bases of target* 
covered at least at 
30X read depth (%) 
Effective target 
region of total 
67.3Mb* for TMBa 
calculation (Mb) 
TMBa 
InDel variants per 
Mb of target region 
covered at 30X 
read depth 





8965 1 48 32 46 12.2 0.08 7 
34757 1 59 40 5 0.9 0.19 0 
13412 1 61 41 11 1.6 0.26 26 
10780 1 37 25 19 3.4 0.42 18 
27328 1 51 34 10 1.6 0.15 58 
34778 2 59 40 9 1.9 0.2 7 
24634 2 61 41 11 1.9 0.26 0 
29513 2 57 38 7 1.8 0.17 9 
27217 2 58 39 24 4.2 0.2 22 
38184 2 52 35 22 3.1 0.15 14 
33053 3 65 44 57 9.4 0.28 13 
25911 3 61 41 9 1.5 0.11 28 
40384 3 56 38 42 6.2 0.11 21 
37762 3 58 39 22 3.9 0.08 17 
32623 3 51 34 42 2.3 0.18 33 
ILBC: Invasive lobular breast cancer. * Clinical research exome v2 (Agilent), 67.3Mb. a Tumour mutation burden. InDel: Insertion and deletion. MMRd: 




Figure 5.12: Correlation between the cumulative weight of mismatch repair 
deficiency associated mutational signatures and the microsatellite instability score 
of the tumours from the ILBC methylation-defined subgroups. 
Scatterplot showing the correlation between the cumulative weight of mismatch repair 
deficiency (MMRd) associated mutational signatures SBS6, SBS15, SBS21 and SBS26 
(on the x-axis) and the microsatellite instability score (MSI-score) calculated using 
MSIsensor (Niu et al., 2014) (on the y-axis) of the tumours in the ILBC methylation-
defined subgroups. The correlation coefficient, R = - 0.13 and P-value = 0.65, indicate 




The TMB of the ILBC tumours was calculated after normalising to the actual 
target region covered by each sample at a minimum read depth of 30X (the applied cut-
off for variant filtering) (Table 5.10). The TMB of ILBC tumours in the methylation-
defined subgroups ranged from 5 to 56 mutations/Mb (Table 5.10). The average TMB in 
Subgroup 1 was 17 mutations/Mb compared with 14 mutations/Mb in Subgroup 2. 
Tumours in Subgroup 3 had the highest TMB ranging from 8 to 56 (average 33 
mutations/Mb) however, there was no significant difference in the mean TMB between 
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the three subgroups (ANOVA, P-value = 0.13). The rate of InDel variants (total number 
of InDel variants detected per Mb of target region covered at a minimum read depth of 
30X) was also higher in Subgroup 3 (mean=4.7) when compared with Subgroup 1 
(mean=3.9) and Subgroup 2 (mean=2.6) (Table 5.10). While no significant correlation 
was observed between the cumulative weight of the MMRd associated mutational 
signatures and the TMB of the tumours (Figure 5.13a), the TMB showed a strong positive 




Figure 5.13: Correlation between the tumour mutation burden of tumours from the 
ILBC methylation-defined subgroups with mismatch repair deficiency associated 
mutational signatures and total number of somatic insertion and deletion variants 
in the tumours. 
Scatterplots showing the correlation between a) the cumulative weight of mismatch repair 
deficiency (MMRd) associated signatures (on the x-axis) and the tumour mutation burden 
(TMB) (on the y-axis), R = -0.087, P-value = 0.76 and b) the TMB and the rate of somatic 
insertion and deletion (InDel) variants (R = 0.83, P-value = 0.00011), identified in the 
tumours from the ILBC methylation-defined subgroups. The correlation coefficient, R 
and P-value indicating the significance of the association are also marked on the top-left 
of the plot. 
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5.6.4 Methylation status of mismatch repair deficiency related genes 
As promoter hypermethylation of mismatch repair genes, in particular MLH1, has 
been reported to be associated with MMRd (Bevilacqua & Simpson, 2000; Kuismanen et 
al., 2000; Salvesen et al., 2000), the association between the methylation status of 
mismatch repair genes MLH1, MSH2, MSH3, MSH6, PMS1 and PMS2, and MMRd 
associated mutational signatures were investigated. The ILBC tumours in all three 
methylation-defined subgroups showed a consistent hypomethylation pattern (beta-value 
< 0.50) across the promoter regions of MSH2, MSH3, MSH6, PMS1 and PMS2 (Figure 
5.15). However, the methylation pattern across the TSS1500 region of MLH1 (14 CpGs, 
973 bp) was variable across the ILBC tumours (Figure 5.14). The variable region 
overlapped the functional promoter region of MLH1 as described in (James G Herman et 
al., 1998) (GenBank U83845). Hypermethylation (beta-value > 0.50) was observed at six 
CpG positions across this variable region with 3 CpGs; cg02103401, cg24607398 and 
cg10990993 found to be hypermethylated in 9/15 (60%), 11/15 (73%) and 12/15 (80%) 
of the ILBC tumours. However, DNA methylation level at these 14 CpG positions located 
in the TSS1500 region did not show any significant correlation with the cumulative 




Figure 5.14: Methylation patterns of ILBC tumours at MLH1. 
Plots showing the methylation patterns of tumours from the ILBC methylation-defined 
subgroups at the promoter region of MLH1 a) shows the total MLH1 gene region covered 
by the CpG probes in the assay and b) shows a higher resolution of the TSS1500 region 
of the MLH1 gene. The CpG positions overlapping different genomic locations of the 
gene are shown on the x-axis and the methylation level (beta-value) of the samples are 
shown on the y-axis. Genomic coordinates for the regions are marked in the 
corresponding plot in the top-left corner. The different colour lines represent different 
samples belonging to the ILBC methylation-defined subgroups as indicated in the legend 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.15: Methylation pattern of ILBC tumours at mismatch repair genes.  
Plots showing the methylation patterns of ILBC tumours from the methylation-defined 
subgroups across the genes associated with mismatch repair; a) MSH2 b) MSH3 c) MSH6 
d) PMS1 and e) PMS2. Similar data for MLH1 is shown in the Figure 5.14. The CpG 
positions overlapping different genomic locations of the genes are shown on the x-axis 
and the methylation level (beta-value) of the samples are shown on the y-axis. Genomic 
coordinates for the regions are marked in the corresponding plot in the top-left corner. 
The different colour lines represent different samples belonging to the ILBC methylation-


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 5.11: Correlation between DNA methylation at each CpG position in the 
TSS1500 region of MLH1 and mismatch repair deficiency and microsatellite 
instability score of the ILBC tumours. 






tumours, n (%) 
R P-value R P-value 
cg02103401 9 (60) -0.33 0.23 0.059 0.84 
cg24607398 11 (73) -0.47 0.076 0.023 0.94 
cg10990993 12 (80) -0.17 0.54 -0.037 0.9 
cg04726821 5 (33) -0.38 0.16 0.01 0.97 
cg11291081 3 (20) -0.32 0.25 -0.011 0.97 
cg05670953 4 (27) -0.35 0.21 -0.006 0.98 
cg18320188 0 (0) -0.13 0.64 0.062 0.83 
cg04841293 0 (0) 0.052 0.85 -0.2 0.47 
cg05845319 1 (7) -0.15 0.6 -0.46 0.083 
cg21109167 1 (7) -0.11 0.71 -0.15 0.58 
cg03901257 0 (0) 0.074 0.79 -0.36 0.18 
cg02279071 0 (0) 0.075 0.79 -0.32 0.24 
cg14751544 0 (0) -0.38 0.17 -0.49 0.065 
cg16764580 0 (0) 0.31 0.26 -0.35 0.2 
* Genomic region from -200 to -1500 nucleotides upstream of the transcription start site. ILBC: 
Invasive lobular breast cancer. R: Pearson’s correlation coefficient. a Mismatch repair deficiency.  


















This chapter presents the results of the investigation of the exomic somatic mutation 
profiles of ILBC tumours within a selection of cases from the DNA methylation defined 
ILBC subgroups identified in Chapter 4. Mutational signatures present in the ILBC 
tumours suggested a potential involvement of MMRd in the tumourigenesis and 
progression of some of these ILBCs. Since WES using FFPE DNA was not previously 
used in our lab, a pilot study was conducted. Data from the pilot study was evaluated to 
test the effect of DNA quality and quantity on the sequencing data quality and the 
suitability of GC-DNA to be used as the germline reference sample for detecting somatic 
variants and identifying mutational signatures. 
 
Input DNA quality and quantity are important factors to consider while preparing 
libraries for next generation sequencing experiments. Comparison of the sequencing 
metrics of two tumour DNA samples with different quantities of input DNA from the 
pilot study showed that Sample 2-FFPE-rep with higher input DNA, showed a nominally 
higher depth and breadth of coverage compared with Sample 2-FFPE (Table 5.3). A 
higher input DNA quantity also seemed to reduce the PCR duplication rate. PCR 
duplicates represent the fraction of sequencing reads that arise from the same original 
DNA template. One of the main reasons for high PCR duplication rates is low starting 
input DNA amount that leads to over-amplification of the same DNA template during 
library preparation (Akbari et al., 2005). This is reflected in the case of Sample 2-FFPE 
and Sample 2-FFPE-rep. Although, a better sequencing metrics was observed with 
increased amount of input DNA, the difference was not large. However, this may be 
because this comparison involved two aliquots of the same DNA extraction. Two DNA 
samples with the same DNA quality may have minimised the impact of different DNA 
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quantities. Although the library preparation kit by Agilent is designed for low input DNA, 
the pilot data suggested an improvement in the sequencing data quality when higher 
amount of input DNA was used for library preparation. In the main experiment, the DNA 
quality (ΔΔCq score) showed a large variation, ranging from 0.04 to 4.6 for the tumour 
DNA samples (Table 5.7) and from -0.84 to 0.59 for the germline DNA samples (Table 
5.8). Therefore, based on the evaluation of Sample 2-FFPE and Sample 2-FFPE-rep, 200 
ng of input DNA was used in the main experiment for all the samples. However, it should 
be noted that this conclusion was based on the comparison of only two samples. 
 
DNA extracted from FFPE tumour tissues are highly degraded and fragmented. 
Formalin fixation reduces the efficiency of FFPE derived DNA for PCR amplification 
due to DNA-protein crosslinks that increases the sensitivity of DNA to mechanical stress 
and decreases its accessibility for enzymes (Do & Dobrovic, 2015). Excessive 
fragmentation could also lead to FFPE-DNA fragments that are too small for Illumina 
bridge amplification (Bentley et al., 2008). Therefore, an accurate quality and quantity 
estimation of amplifiable DNA is crucial before library preparation for obtaining uniform 
data quality and coverage (Quach et al., 2004; Do & Dobrovic, 2015). The Qubit assay 
quantifies the absolute amount of double stranded DNA present in a sample that also 
includes DNA fragments that are not suitable for amplification. The FFPE NGS qPCR 
QC assay (Agilent), which was used in this study for DNA quantification, measures the 
concentration of amplifiable DNA fragments. It is a PCR-based assay that amplifies two 
different genomic regions and generates amplicons of sizes, 42 bp and 123 bp. The DNA 
integrity score (ΔΔCq) is calculated by comparing the cycle threshold values (Cq) for 
amplicon A (42bp) and amplicon B (123bp) of the sample with a reference DNA with 
high molecular weight. A lower ΔΔCq score represents a sample with more amplifiable 
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DNA. The input DNA quantity was adjusted based on the ΔΔCq score before library 
preparation as per manufacturer’s instructions. For samples with ΔΔCq score > 1, 
representing sample DNA with low amplifiability, the input DNA quantity was calculated 
based on the qPCR results thus, considering the exact amount of amplifiable DNA in the 
calculation. In addition to being a measure for DNA quality and amplifiability, ΔΔCq 
score was also found to be predictive of the sequencing data quality in the tumour and 
germline DNA samples from the ILBC methylation-defined subgroups. High ΔΔCq score 
representing samples with lower amplifiability were found to be associated with lower 
mean target depth of coverage and higher PCR duplication rates in the tumour DNA 
samples. Therefore, the ΔΔCq score represents an important predictor of sequencing 
performance at the very initial stage of the assay and may be used to make informed 
decisions regarding sample selection. 
 
To evaluate the robustness and sensitivity of the WES assay, the sequencing data 
qualities of the tumour samples and their technical replicates from the pilot study were 
compared. We did not observe a large difference in the sequencing metrics of Sample 1-
FFPE and Sample 1-FFPE-rep (Table 5.3). Small variation observed in the target depth 
of coverage and percent of target covered at a read depth of 30X may be related to 
differences in sample handing during library preparation. Variations introduced due to 
differences in sample handling during library preparation is evident in the case of Sample 
1-FFPE and Sample 1-FFPE-rep (Figure 5.5). Looking at their post-hybridisation library 
profiles (Figure 5.5a, Figure 5.5b), differences in the library fragment size distribution 
can be noted between the profiles of the same tumour DNA sample. Cluster generation 
and sequencing efficiency on Illumina systems are known to be influenced by the library 
fragment size (Head et al., 2014). Smaller fragments tend to cluster more efficiently to 
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the flow cell than the larger fragments. This may partly explain small differences 
observed in the mean target depth of coverage and percentage of target covered for 
Sample 1-FFPE and Sample 1-FFPE-rep. In the case of Sample 2-FFPE and Sample 2-
FFPE-rep, a slightly better sequencing performance was observed for Sample 2-FFPE-
rep that may be attributed to the higher amount of input DNA used for this sample. As 
discussed earlier, higher input DNA was not found to have a large impact on the 
sequencing data quality as this comparison involved two aliquots of the same DNA 
sample thus, two samples with the same DNA quality. 
 
Since, the tumour DNA samples and their respective technical replicates were the 
duplicate aliquots of the same stock sample, we expected to see a good concordance 
between the SSNVs identified in them. However, comparing the SSNVs between the 
tumour samples and their respective replicate samples showed a low overlap. Between 
Sample 1-FFPE and Sample 1-FFPE-rep, only 41% of SSNVsWB and 53% of the 
SSNVsGC were concordant (Figure 5.7a, Figure 5.7b). In the case of Sample 2-FFPE and 
Sample 2-FFPE-rep, only 64% of SSNVsWB and 58% of SSNVsGC were concordant  
(Figure 5.7c, Figure 5.7d). One of the possible explanations of this high discordant rate 
observed between the tumour samples and their respective technical replicates could be 
the low target overlap observed between the samples. At a minimum read depth of 30X 
(the applied threshold for variant filtering), only 59% of the target bases overlapped 
between both Sample 1-FFPE and Sample 1-FFPE-rep and 65% of the target bases 
overlapped between both Sample 2-FFPE and Sample 2-FFPE-rep. The SSNVs detected 
only in the common target region were compared to calculate the concordance rate 
between the samples thus, resulting in a high observed discordance. Other reason for the 
discordance could be the sequencing artefacts that may be present even after variant 
Chapter 5 
258 
filtering. Since the tumour DNA showed a range of DNA quality (ΔΔCq score) and the 
percentage of target covered at a minimum read depth of 30X also varied across the 
tumour samples, the applied variant filters were not suitable for all the samples. The 
concordance level between the tumour DNA samples and their technical replicates was 
low (~3%) before any variant filtering and although, a considerable improvement in the 
concordance rates between the tumour samples and their technical replicates was 
observed after variant filtering (minimum read depth of 30X and minimum variant allele 
fraction of 0.2), artefacts still remained. Applying a higher read depth and allele frequency 
filters may have further reduced the sequencing artefact rates however, this would also 
lead to the loss of a large portion of target region as the percentage of target covered 
reduced with increasing read depths for both the tumour and the germline reference 
samples (44% target covered at 50X read depth and 21% at 100X read depth for FFPE 
versus 24% at 50X and 8% at 100X read depth for germline, GC-DNA and WB-DNA 
samples). Applying higher thresholds for variant filtering would also increase the chance 
of removing some true variants present at lower variant allele fractions and depth and 
hence more stringent filtering cut-offs were not applied. Poor sequence read depth in the 
germline reference sample may lead to calling germline events as somatic. To mitigate 
this, variant filtering may be performed based on whether the variants were reported in 
dbSNP to remove germline variants and to get a more refined list of somatic variants. 
There are other approaches that could be applied to further refine the somatic variant 
identification such as variant calling using two different somatic variant caller and using 
the common variants identified by the two callers as the final set for downstream analyses. 
 
The suitability of dried blood spots stored on Guthrie Cards to be used as the 
matching germline reference sample was tested in the pilot study. Guthrie Cards provide 
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a means for long term blood storage that has been proved to be an efficient and cost-
effective alternative to conventional blood freezing for genomic and epigenomic studies 
(Mei et al., 2001; H He et al., 2007; Mas et al., 2007; Al Safar et al., 2011; Ghantous et 
al., 2014; Nguyen-Dumont et al., 2015). Blood samples collected on a GC can be stored 
at room temperature indefinitely prior to DNA extraction, thus reducing the cost and 
infrastructure requirements for low temperature storage. The overall sequencing 
performance of GC-DNA and WB-DNA was similar for both the ILBC cases in the pilot 
study (Table 5.3). However, comparing SSNVsWB and SSNVsGC, a low concordance level 
of approximately 40% and 55% was observed between the two variant call sets for 
Sample 1-FFPE and Sample 2-FFPE, respectively (Figure 5.3). The low concordance 
level between SSNVsWB and SSNVsGC could be explained by the difference in the target 
region commonly covered by the WB-DNA and GC-DNA. At a minimum read depth of 
30X, only 33% of the target region was found to be commonly covered by both Sample 
1-WB and Sample 1-GC and only 34% of the target region was commonly covered by 
both Sample 2-WB and Sample 2-GC (Table 5.4). Since the overlapping target region 
between the two sources of germline reference samples was low (over 30% for both the 
samples), it resulted in the identification of different sets of somatic variants with low 
concordance, when the two sources of germline DNA were used as the reference samples. 
Although, considerable discordance was observed between SSNVsWB and SSNVsGC, the 
expected mutational signature, SBS3 was detected as a primary signature in SSNVsGC for 
both Sample 2-FFPE and Sample 2-FFPE-rep that supported the suitability of GC-DNA 
to be used as the germline reference sample in somatic variant identification and 




The evaluation of the mutational signatures identified in the tumours from the ILBC 
methylation-defined subgroups, suggested a common occurrence of MMRd associated 
signatures SBS6, SBS15, SBS21 and SBS26 in the ILBC tumours. SBS6 was displayed 
by 12/15 (80%) of the ILBC tumours suggesting a possible mismatch repair defects in 
these tumours. However, it could not be supported by the occurrence of any somatic or 
germline pathogenic variant in the mismatch repair genes in any of these samples. This 
could, however, be due to the limited sensitivity of the assay as genetic variations (both 
somatic and germline) of variant allele fraction of 0.2 or more were confidently detected 
in this study and variants present at lower variant allele fraction within the mismatch 
repair genes could not be sensitively detected. Although the presence of MMRd 
associated signatures was not explained by any genetic variants in the mismatch repair 
genes in this study, we found hypermethylation (average beta-value > 50%) at three CpG 
positions (259 bp) located in the TSS1500 of MLH1 in more than 50% of the ILBC 
tumours. The functional promoter of MLH1 has been well-characterised and described to 
be located proximal to the TSS of MLH1. Hypermethylation at this region was found to 
be associated with loss of MLH1 expression (James G Herman et al., 1998; Deng et al., 
1999). Although DNA methylation at the CpG positions located in the TSS1500 region 
of MLH1 did not show any correlation with the MMRd somatic profile and MSI status of 
the tumours, it does not invalidate the impact of hypermethylation at these CpGs on the 
gene expression of MLH1. Microsatellite instability was indicated in 13/15 (87%) of the 
ILBC tumours. Features of MMRd and microsatellite instability have been previously 
reported in breast cancers (Yee et al., 1994; Shaw et al., 1996; Murata et al., 2005; Kappil 
et al., 2016; Malik et al., 2019). Murata et. al., (2002), identified somatic genetic variants 
in MSH2 and hypermethylation at MLH1 promoter as the two main alterations 
contributing to MMRd in breast cancers (Murata et al., 2002). In another study, Murata 
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et al., (2005), reported a reduced expression of MLH1 and MSH2 in 31% (26/83) and 28% 
(23/83) of the sporadic breast cancer cases, respectively, with loss of MLH1 expression 
predominantly caused by promoter hypermethylation in these cases. Microsatellite 
instability has been previously reported in ILBCs by two different studies (Aldaz et al., 
1995; Contegiacomo et al., 1995). Aldaz et al., (1995) reported a significantly higher 
frequency of MSI in ILBC cases (39%, 9/23) compared with ductal breast cancers (14%, 
7/52), (P-value= 0.012) (Aldaz et al., 1995). Another group reported an association 
between MSI with lobular histology and increased lymph node involvement 
(Contegiacomo et al., 1995). Both these studies used MSI markers to determine the 
microsatellite instability status of the tumour as opposed to computational approach used 
in this study. The mutational signature analysis of the ILBC samples suggested a possible 
role for MMRd in ILBC tumourigenesis. However, the data did not allow us to confirm 
the finding by associating the signatures with genetic variations in genes involved in 
MMR. Since many of the mutational signatures detected were driven predominantly by 
C>T substitution, which is also associated with formalin fixation, it may be possible that 
FFPE-induced artefact confounded the accurate signature assignment. However, the 
presence of expected signature SBS3 in Sample 2 from the pilot study gave us some 
reassurance that the mutational signatures algorithm was able to detect true signatures 
despite of the noise present in the data. Despite its limitations this study presents as an 
interesting base for future studies. Testing the ILBC tumours for MMRd using 
immunohistochemistry could be the next step forward.  As artefactual variants bias the 
mutational profiles, it is crucial to introduce methodologies to reduce FFPE-induced 




One of the main limitations of this study was low mean target depth of coverage 
and a low percentage of target coverage, which considerably reduced the breadth of 
analysis that could be done using the data. On an average, somatic variants were 
confidently detected only across 55% of the target region, which greatly limited the 
analysis to a small genomic region. The highly fragmented FFPE DNA samples further 
affected the data quality by introducing a large number of sequencing artefacts that were 
present at a variant allele fraction > 20%, as demonstrated by the sequencing artefacts 
associated mutational signatures in the tumour samples. Although we made adjustments 
in the sequencing data yield and additional sequencing was added to account for PCR 
duplication, overlapping reads and off-target coverage based on the results from the pilot 
study however, it was not reflected in the sequencing output of the main experiment. The 
mean target depth of coverage was lower (mean 99X for tumour DNA and 38X for 
germline DNA sample) than expected (~150X mapped for tumour DNA and 40X-50X 
mapped for germline DNA sample). One reason for poor yield may be the poorer FFPE 
DNA quality of the samples in the main experiment compared with the samples in the 
pilot study. Since the complexity of the library was poor, i.e., the proportion of unique 
DNA templates in the library was low, increasing the sequencing data did not improve 
the depth of target coverage. This could suggest that Agilent SureSelect XT low input kit 
may not be the best suited kit for poor quality FFPE tumour DNA sample type. Library 
preparation kits that use PCR free library preparation workflow could be a better suited 
chemistry for maximising the data quality obtained from the FFPE samples. However, 
removing PCR amplification may increase the input DNA requirement, which is often 
limited in the case of clinical FFPE samples. Some of the parameters that could also affect 
sequencing data quality and therefore somatic variant calling are DNA insert size, 
mapping quality and percentage of overlapping reads. Both the pilot study and the main 
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experiment generated 150 bp paired end reads, which may not be the most appropriate 
sequencing read length for the FFPE DNA as they are highly fragmented. Since the FFPE 
DNA fragments size are smaller that results in smaller insert size, selecting a sequencing 
read length of 150 bp leads to a higher percentage of overlapping reads. As target 
coverage was non-uniform across the samples, low concordance in somatic variants were 
observed between the FFPE samples and their replicates. Across the overlapping target 
region, the FFPE samples and their replicates had many unique variants that were 
recorded only in one of the replicates possibly because of sufficient depth in one replicate 
but not in another. Some of these limitations could be overcome by using DNA repair kits 
for repairing FFPE-derived DNA before sequencing. Further detail of the quality metrics 
discussed above are provided in appendix (Additional Table 1). 
5.8 Summary 
Although this study was limited by the sequencing data quality, a possible 
association between MMRd and ILBC development and progression has been indicated 
that may be related to MLH1 promoter hypermethylation. Mismatch repair genes have 
been studied extensively in colorectal cancers however, the involvement of MMRd in 
ILBC is not well-characterised. Experimental validation of the MSI findings presented 
here will be an important future work. Considering the potential for immunotherapy in 
the context of MSI high tumours, it is possible that at least a subset of ILBC could benefit 
from these therapeutic approaches. Further research could look at the mismatch repair 
genes in larger studies for testing the germline DNA to determine if the mismatch repair 
genes should be on panel tests for ILBC susceptibility.
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Chapter 6 Concluding Remarks 
ILBC is a breast cancer subtype with distinct clinical and biological features. 
Although ILBC tumours commonly have features associated with good prognosis, 
clinicians still face many challenges in the long-term management of women with ILBC. 
Some of the major challenges relate to the difficulties in detecting ILBC at an early stage, 
their highly invasive nature and their tendency for distant metastasis. Recent research 
efforts have demonstrated that ILBC tumours have distinctive genomic (Ciriello et al., 
2015), transcriptomic (Zhao et al., 2004; Bertucci et al., 2008) and proteomic (Oliveira 
et al., 2016) features that has further increased our understanding of this subtype. One of 
the aims of this thesis was to examine the genome-wide DNA methylation profile of this 
subtype. The analysis identified 53,898 DMPs between ILBC and non-ILBC tumours that 
overlapped 13,763 genes and 8,456 intergenic regions. A similar differential methylation 
profile was observed when the analysis was limited to a subset of luminal A ILBC and 
luminal A non-ILBC tumours, which suggested that the observed methylation differences 
were specific to ILBC and non-ILBC tumours and are not influenced by the hormone 
receptor expression status of the tumours. Many of the differentially methylated genes 
were found to be involved in biological pathways related to metabolism of RNA (R-HSA-
8953854), mRNA processing (GO:0006397), RNA splicing (GO:0008380), cell cycle (R-
HSA-1640170) and DNA repair (GO:0006281). Although this work identified some 
differences between ILBC and non-ILBC tumours at genome-wide DNA methylation 
level, further studies are needed to fully understand the impact of such widespread 
genome-wide DNA methylation changes on gene function. 
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Investigating the tumour DNA methylation has been shown to be an efficient 
approach to study tumour heterogeneity (Holm et al., 2010; Fleischer et al., 2017; S 
Zhang et al., 2018). ILBC is a heterogeneous group of diseases with varying clinical 
outcomes however, they are often referred to as a single breast cancer subtype, which 
does not factor in the underlying biological and molecular heterogeneity within ILBC. 
This generalised approach could limit the opportunity for efficient therapeutic options for 
women with ILBC. This study exemplified the heterogeneity within ILBC tumours by 
profiling their genome-wide DNA methylation. Scanning of the ILBC methylome 
revealed 2,771 regions of variable methylation in ILBC tumours. Replication of the 
variable methylation analysis in TCGA dataset (ILBC, n=168), identified 2,760 VMRs, 
of which 763 (28%) overlapped with the study set. The ten most significant VMRs 
identified in the study set ranked highly in the TCGA dataset. A pooled survival analysis 
of the study set and TCGA data, after adjustment for age at diagnosis and tumour stage 
showed that methylation was associated with overall survival for four genes: APC (HR = 
1.18, 95% CI: 1.02-1.36), TMEM101 (HR=1.23, 95% CI: 1.02-1.48), HCG4P3 (HR= 
1.37, 95% CI: 1.05-1.79) and CELF2 (HR=1.21, 95% CI: 1.02-1.43), and promoter 
methylation at these four genes were identified as potential prognostic biomarkers for 
women with ILBC. Although, 2,771 VMRs were identified across the genome, only the 
ten most significant VMRs were tested for their association with survival to minimise the 
multiple testing burden. It is possible that many other VMRs or individual CpG sites may 
be associated with survival. This finding provides a base for important future works and 
could lead to the development of refined molecular signatures for enhanced prediction of 
ILBC survival with clinical utility, which could not be achieved in the current study due 
to limited power. These VMRs could also be investigated for their diagnostic potential 
and if validated in larger studies, could serve in early ILBC diagnosis. 
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The pioneer work for refining breast cancer classification using gene-expression 
profiling was largely based on IDBC and only included a small number of ILBC samples 
(n = 2) (Perou et al., 2000). More research followed that was mainly focused on further 
refining the gene-expression based intrinsic subtypes of breast cancer. This study 
provided data to support that homogeneous subgroups of ILBC can be identified using 
the genome-wide tumour DNA measurement. This approach defined three subgroups of 
ILBC via unsupervised cluster analysis. It was shown that three subgroups of ILBC (as 
defined by genome-wide DNA methylation) had significantly (P-value < 0.01) different 
methylation levels at the DMPs, some important differences in epidemiological risk 
factors and provided some evidence for differences in patient prognosis. One of the 
important findings of the unsupervised cluster analysis was the identification of ILBC 
Subgroup 1, which was identified as the most distinct ILBC subgroup defined by a 
predominantly hypomethylated profiles when compared to the other two subgroups. 
Tumours from this subgroup clustered alongside the triple-negative non-ILBC cases and 
were found to be more similar to the TNBC cases in terms of their genome-wide DNA 
methylation profile compared with the tumours in other two methylation-defined 
subgroups (difference in global methylation pattern, Subgroup 1 versus Subgroup 2, 
ANNOVA, P-value = 3.9x10-6, Subgroup 1 versus Subgroup 3, P-value = 9.4x10-10 ; 
Subgroup 1 versus TNBC, P-value = 0.37). Survival analysis using the cox proportional 
hazard model showed that Subgroup 1 had a poorer overall survival compared with 
Subgroup 2 (HR: 0.59, 95% CI: 0.19-1.79) and Subgroup 3 (HR: 0.16, 95% CI: 0.03-
0.88), after adjusting for age and year of diagnosis that further suggested that Subgroup 
1 may represent a more aggressive form of ILBC. Furthermore, the regions of differential 
methylation between Subgroup 1 and Subgroup 2 showed a significant enrichment of 
genes involved in immune regulation suggesting that Subgroup 1 may represent a subset 
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of ILBC tumours with enhanced immune activity as described in previous studies 
(Ciriello et al., 2015; Michaut et al., 2016). Future work investigating Subgroup 1 
identified in this research with more aggressive clinical behaviour (worse prognosis), may 
identify additional important targets for precision medicine. 
 
Another important finding from the ILBC methylation clustering was the 
enrichment of Subgroup 3 for cases who had a mother with a history of cancer and both 
Subgroup 2 and Subgroup 3 for women who had a female relative with a history of breast 
cancer. This result may indicate that cases in Subgroup 2 and Subgroup 3 could be 
associated with shared germline genetic variations that may be influencing the 
tumourigenic pathway sufficiently to generate the defining methylation patterns in these 
subgroups. This is consistent with the literature that support the association of a strong 
heritable component with ILBC susceptibility (Allen-Brady et al., 2005; Henry & 
Cannon‐Albright, 2019). Further investigation of the samples from Subgroup 2 and 
Subgroup 3 for possible association with a shared heritable component could provide 
important information to support research aimed at identifying subgroup-specific 
predisposition genes associated with ILBC. 
 
Mutational signatures provide an overview of the processes that could have 
contributed to the tumour aetiology with utilities for understanding the cause and 
molecular processes for specific tumour samples. Somatic mutation profiling using WES 
was performed on a subset of samples from the ILBC methylation-defined subgroups to 
further characterise the subgroups via mutational signature analysis. MMRd associated 
signature SBS6 was identified as the most frequently observed mutational signature, 
detected in 12/15 (80%) of the ILBC tumours. Although the three subgroups could not be 
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clearly differentiated based on their mutational signature profile, it pointed towards a 
possible role of MMRd in ILBC tumourigenesis and progression. A computational test 
checking for microsatellite instability indicated 13/15 (87%) of the ILBC tumours as 
microsatellite unstable. This is consistent with prior literature that reports a high 
frequency of microsatellite instability in ILBC tumours (Aldaz et al., 1995; 
Contegiacomo et al., 1995). The status of mismatch repair genes has been studied 
extensively in colorectal cancers and to a lesser extent in all breast cancers but the 
involvement of MMRd in ILBC remains poorly understood. There is growing evidence 
that mismatch repair deficient tumours benefit from therapies involving immune 
checkpoint blockade (Le et al., 2015; Le et al., 2017). Genetic and immunohistochemical 
testing of MMRd are widely available. Future studies on ILBC focusing on the status of 
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Chapter 8 Appendices 
 
 
Additional information 1: R Scripts for data analyses 
 
 
Differentially methylated positions (DMPs) 
 
# load the required R package 
library (limma) 
 
# Create a factor object with information about the comparison groups. 
group <- factor (pheno$group, levels=c (“group 1”, “group 2”)) 
 
# Create a design matrix that contains a coefficient for group comparison. 
design <- model.matrix (~ group) 
 
# Make pair-wise comparison 
fit <- lmFit (M-value, design) 
fit <- eBayes (fit) 
 
# Extract a table of the top-ranked genes from a linear model fit. 
topTable (fit, coef, number = nrow (M-value), sort.by= "B", adjust.method= 




pheno: A data frame with sample information. 
 
M-value: A matrix of M-values, with unique Illumina probe ID as rownames and unique 
sample IDs as column names. 
 
fit: list containing a linear model fit produced by lmFit. 
 















Differentially methylated regions (DMRs) 
 




# Create a factor object with information about the comparison groups. 
group <- factor (pheno$group, levels = c (“group 1”, “group 2”)) 
 
 
# Create a design matrix that contains a coefficient for group comparison. 
design <- model.matrix (~ 0+ group) 
 
# Construct the contrast matrix corresponding to specified contrasts of a set of parameters. 
cont.matrix <- makeContrasts (group 1vsgroup 2 = group 1- group 2, levels = design) 
 
# Annotate a matrix representing 450K data with probe weights 
DMR <- cpg.annotate (datatype = "array", M-value, what = "M", arraytype = "450K", 
analysis.type = "differential", design = design, contrasts = TRUE, cont.matrix = 
cont.matrix, fdr = 0.01, coef = " group 1vsgroup 2") 
 
# Computes a kernel estimate against a null comparison to identify significantly 
differentially methylated regions. 
dmrcate (DMR, lambda = 1000, C = 2) 
 
# Takes a dmrcate.output object and produces the corresponding GRanges object. 
range <- extractRanges (DMR, genome = "hg19") 
results <- DMR$results 
grange <- data.frame (seqnames = seqnames (range), starts = start (range), ends = end 
(range), strands = strand (range), no.cpgs = range$no.cpgs, Promoters = 
range$overlapping.promoter) 
 
# Generate a data frame of differentially methylated regions. 




pheno: A data frame with sample phenotype information. 
 
M-value: A matrix of M-values, with unique Illumina probe ID as rownames and unique 
sample IDs as column names. 
 
coef: Column name specifying which coefficient or contrast of the linear model is of 
interest. 
 
lambda: Gaussian kernel bandwidth for smoothed-function estimation. 
 





Variably methylated regions (VMRs) 
 
# load the required R package 
library (DMRcate) 
 
# Annotate a matrix representing 450K data with probe weights 
VMR <- cpg.annotate (datatype = "array", M-value, what = "M", arraytype = "450K", 
analysis.type = "variability", contrasts = FALSE, cont.matrix = NULL) 
 
# Computes a kernel estimate against a null comparison to identify significantly variably 
methylated regions. 
VMR <- dmrcate (VMR, lambda = 1000, C = 2) 
range <- extractRanges (VMR, genome = "hg19") 
results <- VMR$results 
grange <- data.frame (seqnames = seqnames (range), starts = start (range), ends = end 
(range), strands = strand (range), no.cpgs = range$no.cpgs, Promoters = 
range$overlapping.promoter) 
 
# Generate a data frame of variably methylated regions. 




M-value: A matrix of M-values, with unique Illumina probe ID as rownames and unique 
sample IDs as column names. 
 
lambda: Gaussian kernel bandwidth for smoothed-function estimation. 
 






























# Create a survival object 
pheno$SurvObj <- with (pheno, Surv(time, status = = 1)) 
 
# Create survival curves from either a formula (e.g. the Kaplan-Meier), a previously fitted 
Cox model, or a previously fitted accelerated failure time model. 




pheno: a data frame in which to interpret the variables named in the formula. 
 
SurvObj: A survival object, usually used as a response variable in a model formula. 
 
time: For right censored data, this is the follow up time. For interval data, the first 
argument is the starting time for the interval. 
 
Subgroup: Comparison groups. 
 
status: The status indicator, 0=alive, 1=dead. 
 




Unsupervised cluster analysis 
 
# Compute and return the distance matrix computed by using the specified distance 
measure to compute the distances between the rows of a data matrix. 
dist.matrix <- dist (as.matrix (t (M-value))) 
 
# Hierarchical cluster analysis on a set of dissimilarities and methods for analysing it. 




dist.matrix: the distance matrix computed by using Euclidean measure to compute the 
distances between the rows of a data matrix. 
 
hc: An object of class hclust which describes the tree produced by the clustering process. 
 
M-value: A matrix of M-values, with unique Illumina probe ID as rownames and unique 
sample IDs as column names. 
 
method: the agglomeration method to be used for clustering. 
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Mutation signature analysis 
 
# Load the required R package 
library(deconstructSigs) 
 
# Read the VCF file 
vcf.to.sigs.input ("file.vcf") 
 
# Given a mutation list, outputs a data frame with counts of how frequently a mutation is 
found within each trinucleotide context per sample ID. 
sigs.input <- mut.to.sigs.input (mut.ref = , sample.id = "sample", chr = "chr", pos = "pos", 
ref = "ref", alt = "alt") 
 
# Load a reference signature 
reference.signatures <- as.data.frame (t(cancer_signatures_v3)) 
 
# Compute mutational signature 




file = location of VCF file that is to be converted. 
 





















Additional Figure 1: Unsupervised cluster analysis of ILBC 
samples (n=151) based on their genome-wide DNA methylation 
profiles. 
Dendrogram showing the unsupervised clustering of ILBC cases (n=151) based on their 
genome-wide DNA methylation levels at 449,005 CpG positions. Each leaf of the 
dendrogram represent a ILBC sample and the length of the branches show the Euclidean 
distance between the two clusters. Higher distance on the dendrogram represents more 
dissimilar clusters and vice-versa. The colour bar “Subgroups from cluster analysis 
involving all breast cancer cases” indicates the ILCB methylation subgroups identified in 
the cluster analysis including all breast cancer samples (ILBC, n=151 and non-ILBC, 
n=341). Subgroup 1, Subgroup 2 and Subgroup 3 are shown in black, violet and yellow 
colour respectively, on the colour bar. Samples that were not classified into any subgroup 
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Additional Figure 1: Unsupervised cluster analysis of TCGA 
breast cancer samples (n=666) based on their genome-wide 
DNA methylation profiles. 
Dendrogram showing the unsupervised clustering of TCGA breast cancer samples (n = 
666) including ILBC, n = 171 and non-ILBC, n = 495, based on their genome-wide DNA 
methylation profiles. Each leaf of the dendrogram represents a breast cancer sample and 
the length of the branches show the Euclidean distance between the two clusters (y-axis). 
Higher distance on the dendrogram represents more dissimilar clusters and vice-versa. 
The colour bar “Subtype” indicates the two breast cancer histological subtypes; i.e., ILBC 
(shown in red) and non-ILBC (shown in turquoise). The colour bars “ER”, “PR” and 
“HER2” indicate the estrogen, progesterone, and human epidermal growth factor receptor 
2 expression status, respectively of the breast tumours. Hormone receptor positive 
tumours are shown in “yellow” and hormone receptor negative tumours are shown in 
“blue” colour. Black boxes show the samples with similar clustering pattern as 






















Additional Table 1: Whole-exome sequencing quality metrics 





















Sample DNA insert 
size (bp) 
Overlapping reads (%) Mean mapping quality 
Tumour    
Sample 1-FFPE 139 44 60 
Sample 1-FFPE-rep 176 40 60 
Sample 2-FFPE 141 44 60 
Sample 2-FFPE-rep 133 45 60 
Germline    
Sample 1-WB 202 31 60 
Sample 1-GC 173 37 60 
Sample 2-WB 188 34 60 
Sample 2-GC 179 36 60 
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Invasive Lobular Breast Cancer :
Using tumour genome-wide DNA methylation for subtyping and aid in 
the identification of susceptibility genes
Medha Suman1, JiHoo Eric Joo1,2, Ee Ming Wong1,2, Tu Nguyen-Dumont1,2, Neil O’Callaghan1, Melissa Yow1, 
ABCFS3, MCCS4, kConFab5, John L. Hopper3, Graham G. Giles3, 4, 6, Roger Milne3,4, Melissa C. Southey1,2,4 .
1	Genetic Epidemiology Laboratory, Department of Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne, 2 Precision Medicine, School of Clinical Sciences at Monash 
Health, Monash University, 3Centre for Biostatistics and Epidemiology, School of Population and Global Health, The University of Melbourne, 4Cancer Epidemiology and Intelligence Division, 
Cancer Council Victoria, 5Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Melbourne, 6 School of Public Health and Preventive Medicine, Monash University
Background
§ Invasive Lobular Breast Cancer (ILC) accounts for 10-15% of all breast cancer cases.
§ Studies suggest that there is a strong familial risk associated with ILC, which is significantly greater than any other breast cancer subtype [1].
§ A whole-genome sequencing project has been conducted in our lab involving 120 early onset and multiple-case ILC families.
§ The extent of genetic variation in these genomes made interpretation challenging.
§ The aim of this project is to assess the genome-wide DNA methylation pattern of ILC to enable further subtyping and interpretation of the germline
genomic data.
Samples and Method
§ Samples (n=152) in this project were sourced from :-
Ø Melbourne Collaborative Cohort Study (MCCS)
Ø Australian Breast Cancer Family Registry (ABCFR)
Ø Kathleen Cuningham Foundation Consortium for research into
Familial Breast cancer (kConFab)
Results (Cont.)Results
§ Multidimensional 
scaling (MDS) was 


























Figure 1: Overall 
methylation similarities 
between samples.
§ E-Cadherin : Approximately 70% of ILC show a complete loss of E-
cadherin protein, average methylation across CDH1 was assessed for
all 152 samples. Hypomethylated promoter regions across most ILC



















Figure 2:  Methylation at CDH1 promoter and gene body.
Figure 3: DNA methylation patterns (x-axis) across the CDH1 gene (20 probes)
§ We identified variably methylated regions (VMRs) between the lobular breast





Gene Description Min FDR
APC Chr 5 Adenomatous polyposis coli, WNT signaling pathway regulator 6.69E-154
TMEM101 Chr 17 Transmembrane protein 101, NF-kappa-B signalling pathway 3.88E-112
HIST3H2A Chr 1 Histone Cluster 3 H2A, nucleosome structure maintenance 3.18E-106
ISM1 Chr 20 Isthmin1(novel endogenous angiogenesis inhibitor) 1.87E-97
ASCL2 Chr 11 Achaete-Scute Family BHLH Transcription Factor 2, Human Early Embryo Development 1.33E-91
NKX6-2 Chr 10 NK6 homeobox 2, transcription factor activity 5.75E-83
CCDC108 Chr 2 Coiled-coil domain containing 108, 8.88E-81
DNAJB6 Chr 7 DnaJ heat shock protein family (Hsp40) member B6, protein folding 3.26E-79
SGCE Chr 7 sarcoglycan epsilon, Paternally expressed imprinted gene 2.35E-77
SPPL2B Chr 19 Signal peptide peptidase like 2B, immune response 2.45E-77
Table1: List of top 10 variably methylated regions (VMRs).
Figure 4: Methylation pattern at the two most variably methylated regions across the APC promoter (A) and
TMEM101 (B).
§ DNA methylation of two other APC interacting genes (JUP, AXIN1).
§ Formalin-fixed paraffin-embedded (FFPE) tumor-enriched DNA was prepared using
macrodissection and run on the Infinium HumanMethylation450K Beadchip array to
generate a genome-wide methylation data at ~450,000 methylation sites.
§ The raw intensity data was preprocessed and normalized in R programming software
using minfi, a Bioconductor package for analysis of DNA methylation microarray data [2].
Figure 5: Methylation pattern at the two most variably methylated gene promoters (JUP is shown in A and
AXIN1 shown in (B).
A B
A B AXIN1	PromoterJUP	Promoter
§ Our genome-wide DNA methylation data suggests that there is large
heterogeneity within the invasive lobular breast cancer subtype. This
heterogeneity is observed across multiple regions including key
tumour suppressor genes such as APC and CDH1 (exon 1).
References:
1. Allen-Brady et. al (2005). International Journal of Cancer. 117 (4): 655–61.
2. Aryee MJ et. al (2014) Bioinformatics, 30(10), pp. 1363–1369. 
3. Peters TJ et. al (2015) Epigenetics & Chromatin, 8, pp. 6.
§ A small domain 
(~3 CpG probes) 
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§ Our study identified three groups of lobular breast cancer based on
their genome-wide DNA methylation pattern.
§ DMG analysis identified group 1 as the most hypomethylated group
and group 3 as the most hypermethylated group.
§ Survival analysis does not indicate any significant association
between the difference in methylation and the overall survival.
However, small study size might be a reason.
§ We propose to do somatic whole exome sequencing on the 
methylation groups with an aim to identify any potential difference 
in their mutation profile.
§ We also propose do expression profiling on the top DMGs to see if
the methylation has any potential effect on the gene expression. 
Medha Suman1, JiHoon Eric Joo1, Ee Ming Wong1,2, Tu Nguyen-Dumont1,2, Neil O’Callaghan1, Melissa Yow1, ABCFS3, MCCS4,
kConFab5, John L. Hopper3, Graham G. Giles3, 4, 6, Roger Milne2,3,4, Melissa C. Southey1,2,4 .
1 Genetic Epidemiology Laboratory, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne, 2 Precision Medicine, School of Clinical Sciences at Monash Health, Monash
University, 3Centre for Epidemiology and Biostatistics, School of Population and Clinical Health, The University of Melbourne, 4Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, 5Peter MacCallum
Cancer Centre, Victorian Comprehensive Cancer Centre, Melbourne, 6 School of Public Health and Preventive Medicine, Monash University
§ Invasive Lobular Breast Cancer (ILC) is a distinct subtype of breast cancer and
accounts for 10-15% of all breast cancer cases.
§ A whole-genome sequencing project has been conducted in our lab involving 120
early onset and multiple-case ILC families. The extent of genetic variation in these
genomes made interpretation challenging [1].
§ The aim of this project is to subtype ILC based on variation in tumour DNA
methylation and to aid in the interpretation of the germline genomic data.
B
§ We performed a pair-wise differential
methylation analysis using limma [2] linear fit
model to identify the differentially methylated
genes (DMGs) between the three identified
groups of ILC (Fig 2).
§ The DMGs with < 20% average methylation
difference (Δβ) between the groups were
considered insignificant and were removed
from further analysis.
§ The DMGs with Δβ=positive were defined as
hypermethylated genes and those with
Δβ=negative were defined as hypomethylated
genes.
Figure 1: Hierarchical clustering plot
§ Unsupervised clustering analysis was performed on all breast cancer samples based on their DNA methylation level at 449,005 CpG sites
using “ward.D2” minimum variance method (Fig 1A). Exactly the same analysis was performed on the TCGA breast cancer samples.
TCGA dataset (n= 666)Study Set (n= 492)A
§ B- A very similar clustering
pattern was observed in TCGA
breast cancer samples.
B














Methylation value at ~450,000 
sites across the genome






































Average difference in methylation (Δβ) Average difference in methylation (Δβ) Average difference in methylation (Δβ)
§ An overall survival analysis was
performed to see if there is any
association between the
difference in methylation and
the overall survival between
the groups. However, no
significant association was
observed.
§ A- Lobular samples were found
to cluster into three main
groups (group1, group2 and
group3).
Figure 3 : Density plot showing the average methylation pattern of the three groups of ILC across the functional genomic regions
TSS 1500 TSS 200 5’UTR











Additional File 3: Lorne Cancer Conference, Lorne, Australia 
2018 -Poster presentation. 








Invasive Lobular Breast Cancer : Using tumour genome-wide DNA methylation 
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Background
§ Invasive Lobular Breast Cancer (ILC) is a distinct subtype of breast cancer and accounts for
10-15% of all breast cancer cases.
§ Studies suggest that there is a strong familial risk associated with ILC, which is significantly
greater than any other breast cancer subtype [1].
§ A whole-genome sequencing project has been conducted in our lab involving 120 early
onset and multiple-case ILC families. The extent of genetic variation in these genomes
made interpretation challenging [2].
§ The aim of this project is to subtype ILC based on variation in tumour DNA methylation
and to aid in the interpretation of the germline genomic data.
Samples and Method
§ The samples, lobular (n=151) and non-lobular (predominantly ductal) (n=341) in this
project were sourced from :-
Ø Melbourne Collaborative Cohort Study (MCCS)
Ø Australian Breast Cancer Family Registry (ABCFR)
Ø Kathleen Cuningham Foundation Consortium for research into Familial Breast
cancer (kConFab)
§ DNA was prepared from macrodissected formalin-fixed paraffin-embedded (FFPE) tumour
sections and run on the Infinium HumanMethylation450K Beadchip array to measure
methylation value at ~450,000 sites across the genome.
§ All the samples were pre-processed and normalized together in R using minfi [3].
Results
Group 1 and 2 DMRs 
(Total=1024)
Group 1 and 3 DMRs
(Total=6435)
Group 2 and 3 DMPs
(Total= 121)
Genes and their functions minfdr Gene and their functions minfdr Gene and their functions minfdr









G-protein coupled receptor 
activity and drug binding.
2.94E-70 BOLL
RNA-binding protein, expected role in germ cell 
development.
1.98E-95 EBF3




Transcription factor activity, 
sequence-specific DNA binding.
3.24E-58 VARS
tRNA aminoacylation and gene expression
7.45E-91 GSX1
Sequence-specific DNA 
binding and transcriptional activator activity
2.25E-10












Heparin binding and fibronectin binding.
1.26E-78 TLX3





G-protein coupled receptor activity and drug 
binding.
2.94E-75 LRFN5







poly(A) RNA binding, may have a role in the 
regulation of pre-mRNA splicing.
1.77E-74 FAM43A
Family With Sequence Similarity 43 Member A
0.003113388
C6orf15
Heparin binding and fibronectin 
binding.
5.72E-47 NOTCH4
Evolutionarily conserved intercellular signaling 
pathway
2.57E-73 WNT2B






Key role in apoptosis.
3.19E-71 PAX5




Potential role in cellular senescence.
5.39E-44 RGL2
Ras signaling G-protein signalling-RAS regulation 
pathway.
6.07E-68 EN1
Role in controlling development
0.00481553
Table 1: 10 most differentially methylated regions (DMRs).
Figure 1: Hierarchical clustering plot. § “ward.D2” minimum
variance method was
used for hierarchical
clustering of lobular and
non-lobular breast
cancer samples based on
methylation pattern at
449005 CpG sites (Fig1,
A and B).
§ ER, PR and HER2 status
was available for 413 out
of 492 samples. The
clustering was found not
to be driven by the
hormone receptor
status.
§ Lobular samples were
found to cluster into
three main groups
(group1, group2 and
group3) in all breast
cancer clustering (Fig 1,
B).
§ Differentially methylated probes
(DMPs) were identified using limma
[4].
§ An enrichment of hypermethylated
probes are present in group 2 and 3
compared to group1 (Fig2).
§ Group 2 and group 3 were similar in 
their overall methylation pattern.
Figure 2: Scatterplots showing difference in average methylation of lobular groups across 
the DMPs. 
2
DMPs,n=11848 DMPs, n=42893 DMPs,n=121
Figure 3: Barplot showing the probe proportion of DMPs compared to Illumina450K probes in different genomic locations.
Figure 4: Heatmap of top 1000 DMPs between group 1, 2 and 3.
§ Differentially methylated
regions (DMRs) were calculated
in a pair-wise analysis between
group 1-2, group 1-3 and
group 2-3 using limma.
§ We found an over
representation of RNA genes
differentially methylated
between group 1 and 2 (Table
1).
§ Many of these microRNAs were
found to target genes involved
in important pathways related
to DNA damage repair,
chromatin remodelling and
gene expression.
Summary and future directions
§ Our project has identified two main subgroups of ILC based on genome-wide DNA 
methylation pattern.
§ Combining this information with clinical outcomes, additional tumour characteristics and 
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ILC
Non-ILC
Unsupervised clustering of all breast cancer samples (n=492) 
based on genome-wide DNA methylation pattern
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Genome-wide Variably Methylated Tumour DNA Regions and Association 
with Overall Survival in Invasive Lobular Breast Cancer
BACKGROUND AND AIMS
Medha Suman1, Pierre-Antoine Dugué2,3,4, JiHoon Eric Joo1, Ee Ming Wong1,2, Catriona McLean5, Tu Nguyen-Dumont1,2, John L.
Hopper4, Graham G. Giles3, 4, 6, Roger L. Milne2,3,4, Melissa C. Southey1,2,3.
1 Department of Clinical Pathology, The University of Melbourne, 2Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, 3 Cancer Epidemiology Division, Cancer Council Victoria, 4Centre for
Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, 5Department of Anatomical Pathology, Alfred Hospital, Melbourne, 6 School of Public Health and
Preventive Medicine, Monash University
CONCLUSION AND FUTURE DIRECTIONS
RESULTS
q Higher methylation at APC, TMEM101 and HCG4P3 was found to be strongly
associated with reduced overall survival in ILBC women in the Study set.
q In the TCGA, all the association were consistent and were in similar direction as
the study set.
q Pooled analysis of the two individual studies revealed that APC, TMEM101,
HCG4P3 and CELF2 have predictive value for patient outcome in ILBC women.
q Methylation at ISM1, HIST3H2A, ASCL2, CELF2, EFCAB4B and HES5 showed a






(shown on the x-
axis) and gene 
expression 
levels (shown on 
the y-axis) at the 
genes associated 
with the most 
significant 
VMRs in ILBC 
(TCGA dataset).
q Invasive lobular breast cancer (ILBC) is the second most common histological
subtype of breast cancer accounting for 10-15% of all cases.
q Studies have shown that tumour DNA methylation signatures have potential to
be used as a prognostic and diagnostic biomarker. However, very limited data
exists for ILBC.
q In this study, we aimed to investigate the genome-wide variability of DNA
methylation levels across ILBC tumours and to assess their association with
overall survival.
METHODS
q Tumour DNA was prepared by macrodissecting formalin-fixed paraffin
embedded (FFPE) tumour tissue sections for 130 ILBC cases (sourced from the
Melbourne Collaborative Cohort Study (MCCS) and genome-wide methylation
was measured using Illumina HumanMethylation 450K (HM450K) BeadChip
array.
q Variably methylated regions (VMRs) were identified using the R package
DMRcate [2].
q Cox proportional hazards regression models were used to assess the association
between methylation levels at the 10 most significant VMRs and overall survival.
q Replication of the VMR and survival analyses findings was examined using data
retrieved from The Cancer Genome Atlas (TCGA) [3] for 168 ILBC cases. We
also examined the correlation between methylation and gene expression for the
10 VMRs of interest using the TCGA data.
q 2,771 regions were identified across the genome with variable methylation 
levels.
q The 10 most significant VMRs were located in the promoter regions of  ISM1, 
APC, TMEM101, ASCL2, HIST3H2A, CELF2, HES5, NKX6, HCG4P3 and EFCAB4B 
(Figure 1).
q In TCGA the stronger VMRs remained significant.
Figure 1: Methylation patterns of ILBC (study set) at the 10 most
significant VMRs (gene names marked at the top left corner in each plot).
The X-axis shows the genomic location of the VMRs and the Y-axis shows
the methylation (beta) value of the ILBC samples at these regions. The
samples are represented by individual lines in the plot.
RESULTS (continued)
Study set (n=130)
Recorded deaths (n= 37)
TCGA dataset (n=168)
Recorded deaths (n = 14) Pooled analysis
Gene*
HR (95% CI)




(Adjusted for age and tumour 
stage)
P HR (95% CI) P
APC 1.24 (1.04- 1.49) 0.01 1.06 (0.82- 1.38) 0.63 1.18 (1.02-1.36) 0.03
TMEM101 1.22 (0.99- 1.51) 0.06 1.27 (0.87- 1.85) 0.21 1.23 (1.02-1.48) 0.03
ISM1 0.90 (0.65- 1.26) 0.54 1.48 (0.86- 2.54) 0.15 1.03 (0.77-1.36) 0.83
ASCL2 0.99 (0.71- 1.38) 0.95 1.44 (0.81- 2.57) 0.22 1.08 (0.81-1.45) 0.57
HIST3H2A 1.03 (0.82- 1.29) 0.78 1.23 (0.90- 1.68) 0.18 1.09 (0.91-1.31) 0.33
NKX6 1.01 (0.79- 1.29) 0.91 2.01 (1.28- 3.17) 0.002 1.18 (0.95-1.46) 0.13
HCG4P3 1.25 (0.91- 1.72) 0.16 1.69 (1.05- 2.72) 0.03 1.37 (1.05-1.79) 0.02
HES5 1.13 (0.89- 1.42) 0.29 1.13 (0.76- 1.68) 0.53 1.13 (0.92-1.38) 0.23
CELF2 1.13 (0.93- 1.36) 0.21 1.51 (1.07- 2.13) 0.02 1.21 (1.02-1.43) 0.02
EFCAB4B 0.99 (0.83- 1.19) 0.99 1.25 (0.93- 1.67) 0.14 1.05 (0.90-1.23) 0.49
Table 1: Table lists the hazard ratios (HR) for the association between the methylation levels at the 10 most significant 
VMRs and overall survival in the Study set, its replication in the TCGA dataset and a pooled analysis of the individual 
studies.
* Genes associated with the VMRs.
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R = 0.07 , p =  0.36 
HES5
Average DNA methylation









R = -0.03 , p =  0.68 
R = 0.13 , p =  0.11 
q This study indicates that methylation level at the variable regions may explain 
differences in tumour prognosis within the ILBC subtype.
q APC, TMEM101, HCG4P3 and CELF2 showed prognosis predictive value in ILBC.
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